,PageNo,Text
0,page_0,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 of 1 2 1 Cli nic al I n v esti g ati o n Pl a n Cli nic al I n v esti g ati o n Pl a n/ St u d y Titl e T h e M e dtr o nic H ar m o ny ™ Tr a nsc at h et er P ul m o n ar y V al v e C li nic al St u dy Cli nic al I n v esti g ati o n Pl a n I d e ntifi er M D T 1 6 0 0 4 C O N 0 0 1 St u d y Pr o d uct N a m e H ar m o ny Tr a nsc at h et er P ul m o n ary V alv e a n d D eliv er y S yst e m S p o ns or/L oc al S p o ns or Gl o b al S p o ns or: M e dtr o nic C or o n ary a n d Str uct ur al H e art Cli nic al 8 2 0 0 C or al S e a St N E, M V S 6 6 M o u n ds Vi e w, M N 5 5 1 1 2 U nit e d St at es D oc u m e nt V ersi o n 6. 0 V ersi o n D at e 1 2J U N 2 0 1 9 L e a d Pri nci p al I n v esti g at or(s) C o nfi d e nti alit y St at e m e nt T h e i nf or m ati o n c o nt ai n e d i n t his d oc u m e nt is c o nfi d e nti al a n d t h e pr o pri et ary pr o p e rty of M e dtr o nic. A ny distri b uti o n, c o pyi n g, or discl os ur e wit h o ut t h e pri or writt e n a ut h oriz ati o n of M e dtr o nic is strictly pr o hi bi t e d. P ers o ns t o w h o m t h e i nf or m ati o n is discl os e d m ust k n o w t h at it is c o nfi d e nti al a n d t h at it m ay n ot b e f urt h er discl os e d by t h e m. M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
1,page_1,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e T a bl e of C o nt e nt s T a bl e of C o nt e nt s T a bl e of C o nt e nt s ................................ ................................ ................................ ...................... 2 1. Gl o s s ar y ................................ ................................ ................................ .............................. 6 2. S y n o p si s ................................ ................................ ................................ ............................. 8 3. I ntr o d u cti o n ................................ ................................ ................................ ..................... 1 0 3. 1. B ac k gr o u n d ................................ ................................ ................................ .......................... 1 0 3. 2. P ur p os e ................................ ................................ ................................ ................................ 1 2 4. O bj e cti v e s a n d E n d p oi nt s ................................ ................................ ................................ . 1 2 4. 1. O bj ecti v es ................................ ................................ ................................ ............................. 1 2 4. 1. 1. Pri m ar y O bj ecti v e(s) ................................ ................................ ................................ .............. 1 2 4. 2. Pri m ar y E n d p oi nts ................................ ................................ ................................ ................ 1 2 4. 2. 1. Pri m ar y S af et y E n d p oi nt ................................ ................................ ................................ ........ 1 2 4. 2. 2. Pri m ar y Eff ectiv e n ess E n d p oi nt ................................ ................................ ............................ 1 2 4. 3. A d diti o n al O utc o m e M e as ur es ................................ ................................ .............................. 1 3 4. 4. R ati o n al e f or S el ecti o n of St u d y E n d p oi nts ................................ ................................ ............ 1 4 5. St u d y D e si g n ................................ ................................ ................................ .................... 1 5 5. 1. D ur ati o n ................................ ................................ ................................ ............................... 1 5 5. 2. R ati o n al e ................................ ................................ ................................ .............................. 1 6 6. Pr o d u ct D e s cri pti o n ................................ ................................ ................................ .......... 1 6 6. 1. G e n er al ................................ ................................ ................................ ................................ . 1 6 6. 2. P ac k a gi n g ................................ ................................ ................................ ............................. 1 6 6. 3. Pr o d uct Tr ai ni n g R e q uir e m e nts ................................ ................................ ............................. 1 7 6. 4. Pr o d uc t Acc o u nt a bilit y ................................ ................................ ................................ .......... 1 7 6. 5. Pr o d uct St or a g e ................................ ................................ ................................ .................... 1 8 6. 6. Pr o d uct R et ur n ................................ ................................ ................................ ..................... 1 8 7. S el e cti o n of S u bj e ct s ................................ ................................ ................................ ........ 1 8 7. 1. St u d y P o p ul ati o n ................................ ................................ ................................ .................. 1 8"
2,page_2,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 3 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e 7. 2. S u bj ect E nr oll m e nt ................................ ................................ ................................ ................ 1 8 7. 3. I ncl usi o n Crit eri a ................................ ................................ ................................ ................... 1 9 7. 4. E xcl usi o n Crit eri a ................................ ................................ ................................ .................. 1 9 8. St u d y Pr o c e d ur e s ................................ ................................ ................................ ............. 2 0 8. 1. Sc h e d ul e of E v e nts ................................ ................................ ................................ ................ 2 0 8. 2. S u bj ect C o ns e nt ................................ ................................ ................................ .................... 2 1 8. 3. S u bj ect Scr e e ni n g ................................ ................................ ................................ .................. 2 2 8. 4. H ar m o n y T P V 2 5 R oll -I n P h as e ................................ ................................ ............................... 2 3 8. 5. A d diti o n of m T P V 2 5 C o h ort ................................ ................................ ................................ .. 2 5 8. 6. I m pl a nt C at h eriz ati o n Pr oc e d ur e ................................ ................................ ........................... 2 6 8. 6. 1. P ost -Pr oc e d ur e C ar e ................................ ................................ ................................ ............. 2 7 8. 6. 2. Disc h ar g e Crit eri a ................................ ................................ ................................ .................. 2 7 8. 6. 3. D evic e Ex pl a nt ................................ ................................ ................................ ....................... 2 7 8. 7. S u bj ect E v al u ati o ns ................................ ................................ ................................ ............... 2 7 8. 7. 1. U n pl a n n e d Visits ................................ ................................ ................................ ................... 2 7 8. 7. 2. Miss e d Visits ................................ ................................ ................................ .......................... 2 8 8. 8. S u bst a nti al R a di ati o n D os e L e v el ................................ ................................ ........................... 2 8 8. 9. Ass ess m e nt of S af et y ................................ ................................ ................................ ............ 2 8 8. 1 0. R ec or di n g D at a ................................ ................................ ................................ ................ 2 9 8. 1 1. D e vi ati o n H a n dli n g ................................ ................................ ................................ .......... 2 9 8. 1 2. S u bj ect Wit h dr a w al or Disc o nti n u ati o n ................................ ................................ ............ 3 1 9. Ri s k s a n d B e n efit s ................................ ................................ ................................ ............ 3 1 9. 1. P ot e nti al Ris ks ................................ ................................ ................................ ...................... 3 1 9. 2. P ot e nti al B e n efi ts ................................ ................................ ................................ ................. 3 2 9. 3. Ris k -B e n efit R ati o n al e ................................ ................................ ................................ ........... 3 2 1 0. A d v er s e E v e nt s a n d D e vi c e D efi ci e n ci e s ................................ ................................ ....... 3 3 1 0. 1. D efi niti o ns/ Cl assific ati o ns ................................ ................................ ............................... 3 3 1 0. 2. E v al u ati o ns a n d D oc u m e nt ati o n of A d v ers e E v e nts a n d D e vic e D efici e nci es ...................... 3 5 1 0. 2. 1. R e p orti n g of A dv ers e Ev e nts by I nv esti g at or ................................ ................................ ........ 3 5 1 0. 2. 2. R e p orti n g of A dv ers e Ev e nts by S p o ns or ................................ ................................ .............. 3 7"
3,page_3,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e 1 0. 2. 3. Cl assific ati o n of S eri o us A dv ers e Ev e nts ................................ ................................ ............... 3 8 1 0. 2. 4. Cl assific ati o n of C a us al R el ati o ns hi ps ................................ ................................ ................... 3 8 1 0. 2. 5. R e p orti n g of D e vic e D efici e nci es ................................ ................................ ........................... 3 9 1 0. 3. A ntici p at e d A d v ers e E v e nts ................................ ................................ ............................. 4 0 1 0. 4. E m er g e nc y C o nt act D et ails f or R e p orti n g S A E, U A D E, a n d D e vic e D efici e nci es ................... 4 0 1 1. D at a R e vi e w C o m mitt e e s ................................ ................................ .............................. 4 0 1 1. 1. Scr e e ni n g C o m mitt e e ................................ ................................ ................................ ...... 4 0 1 1. 2. Cli nic al E v e nts C o m mitt e e ................................ ................................ ............................... 4 0 1 1. 3. D at a M o nit ori n g C o m mitt e e ................................ ................................ ............................ 4 1 1 2. St ati sti c al D e s i g n a n d M et h o d s ................................ ................................ ..................... 4 2 1 2. 1. A n al ysis S ets ................................ ................................ ................................ ................... 4 2 1 2. 2. Pri m ar y O bj ecti v es ................................ ................................ ................................ .......... 4 2 1 2. 2. 1. Pri m ar y S af e t y E n d p oi nt ................................ ................................ ................................ ........ 4 3 1 2. 2. 2. Pri m ar y Effic ac y E n d p oi nt ................................ ................................ ................................ ..... 4 3 1 2. 3. A d diti o n al O utc o m e M e as ur es ................................ ................................ ........................ 4 4 1 3. Et hi c s ................................ ................................ ................................ ............................. 4 6 1 3. 1. St at e m e nt(s) of C o m pli a nc e ................................ ................................ ............................. 4 6 1 3. 2. I nstit uti o n al R e vi e w B o ar d/ Et hics C o m mitt e e ................................ ................................ .. 4 7 1 3. 3. R e g ul at or y S u b missi o ns ................................ ................................ ................................ ... 4 8 1 3. 4. Et hic al C o n d uct of t h e St u d y ................................ ................................ ............................ 4 8 1 4. St u d y A d mi ni str ati o n ................................ ................................ ................................ ..... 4 9 1 4. 1. Sit e Acti v ati o n ................................ ................................ ................................ ................. 4 9 1 4. 2. M o nit ori n g ................................ ................................ ................................ ...................... 4 9 1 4. 2. 1. Pr e -St u dy Visits ................................ ................................ ................................ ...................... 5 0 1 4. 2. 2. I nt eri m M o nit ori n g ................................ ................................ ................................ ................ 5 0 1 4. 2. 3. St u dy Cl os e -O ut ................................ ................................ ................................ ..................... 5 0 1 4. 3. A u diti n g ................................ ................................ ................................ .......................... 5 1 1 4. 4. S o urc e D at a/ D oc u m e nts ................................ ................................ ................................ .. 5 1 1 4. 5. C o nfi d e nti alit y ................................ ................................ ................................ ................ 5 2 1 4. 6. D at a M a n a g e m e nt ................................ ................................ ................................ .......... 5 2"
4,page_4,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 5 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e 1 4. 7. Li a bilit y ................................ ................................ ................................ ........................... 5 3 1 4. 8. CI P A m e n d m e nts ................................ ................................ ................................ ............. 5 3 1 4. 9. P u blic ati o n a n d Us e of I nf or m ati o n ................................ ................................ .................. 5 3 1 4. 1 0. S us p e nsi o n or E arl y T er mi n ati o n of t h e St u d y ................................ ............................... 5 4 1 4. 1 1. S us p e nsi o n or E arl y T er mi n ati o n of a St u d y Sit e ................................ ............................ 5 4 1 5. R e c or d R et e nti o n a n d R e p orti n g R e s p o n si biliti e s ................................ ......................... 5 4 1 5. 1. R es p o nsi biliti es of t h e I n v esti g at or ................................ ................................ .................. 5 4 1 5. 2. R es p o nsi biliti es of t h e S p o ns or ................................ ................................ ........................ 5 7 1 5. 3. R ec or d R et e nti o n ................................ ................................ ................................ ............ 6 2 1 6. R ef er e n c e s ................................ ................................ ................................ ..................... 6 2 1 7. A p p e n di c e s ................................ ................................ ................................ .................... 6 4 1 8. V er si o n Hi st or y ................................ ................................ ................................ .............. 6 5 A p p e n di x I: I N F O R M E D C O N S E N T T E M P L A T E ................................ ................................ ......... 6 7 A p p e n di x I I: A D V E R S E E V E N T D E F I N I T I O N S ................................ ................................ ......... 6 8 A p p e n di x I I I: A D V E R S E E V E N T C O D E L I S T ................................ ................................ ............. 7 3 A p p e n di x I V: E C H O C A R D I O G R A P H Y P R O T O C O L ................................ ................................ .... 7 7 A p p e n di x V: R A D I O G R A P H Y P R O T O C O L ................................ ................................ ................. 8 4 A p p e n di x V I: C A R D I A C M A G N E T I C R E S O N A N C E I M A G I N G P R O T O C O L -F U N C T I O N A L P A R A M E T E R S ................................ ................................ ................................ .......................... 8 6 A p p e n di x V I I: C O M P U T E D T O M O G R A P H I C A N G I O G R A P H Y ( C T ) I M A G I N G P R O T O C O L ...... 1 0 3 A p p e n di x V I I I: A N A T O M I C M E A S U R E M E N T S A N D D E V I C E S I Z I N G G U I D E L I N E S ................ 1 0 8 A p p e n di x I X: E X P L A N T P R O T O C O L ................................ ................................ ....................... 1 1 1 A p p e n di x X: I N S T R U C T I O N S F O R U S E D O C U M E N T ................................ .............................. 1 1 2 A p p e n di x X I: S F -3 6 Q U E S T I O N N A I R E ................................ ................................ ................... 1 1 3 A p p e n di x X I I: P O S T -I M P L A N T C O M P U T E D T O M O G R A P H I C A N G I O G R A P H Y ( C T A ) I M A G I N G S U B -S T U D Y P R O T O C O L ................................ ................................ ................................ ......... 1 1 9"
5,page_5,
6,page_6,
7,page_7,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e Titl e T h e M e dtr o nic H ar m o n y Tr a nsc at h et er P ul m o n ar y V al v e Cli nic al St u d y Pr o d uct N a m e H ar m o n y Tr a nsc at h et er P ul m o n ar y V al v e ( T P V) ( M o d el N T P V 0 0 2 2 ) H ar m o n y Tr a nsc at h et er P ul m o n ar y V al v e ( T P V) ( M o d el H T P V 2 5 4 9 5 2) H ar m o n y Tr a nsc at h et er P ul m o n ar y V al v e ( T P V) ( M o d el H T P V 2 5 4 2 5 2) H ar m o n y D eliv er y S yst e m ( D S) ( M o d el N T P V D S 0 0 2 2) H ar m o n y D eliv er y S yst e m ( D S) ( M o d el H T P V D S 0 0 2 5) S p o ns or M e dtr o nic C or o n ar y a n d Str uct ur al H e art Cli nic al 8 2 0 0 C or al S e a St N E, M V S 6 6 M o u n ds Vi e w, M N 5 5 1 1 2 U nit e d St at es L oc al S p o ns or(s) I n v es ti g ati o n P ur p os e T h e p ur p os e of t his st u dy is t o e v al u at e t h e s af et y a n d eff ecti v e n ess of t h e H ar m o n y T P V s yst e m. Pri m ar y O bj ecti v e(s) T h e pri m ar y o bj ecti v e of t his st u d y is t o d e m o nstr at e t h e s af et y a n d eff ecti v e n ess of t h e H ar m o n y T P V s yst e m as m e as ur e d b y fr e e d o m fr o m pr oc e d ur e or d evic e -r el at e d m ort alit y at 3 0 d a ys a n d p erc e nt a g e of s u bj ects wit h acc e pt a bl e h e m o d y n a mic f u ncti o n at 6 m o nt hs. Pri m ar y S af et y E n d p oi nt Fr e e d o m fr o m pr oc e d ur e - or d evic e -r el at e d m ort alit y at 3 0 d a ys. Pri m ar y Eff ecti v e n ess E n d p oi nt P erc e nt a g e of s u bj ects wit h acc e pt a bl e h e m o d y n a mic f u ncti o n c o m p osit e at 6 m o nt hs as d efi n e d b y: • M e a n R V O T gr a di e nt as m e as ur e d b y c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p h y ≤ 4 0 m m H g o If a c at h et eriz ati o n is p erf or m e d f or cli nic al p ur p os es, t h e c at h et eriz ati o n p e a k gr a di e nt m e as ur e m e nt will s u p ers e d e t h e c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p h y m e as ur e m e nt a n d b e us e d t o s u p p ort t h e pri m ar y e n d p oi nt. Acc e pt a bl e h e m o d y n a mic f u ncti o n as m e as ur e d b y c at h et eriz ati o n will b e c o nsi d er e d t o b e p e a k gr a d i e nt ≤ 4 0 m m H g. -A N D - • P ul m o n ar y r e g ur git a nt fr acti o n as m e as ur e d b y m a g n etic r es o n a nc e i m a gi n g < 2 0 % 2. S y n o p si s"
8,page_8,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e o If m a g n etic r es o n a nc e i m a gi n g is c o ntr ai n dic at e d, a c o nti n u o us - w a v e D o p pl er ec h oc ar di o gr a p h y m e as ur e m e nt will b e us e d t o s u p p ort t h e pri m ar y e n d p oi nt. Acc e pt a bl e h e m o d y n a mic f u ncti o n as m e as ur e d b y c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p h y will b e c o nsi d er e d t o b e < m o d er at e p ul m o n ar y r e g ur git ati o n. A d diti o n al O utc o m e M e as ur es • T ec h nic al s ucc ess at exit fr o m c at h et eriz ati o n l a b/ o p er ati n g r o o m • D evic e s ucc ess o ut t o 5 y e ars • Pr oc e d ur al s ucc ess at 3 0 d a ys • Fr e e d o m fr o m T P V d ysf u ncti o n o ut t o 5 y e ars • Ass ess m e nt of s af et y • C h ar act eriz e q u alit y of lif e sc or es o v er ti m e • C h ar act eriz e ri g ht v e ntricl e r e m o d eli n g f oll o wi n g T P V i m pl a nt • C o nfir m ati o n of t h e pr oc e d ur al f e asi bi lit y, h e m o d y n a mic p erf or m a nc e a n d s af et y pr ofil e of H ar m o n y T P V 2 5 (r oll -i n c o h ort) • C o nfir m ati o n of t h e pr oc e d ur al f e asi bilit y, h e m o d y n a mic p erf or m a nc e a n d s af et y pr ofil e of t h e m o difi e d T P V 2 5 ( 1 0 U S i m pl a nts) St u d y D esi g n M ulti -c e nt er, pr os p ecti v e, n o n -r a n d o miz e d, i nt er v e nti o n al, i n v esti g ati o n al I n v esti g ati v e Sit es U p t o 1 5 i n v esti g ati o n al sit es i n t h e U nit e d St at es, C a n a d a, a n d J a p a n S a m pl e Siz e • Pi v ot al c o h ort: Pri m ar y a n al ysis f or u p t o 4 0 s u bj ects i m pl a nt e d i ncl u di n g t h e H ar m o n y T P V 2 5 R oll -I n c o h o rt • A d diti o n al a n al ysis f or t h e H ar m o n y m o difi e d T P V 2 5 ( m T P V 2 5) c o h ort: t e n s u bj ects i m pl a nt e d i n t h e U nit e d St at es, a n d u p t o fi v e s u bj ects i m pl a nt e d i n C a n a d a a n d/ or J a p a n P ati e nt P o p ul ati o n P ati e nts w h o h a v e c o n g e nit al h e art dis e as e a n d ar e cli nic all y i n dic at e d f or p ul m o n ar y v al v e r e pl ac e m e nt. I ncl usi o n Crit eri a • S u bj ect h as p ul m o n ar y r e g ur git ati o n as p er o n e or m or e of t h e f oll o wi n g crit eri a: o S ev er e p ul m o n ar y r e g ur git ati o n as m e as ur e d b y c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p h y, or o P ul m o n ar y r e g ur git a nt fr acti o n ≥ 3 0 % as m e as ur e d b y c ar di ac m a g n etic r es o n a nc e i m a gi n g • Cli nic al i n dic ati o n f or s ur gic al pl ac e m e nt of a R V -P A c o n d uit or pr ost h etic p ul m o n ar y v al v e p er o n e or m or e of t h e f oll o wi n g crit eri a: o S u bj ect is s y m pt o m atic s ec o n d ar y t o p ul m o n ar y i ns uffi ci e nc y ( e. g. ex ercis e i nt ol er a nc e, fl ui d o v erl o a d) as cl assifi e d b y t h e i n v esti g at or, or o S u bj ect h as ri g ht v e ntric ul ar e n d di ast olic v ol u m e i n d ex ( R V E D Vi) ≥ 1 5 0 ml/ m 2, or o S u bj ect h as R V E D V: L V E D V R ati o ≥ 2. 0 • S u bj ect is willi n g t o c o ns e nt t o p artici p at e i n t h e st u d y a n d will c o m mit t o c o m pl eti o n of all f oll o w -u p r e q uir e m e nts E xcl usi o n Crit eri a • A n at o my u n a bl e t o acc o m m o d at e a 2 5 Fr d eli v er y s yst e m • O bstr ucti o n of t h e c e ntr al v ei ns • Cli nic al or bi ol o gic al si g ns of i nf ecti o n i ncl u di n g acti v e e n d oc ar ditis • Pl a n n e d c o nc o mit a nt pr oc e d ur e at ti m e of i m pl a nt • P ositi v e pr e g n a nc y t est at b as eli n e ( pri or t o C T a n gi o gr a p h y a n d a g ai n pri or t o i m pl a nt pr oc e d ur e) i n f e m al e s u bj ects of c hil d b e ari n g p ot e nti al"
9,page_9,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 of 1 2 1 • P ati e nts wit h ri g ht v e ntric ul ar o utfl o w tr act o bstr ucti o n ( R V O T O) l esi o ns s ur gic all y tr e at e d wit h a n R V -P A c o n d uit i m pl a nt • A m aj or or pr o gr essi v e n o n -c ar di ac dis e as e ( e. g. li v er f ail ur e, r e n al f ail ur e, c a nc er) t h at r es ults i n a lif e ex p ect a nc y of l ess t h a n o n e y e ar • Pl a n n e d i m pl a nt ati o n of t h e H ar m o n y T P V i n t h e l eft h e a rt • R V O T a n at o my or m or p h ol o g y t h at is u nf a v or a bl e f or d evic e a nc h ori n g • K n o w n all er g y t o as piri n, h e p ari n, or nic k el • Ec h oc ar di o gr a p hic evi d e nc e of i ntr ac ar di ac m ass, t hr o m b us, or v e g et ati o n • Pr e -existi n g pr ost h etic h e art v al v e or pr ost h etic ri n g i n a n y p osit i o n St u d y Pr oc e d ur es a n d Ass ess m e nts • Cli nic al ass ess m e nt at pr e - a n d p ost -i m pl a nt, 1 m o nt h, 6 m o nt hs, 1 y e ar, a n d a n n u all y t hr o u g h 5 y e ars • Ec h oc ar di o gr a p h y at pr e - a n d p ost -i m pl a nt, 1 m o nt h, 6 m o nt hs, 1 y e ar, a n d a n n u all y t hr o u g h 5 y e ars • C ar di ac m a g n etic r es o n a nc e ( C M R) at pr e -i m pl a nt, 6 m o nt hs, 2 y e ars, a n d 5 y e ars • C M R at 1 m o nt h f or t h e m T P V 2 5 c o h ort • C T C ar di ac A n gi o gr a p h y at pr e -i m pl a nt • C T C ar di ac A n gi o gr a p h y at p ost -i m pl a nt f or t h e m T P V 2 5 c o h ort a n d f or T P V 2 5 s u bj ects p artici p ati n g i n t h e C T s u b -st u d y • Fl u or osc o p y at i m pl a nt, 1 m o nt h, 6 m o nt hs, 1 y e ar, a n d 5 y e ars • S F -3 6 at pr e -i m pl a nt, 1 m o nt h, 6 m o nt hs, 1 y e ar, a n d a n n u all y t hr o u g h 5 y e ars Pr of essi o n al S er vic es • I n d e p e n d e nt Ec h oc ar di o gr a p h y C or e L a b or at or y • I n d e p e n d e nt C M R C or e L a b or at or y • I n d e p e n d e nt E x pl a nt P at h ol o g y C or e L a b or at or y • P ati e nt Scr e e ni n g C o m mitt e e • I n d e p e n d e nt Cli nic al E v e nts C o m mitt e e • I n d e p e n d e nt D at a M o nit ori n g C o m mitt e e 3. 1. B a c k gr o u n d 3. I ntr o d u cti o n"
10,page_10,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 of 1 2 1"
11,page_11,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 2 of 1 2 1 3. 2. P ur p o s e T h e p ur p os e of t his st u dy is t o e v al u at e t h e s af ety a n d eff ectiv e n ess of t h e H ar m o ny T P V s yst e m. 4. 1. O bj e cti v e s 4. 1. 1. Pri m ar y O bj e cti v e( s ) T h e pri m ar y o bj ecti v e of t his st u dy is t o d e m o nstr at e t h e s af ety a n d eff ecti v e n ess of t h e H ar m o ny T P V s yst e m as m e as ur e d b y fr e e d o m fr o m pr oc e d ur e or d e vic e -r el at e d m ort alit y at 3 0 d a ys a n d p erc e nt a g e of s u bj ects wit h acc e pt a bl e h e m o dy n a mic f u ncti o n at 6 m o nt hs. 4. 2. Pri m ar y E n d p oi nt s T h e f oll o wi n g e n d p oi nts will b e us e d t o e v al u at e t h e pri m ar y st u dy o bj ectiv e: 4. 2. 1. Pri m ar y S af et y E n d p oi nt ➢ Fr e e d o m fr o m pr oc e d ur e - or d evic e -r el at e d m ort alit y at 3 0 d a ys 4. 2. 2. Pri m ar y Eff e cti v e n e s s E n d p oi nt ➢ P erc e nt a g e of s u bj ects wit h acc e pt a bl e h e m o dy n a mic f u ncti o n c o m p osit e at 6 m o nt hs as d efi n e d by: 4. O bj e cti v e s a n d E n d p oi nt s"
12,page_12,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 3 of 1 2 1 • M e a n R V O T gr a di e nt as m e as ur e d by c o nti n u o us -w av e D o p pl er ec h oc ar di o gr a p hy ≤ 4 0 m m H g o If a c at h et eriz ati o n is p erf or m e d f or cli nic al p ur p os es, t h e c at h et eriz ati o n p e a k gr a di e nt m e as ur e m e nt will s u p ers e d e t h e c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy m e as ur e m e nt a n d b e us e d t o s u p p ort t h e pri m ary e n d p oi nt. Acc e pt a bl e h e m o dy n a mic f u ncti o n as m e as ur e d by c at h et eriz ati o n will b e c o nsi d er e d t o b e p e a k gr a di e nt ≤ 4 0 m m H g. -A N D - • P ul m o n ar y r e g ur git a nt fr acti o n as m e as ur e d by m a g n etic r es o n a nc e i m a gi n g < 2 0 % o If m a g n etic r es o n a nc e i m a gi n g is c o ntr ai n dic at e d, a c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy m e a s ur e m e nt will b e us e d t o s u p p ort t h e pri m ary e n d p oi nt. Acc e pt a bl e h e m o dy n a mic f u ncti o n as m e as ur e d by c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy will b e c o nsi d er e d t o b e < m o d er at e p ul m o n ar y r e g ur git ati o n. 4. 3. A d diti o n a l O ut c o m e M e a s ur e s ➢ T ec h nic al s ucc ess at ex it fr o m c at h et eriz ati o n l a b/ o p er ati n g r o o m ( O R), as d efi n e d as: • N o d evic e - or pr oc e d ur al -r el at e d m ort ality, wit h • S ucc essf ul acc ess, d eli v er y a n d r etri ev al of t h e d eliv ery s yst e m, a n d • D e pl oy m e nt a n d c orr ect p ositi o n i n g (i ncl u di n g mi n or r e p ositi o ni n g if n e e d e d) of t h e si n gl e i nt e n d e d d evic e, a n d • N o n e e d f or a d diti o n al u n pl a n n e d or e m er g e ncy s ur g er y or r e -i nt er v e nti o n r el at e d t o t h e d e vic e or acc ess pr oc e d ur e ➢ D evic e s ucc ess o ut t o 5 y e ars, as d efi n e d as: • N o d evic e - or pr oc e d ur al -r el at e d m ort ality, wit h • Ori gi n al i nt e n d e d d evic e i n pl ac e, a n d • N o a d diti o n al s ur gic al or i nt er v e nti o n al pr oc e d ur es r el at e d t o acc ess or t h e d e vic e si nc e c o m pl eti o n of t h e ori gi n al pr oc e d ur e (i. e., exit fr o m t h e c at h et eriz ati o n l a b), a n d • I nt e n d e d p erf or m a nc e of t h e d e vic e, as d efi n e d as: o Str uct ur al p erf or m a nc e: N o mi gr ati o n, e m b oliz ati o n, d et ac h m e nt, m aj or st e nt fr act ur e, h e m ol ysis, t hr o m b osis, e n d oc ar ditis, a n d o H e m o dy n a mic p erf or m a nc e: R eli ef of i ns uffici e nc y ( P R < m o d er at e) wit h o ut pr o d uci n g t h e o p p osit e ( m e a n R V O T gr a di e nt > 4 0 m m H g) as m e as ur e d by c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy 1, a n d • A bs e nc e of p ar a -d evic e c o m plic ati o ns, as d efi n e d by: o P VL ≥ m o d er at e, or o Er osi o n, or 1 If a c at h et eriz ati o n is p erf or m e d f or cli ni c al p ur p os es, t h e c at h et eri z ati o n p e a k gr a di e nt m e as ur e m e nt will s u p ers e d e t h e c o nti n u o us -w a v e D o p pl er e c h o c ar di o gr a p h y m e as ur e m e nt a n d b e u s e d t o s u p p ort t h e o ut c o m e m e as ur e."
13,page_13,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 4 of 1 2 1 o R V O T or P A r u pt ur e ➢ Pr oc e d ur al s ucc ess at 3 0 d a ys, as d efi n e d as: • D evic e s ucc ess at 3 0 d a ys, a n d • N o n e of t h e f oll o wi n g d e vic e - or pr oc e d ur e -r el at e d s eri o us a d v ers e ev e nts: o Lif e -t hr e at e ni n g m aj or bl e e d o M aj or v asc ul ar or c ar di ac str uct ur al c o m plic ati o ns r e q ui r e d u n pl a n n e d r ei nt erv e nti o n or s ur g er y o St a g e 2 or 3 ac ut e ki d n e y i nj ur y ( A KI) (i ncl u d es n e w di al ysis) o P ul m o n ar y e m b olis m o S e v er e h e art f ail ur e ( H F) or h y p ot e nsi o n r e q uiri n g I V i n otr o p e, ultr afiltr ati o n, or m ec h a nic al circ ul at ory s u p p ort o Pr ol o n g e d i nt u b ati o n > 4 8 h o urs ➢ Fr e e d o m fr o m T P V dysf u ncti o n o ut t o 5 y e ars. ➢ Ass ess m e nt of s af ety, d efi n e d as ass ess m e nt of: • All pr oc e d ur e -r el at e d s eri o us a d v ers e e v e nts • All d e vic e -r el at e d s eri o us a dv ers e e v e nts • D e at h ( all -c a us e, pr oc e d ur al, a n d d e vic e -r el at e d) • C h ar act eriz a ti o n of q u alit y of lif e sc or es ov er ti m e as ass ess e d by t h e S F -3 6 at pr e - i m pl a nt, 1 m o nt h p ost -i m pl a nt, 6 m o nt hs p ost -i m pl a nt, a n d a n n u ally p ost -i m pl a nt o ut t o 5 y e ars • C h ar act eriz ati o n of ri g ht v e ntricl e r e m o d eli n g f oll o wi n g T P V i m pl a nt as ass ess e d vi a C M R 4. 4. R ati o n al e f or S el e cti o n of St u d y E n d p oi nt s T h e b asis f or t h e s el ecti o n of t h es e e n d p oi nts i ncl u d es t h e f oll o wi n g c o nsi d er ati o ns: • T h e y ar e cli nic ally r el e v a nt a n d a d dr ess i m p ort a nt s af et y a n d eff ectiv e n ess as p ects of t h e M e dtr o nic H ar m o ny T P V s yst e m. • T h e y ar e o bj ecti v el y d efi n e d a n d m e as ur a bl e i n t h e m aj ority of s u bj ects. • T h e y ar e c o nsist e nt wit h c urr e nt e n d p oi nts i n T P V cli nic al st u di es."
14,page_14,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 5 of 1 2 1 T his is a pr os p ecti v e, n o n -r a n d o miz e d, m ulti -c e nt er st u dy. U p t o 4 0 s u bj ects will b e i m pl a nt e d at a t ot al u p t o 1 5 c e nt ers i n t h e U nit e d St at es, C a n a d a, a n d J a p a n. It is a ntici p at e d t h at m or e t h a n 4 0 s u bj ects will b e e n r oll e d (i. e. c o ns e nt e d) t o m e et t h e t ar g et of u p t o 4 0 i m pl a nts as n ot all s u bj ects will b e a n at o mic all y s uit a bl e f or i m pl a nt ati o n. N o sit e s h all i m pl a nt m or e t h a n 1 0 s u bj ects i n t h e pi v ot al c o h ort t o av oi d bi as of t h e st u dy r es ults. S u bj ects w h o disc o nti n u e p artici p ati o n pr e m at ur el y f oll o wi n g i m pl a nt will b e i ncl u d e d i n t h e a n alysis of r es ults ( as a p pr o pri at e) a n d will n ot b e r e pl ac e d i n t h e e nr oll m e nt of t ot al st u dy s u bj ects i m pl a nt e d. All i m pl a nt e d s u bj ects will r ec ei v e t h e H ar m o ny T P V. E ac h i m pl a nt e d s u bj ect will b e f oll o w e d f or fi v e y e ars or u ntil t h e s u bj ect's H ar m o ny T P V is ex pl a nt e d. T h e a d diti o n of t h e s ec o n d d e vic e siz e ( H ar m o ny T P V 2 5) is i nt e n d e d t o ex p a n d t h e n u m b er of p ati e nts a n at o mic all y s uit a bl e f or i m pl a nt ati o n a n d will i ncl u d e a R oll -I n c o h ort of H ar m o ny T P V 2 5 s u bj ects. T h e R oll -I n p h as e is d escri b e d i n S ecti o n 8. 4. H ar m o n y T P V 2 5 R oll -I n P h as e . T h e a d diti o n of t h e l ar g er siz e d v al v e c o m pl et e d t h e piv ot al c o h ort of 4 0. F oll o wi n g t h e c o m pl eti o n of t h e 4 0 piv ot al c o h ort of t h e T P V 2 2 a n d T P V 2 5, t h e T P V 2 5 w as m o difi e d a n d is r ef err e d t o as m o difi e d T P V 2 5 ( m T P V 2 5). T h er e will b e a n a d d e d c o h ort of u p t o 1 5 s u bj ects i m pl a nt e d wit h t h e m T P V 2 5. T his a d diti o n al c o h ort will i ncl u d e 1 0 U S i m pl a nts a n d u p t o 5 O U S i m pl a nts fr o m C a n a d a a n d/ or J a p a n. T h e m T P V 2 5 c o h ort is d escri b e d i n S ecti o n 8. 5. A d diti o n of m T P V 2 5 C o h ort . T h e st u dy m et h o ds i ncl u d e t h e f oll o wi n g m e as ur es t o mi ni miz e p ot e nti al s o urc es of bi as: • A Scr e e ni n g C o m mitt e e c o m pris e d of a s u bs et of st u dy i n v esti g at ors will c o nfir m s u bj ect eli gi bilit y a n d a n at o mic s uit a bilit y • A n ext er n al, i n d e p e n d e nt Cli nic al E v e nts C o m mitt e e ( C E C) will r e vi e w a n d a dj u dic at e, at mi ni m u m, all d e at hs a n d e n d p oi nt r el at e d a d v ers e ev e nts. S af ety e n d p oi nt r es ults will b e b as e d o n C E C a dj u dic ati o ns. • All sit es will f oll o w a st a n d ar diz e d pr ot oc ol f or ac q uisiti o n of ec h oc ar di o gr a p hic e n d p oi nt d at a. • A n Ec h o C or e L a b will ev al u at e all ec h oc ar di o gr a ms. • A C M R C or e L a b will e v al u at e all f u ncti o n al C M R r es ults. • St u dy e n d p oi nts, w h e n a p pr o pri at e, will b e b as e d o n C E C or C or e L a b ass ess m e nts. • St u dy sit es will f oll o w t h eir i nstit uti o n al pr oc e d ur es f or m ai nt e n a nc e of ec h oc ar di o gr a p hy a n d i m a gi n g e q ui p m e nt us e d f or ass essi n g t h e st u dy v ari a bl es. 5. 1. D ur ati o n S u bj ects will b e c o ns e nt e d f or p ar tici p ati o n i n t h e st u dy f or f oll o w -u p t hr o u g h 5 y e ars. T h e e nr oll m e nt p eri o d f or t his st u dy is esti m at e d t o b e b et w e e n 1 8 t o 2 4 m o nt hs; t h er ef or e, t h e esti m at e d t ot al d ur ati o n of t h e st u dy (first s u bj ect e nr oll e d t o l ast s u bj ect c o m pl eti n g t h e l ast f oll o w -u p ex a m) is esti m at e d t o b e 7 y e ars. 5. St u d y D e si g n"
15,page_15,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 6 of 1 2 1 W h e n t h e H ar m o ny T P V s yst e m r ec ei v es m ark eti n g a p pr o v al d uri n g t h e c o urs e of t his cli nic al tri al, t h e f oll o w -u p ass ess m e nts will c o nti n u e u ntil all s u bj ects h a v e c o m pl et e d 5 y e ars of f oll o w -u p. 5. 2. R ati o n al e T h e cli nic al st u dy d esi g n f or t his st u dy ali g ns wit h ot h er T P V st u di es, i ncl u di n g t h e M e dtr o nic N ativ e O utfl o w Tr act Tr a nsc at h et er P ul m o n ary V alv e R es e arc h Cli nic al St u dy. R es ults fr o m t h e M e dtr o nic N ati v e O utfl o w Tr act Tr a nsc at h et er P ul m o n ar y V al v e R es e a rc h Cli nic al St u dy s u p p ort j ustific ati o n of f urt h er i nv esti g ati o n of t his d e vic e i n h u m a ns a n d d e m o nstr at e t h es e e v al u ati o ns of cli nic al d at a a r e r el e v a nt t o t h e pr o p os e d i n v esti g ati o n. 6. 1. G e n er al T h e H ar m o ny T P V ( M o d el N T P V 0 0 2 2) is c o m pris e d of a 2 2 m m p orci n e p eric ar di u m v al v e, s e w n t o a p ol y est er -c ov er e d as y m m etric al h o ur gl ass niti n ol fr a m e. T h e H ar m o ny T P V 2 5 a n d m T P V 2 5 ( M o d el H T P V 2 5 4 9 5 2 a n d H T P V 2 5 4 2 5 2, r es p ectiv ely) is c o m pris e d of a 2 5 m m p orci n e p eric ar di u m v al v e, s e w n t o a p ol y est er c o v er e d asy m m etric al h o ur gl ass niti n ol fr a m e wit h l ar g er di a m et er i nfl o w a n d o utfl o w as w ell as s h ort er l e n gt h c o m p ar e d t o T P V 2 2. All T P V siz es ar e pr oc ess e d w it h a n a nti -mi n er aliz ati o n tr e at m e nt of al p h a -a mi n o ol eic aci d ( A O A ®), a c o m p o u n d d eri v e d fr o m ol eic aci d, a n at ur ally occ urri n g l o n g -c h ai n f atty aci d. T h e H ar m o ny D eliv ery S yst e m ( D S) f or t h e T P V 2 2, T P V 2 5, a n d m T P V 2 5 ( N T P V D S 0 0 2 2 a n d H T P V D S 0 0 2 5) ar e all 2 5 Fr d eliv ery s yst e ms usi n g a c oil l o a di n g c at h et er. R ef er t o t h e H ar m o ny T P V a n d D S I nstr ucti o ns f or Us e (I F U) d oc u m e nts f or e ac h d e vic e f or f ull i nf or m ati o n r e g ar di n g t h e pr o d uct, w hic h i ncl u d es a d escri pti o n of t h e pr o d ucts b ei n g i n v esti g at e d, m a n uf ac t ur er i nf or m ati o n, p ac k a gi n g i nf or m ati o n, i nt e n d e d p o p ul ati o n d escri pti o n, a n d i nstr ucti o ns f or pr o d uct us e. 6. 2. P a c k a gi n g L a b eli n g of t h e H ar m o ny T P V syst e m will b e pr ovi d e d i n E n glis h a n d t h e l oc al l a n g u a g e, if n e e d e d acc or di n g t o l oc al r e q uir e m e nts. T h e l a b eli n g will i n dic at e t h at t h e d e vic e is f or i n v esti g ati o n al us e o nl y, a n d o nl y t o b e us e d by q u alifi e d i n v esti g at ors, a n d c o nsist e nt wit h t h e r e q uir e m e nts of t h e g e o gr a p hi es w h er e t h e tri al is c o n d uct e d. T h e I F U f or t h e H ar m o ny T P V s yst e m us e d i n t his tri al will b e pr ovi d e d as a s e p ar at e d oc u m e nt. If c h a n g es ar e m a d e t o t h e l a b eli n g, t h e y will b e pr ovi d e d u n d er s e p ar at e c ov er t o t h e a p pr o pri at e a ut h oriti es p er l oc al r e q uir e m e nts. 6. Pr o d u ct D e s cri pti o n"
16,page_16,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 7 of 1 2 1 6. 3. Pr o d u ct Tr ai ni n g R e q uir e m e nt s Pri or t o first p ati e nt i m pl a nt at a n i nv esti g ati v e sit e, M e dtr o nic will pr o vi d e pr o d uct tr ai ni n g t o t h e i m pl a nti n g p hysici a n(s). I m pl a nti n g p hysici a ns will r ec ei v e di d actic pr o d uct tr ai ni n g a n d h a n ds -o n d e vic e tr ai ni n g. At a mi ni m u m, t h e first c as e at e ac h i nv esti g ati v e sit e f or e ac h v alv e siz e will b e s u p p ort e d b y a n ex p eri e nc e d H ar m o ny T P V i m pl a nt er. A d dit i o n al i m pl a nt s u p p ort m a y b e pr ovi d e d as n e e d e d. 6. 4. Pr o d u ct A c c o u nt a bilit y T h e H ar m o ny T P V a n d D S ar e n ot a p pr ov e d f or us e i n a ny g e o gr a p hy, a n d t h er ef or e ar e c o nsi d er e d i nv esti g ati o n al d evic es. T h e i nv esti g at or s h all m ai nt ai n a d e q u at e r ec or ds of t h e r ec ei pt a n d dis p ositi o n of all i nv esti g ati o n al d e vic es. C e nt ers ar e r e q uir e d t o m ai nt ai n i n v esti g ati o n al d e vic e r ec or ds t h at c o nt ai n t h e f oll o wi n g i nf or m ati o n: • I nv esti g ati o n al d evic e n a m e • D evic e s eri al n u m b er ( w h e n a p plic a bl e) • L ot n u m b er ( w h e n a p plic a bl e) • Us e by d at e • D at e of r ec ei pt of d evic e • N a m e of p ers o n r ec ei vi n g t h e d e vic e • N a m e of p ers o n usi n g t h e d e vic e ( w h e n a p plic a bl e) • D at e of us e ( w h e n a p plic a bl e) • I D n u m b er of s u bj ect r ec eivi n g t h e d e vic e ( w h e n ap plic a bl e) • Dis p ositi o n ( u n us e d, dis p os e d of, i m pl a nt e d, or r et ur n e d t o M e dtr o nic) F or d evic es t h at ar e r et ur n e d t o M e dtr o nic or dis p os e d of, c e nt ers ar e r e q uir e d t o d oc u m e nt t h e f oll o wi n g a d diti o n al i nf or m ati o n: • T h e q u a ntit y a n d r e as o n f or t h e d evic e b ei n g r et ur n e d t o M e dtr o nic or dis p os e d of • N a m e of t h e p ers o n w h o dis p os e d of e ac h d evic e • D at e of s hi p m e nt b ac k t o M e dtr o nic At t h e c o m pl eti o n of t h e st u dy i m pl a nt p eri o d, t h e i nv esti g at or m ust r et ur n all u n us e d d e vic es a n d a c o py of t h e c o m pl et e d d evic e i nv e nt or y t o M e dtr o nic. T h e i nv esti g at or’s c o py of t h e d e vic e r ec o ncili ati o n r ec or ds m ust d oc u m e nt a ny u n us e d d evic es t h at h a v e b e e n r et ur n e d t o M e dtr o nic as w ell as all pr o d uct us a g e i ncl u di n g o p e n e d b ut n o n -i m pl a nt e d d evic es."
17,page_17,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 8 of 1 2 1 6. 5. Pr o d u ct St or a g e T h e H ar m o ny T P V a n d D S ar e n ot a p pr ov e d f or us e i n a ny g e o gr a p hy, a n d t h er ef or e ar e c o nsi d er e d i nv esti g ati o n al d evic es. As s uc h, t h e y s h o ul d b e st or e d as l a b el e d a n d i n a s ec ur e/l oc k e d st or a g e ar e a wit h acc ess li mit e d o nly t o a p pr o v e d st u dy st aff. T h e m et h o d of st or a g e s h o ul d pr e v e nt t h e us e of t h es e i nv esti g ati o n al d evic es f or a p plic ati o ns ot h er t h a n d escri b e d i n t his Cli nic al I nv esti g ati o n Pl a n ( CI P). T h e i nv esti g at or s h all m ai nt ai n a d e q u at e r ec or ds of t h e r ec ei pt a n d dis p ositi o n of all i nv esti g ati o n al d evic es. 6. 6. Pr o d u c t R et ur n I n t h e e v e nt of a d e vic e m alf u ncti o n of t h e H ar m o ny T P V syst e m pri or t o i m pl a nt, or i n t h e ev e nt t h e H ar m o ny T P V is ex pl a nt e d aft er i m pl a nt ( d u e t o r ei nt er v e nti o n or a ut o psy), t h e H ar m o ny T P V a n d/ or aff ect e d c o m p o n e nts s h o ul d b e s e nt t o M e dtr o nic. A d diti o n al d et a ils s urr o u n di n g t h e d evic e r et ur n pr oc ess ar e c o nt ai n e d wit hi n t h e M e dtr o nic ex pl a nt kit t h at will b e pr ovi d e d u p o n n otific ati o n of a d e vic e m alf u ncti o n or ex pl a nt. T o o bt ai n a pr o d uct r et ur n kit, c o nt act a M e dtr o nic R e pr es e nt ativ e. If a k it is n ot av ail a b l e, pl ac e t h e ex pl a nt e d v al v e i n a c o nt ai n er of gl ut ar al d e h y d e or 1 0 % b uff er e d f or m ali n i m m e di at el y aft er excisi o n. S p ecific p at h ol o gic al st u di es of a n ex pl a nt e d v alv e will b e c o n d uct e d u n d er t h e dir ecti o n of a c o ns ulti n g p at h ol o gist. A w ritt e n s u m m ar y of t h e fi n di n gs will b e r et ur n e d t o t h e p hysici a n. F or s p ecific i nstr ucti o ns r e g ar di n g ex pl a nt, r ef er t o A p p e n di x I X: E X PL A N T P R O T O C OL . 7. 1. St u d y P o p ul ati o n T h e p o p ul ati o n i ncl u d es p ati e nts w h o h av e c o n g e nit al h e art dis e as e a n d ar e cli nic all y i n dic at e d f or p ul m o n ary v alv e r e pl ac e m e nt. 7. 2. S u bj e ct E nr oll m e nt T h e pr oc ess of s u bj ect e nr oll m e nt is as f oll o ws: 7. S el e cti o n of S u bj e ct s"
18,page_18,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 9 of 1 2 1 1. P ati e nts i d e ntifi e d b y or pr es e nt e d t o t h e st u dy sit e w h o h a v e c o n g e nit al h e art dis e as e a n d ar e cli nic all y i n dic at e d f or p ul m o n ar y v alv e r e pl ac e m e nt will b e scr e e n e d by t h e i n v esti g at or or d esi g n e e f or t h e crit eri a d escri b e d i n S ecti o n 7. 3 . I ncl usi o n Crit eri a a n d S ecti o n 7. 4 . E xcl usi o n Crit eri a , usi n g av ail a bl e m e dic al r ec or ds, i ncl u di n g r el ev a nt i m a gi n g st u di es pr e vi o usl y p erf or m e d f or di a g n ostic p ur p os es. 2. If t h e p ati e nt is d e e m e d a p ot e nti al c a n di d at e f or t h e st u dy, t h e i nv esti g ati o n al st at us of t h e H ar m o ny T P V a n d all as p ects of t h e st u dy will b e ex p l ai n e d t o t h e p ati e nt. T h e p ati e nt will t h e n b e i nvit e d t o p artici p at e i n t h e st u dy. 3. If t h e p ati e nt a gr e es t o p artici p at e, writt e n i nf or m e d c o ns e nt will b e o bt ai n e d. T his will b e c o nsi d er e d t h e p oi nt of e nr oll m e nt, a n d t h e s u bj ect will b e assi g n e d a s u bj ec t I D n u m b er. 7. 3. I n cl u si o n Crit eri a • S u bj ect h as p ul m o n ary r e g ur git ati o n as p er o n e or m or e of t h e f oll o wi n g crit eri a: o S e v er e p ul m o n ar y r e g ur git ati o n as m e as ur e d by c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy, or o P ul m o n ar y r e g ur git a nt fr acti o n ≥ 3 0 % as m e as ur e d b y c ar di ac m a g n etic r es o n a nc e i m a gi n g • Cli nic al i n dic ati o n f or s ur gic al pl ac e m e nt of a R V -P A c o n d uit or pr ost h etic p ul m o n ar y v al v e p er o n e or m or e of t h e f oll o wi n g crit eri a: o S u bj ect is sy m pt o m atic s ec o n d ar y t o p ul m o n ar y i ns uffici e nc y ( e. g. ex ercis e i nt ol er a nc e, fl ui d o v erl o a d) as cl assifi e d b y t h e i n v esti g at or, or o S u bj ect h as ri g ht v e ntric ul ar e n d di ast olic v ol u m e i n d ex ( R V E D Vi) ≥ 1 5 0 ml / m 2, or o S u bj ect h as R V E D V: L V E D V R ati o ≥ 2. 0 • S u bj ect is willi n g t o c o ns e nt t o p artici p at e i n t h e st u dy a n d will c o m mit t o c o m pl eti o n of all f oll o w -u p r e q uir e m e nts 7. 4. E x cl u si o n Crit eri a • A n at o m y u n a bl e t o acc o m m o d at e a 2 5 Fr d eliv ery syst e m • O bstr ucti o n of t h e c e ntr al v ei ns • Cli nic al or bi ol o gic al si g ns of i nf ecti o n i ncl u di n g activ e en d oc ar ditis • Pl a n n e d c o nc o mit a nt pr oc e d ur e at ti m e of H ar m o ny T P V i m pl a nt • P ositi v e pr e g n a ncy t est at b as eli n e ( pri or t o C T a n gi o gr a p hy a n d a g ai n pri or t o i m pl a nt pr oc e d ur e) i n f e m al e s u bj ects of c hil d b e ari n g p ot e nti al • P ati e nts wit h ri g ht v e ntric ul ar o utfl o w tr act o bstr ucti o n ( R V O T O) l esi o ns s ur gic ally tr e at e d wit h a R V - P A c o n d uit i m pl a nt • A m aj or or pr o gr essiv e n o n -c ar di ac dis e as e ( e. g. liv er f ail ur e, r e n al f ail ur e, c a nc er) t h at r es ults i n a lif e ex p ect a nc y of l ess t h a n o n e y e ar • Pl a n n e d i m pl a nt ati o n of t h e H ar m o ny T P V i n t h e l eft h e art"
19,page_19,
20,page_20,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 1 of 1 2 1 5 If a C M R f u ncti o n al ex a m h as b e e n p erf or m e d f or r o uti n e d i a g n ostic p ur p os es pri or t o c o ns e nti n g, it c a n b e us e d as t h e pr e - i m pl a nt C M R f u ncti o n al ex a m, pr o vi d e d it w as p erf or m e d wit hi n 5 2 w e eks pri or t o i m pl a nt. T h e Pri nci p al I nv esti g at or m ust d et er mi n e if t h e ex a m c o nt ai ns t h e pr ot oc ol -r e q uir e d d at a a n d r e m ai n s a d e q u at e f or s u bj ect ev al u ati o n. 6 F u ncti o n al C M R at t h e 1 m o nt h visit will b e r e q uir e d f or s u bj ects i m pl a nt e d wit h m T P V 2 5. 7 C T p ost i m pl a nt wi ll b e r e q uir e d f or s u bj ects i m pl a nt e d wit h T P V 2 5 w h o ar e p artici p ati n g i n t h e P ost I m pl a nt C T s u b -st u dy f oll o wi n g A p p e n di x XII . 8 If a C T c ar di ac a n gi o gr a p hy ex a m h as pr evi o usl y b e e n p erf or m e d pri or t o c o ns e nti n g, it c a n b e us e d as t h e pr e -i m pl a nt C T ex a m, pr o vi d e d it w as p erf or m e d wit hi n 2 y e ars pri or t o i m pl a nt. T h e Pri nci p al I n v esti g at or m ust d et er mi n e if t h e ex a m c o nt ai ns t h e pr ot oc ol -r e q uir e d d at a a n d r e m ai ns a d e q u at e f or s u bj ect ev al u ati o n ( e. g. s u bj ect h as n ot u n d er g o n e si g nific a nt gr o wt h i n t h e i nt eri m). Pr e -i m pl a nt C T a n gi o gr a p hy will f oll o w A p p e n dix VII. 9 C T at disc h ar g e will b e r e q uir e d f or s u bj ects i m pl a nt e d wit h t h e m T P V 2 5 w h o ar e p artici p ati n g i n t h e P ost I m pl a nt C T s u b -st u dy f oll o wi n g A p p e n di x XII . 1 0 S F -3 6 is s uit a bl e f or s elf -a d mi nistr ati o n or a d mi nistr ati o n by a n i nt er vi e w er i n p er s o n or by t el e p h o n e. 1 1 T h e pr e -i m pl a nt S F -3 6 c a n b e a d mi nist er e d aft er a s u bj ect h as b e e n ev al u at e d by t h e scr e e ni n g c o m mitt e e b ut pri or t o i m pl a nt. 1 2 I nv esti g at ors ar e r e q uir e d t o ev al u at e a n d d oc u m e nt i n t h e s u bj ect’s m e dic al r ec or ds all a dv ers e ev e nts a n d d evic e d efici e nci es o bs er v e d i n st u dy s u bj ects fr o m t h e ti m e t h ey ar e e nr oll e d (c o ns e nt e d) u ntil t h ey ar e exit e d fr o m t h e st u dy. 8. 2. S u bj e ct C o n s e nt Pri or t o e nr olli n g i n t h e st u dy, p ati e nts s h o ul d b e f ull y i nf or m e d of t h e d et ails of st u dy p artici p ati o n as r e q uir e d b y a p plic a bl e r e g ul ati o ns, t h e sit e’s I R B/ E C a n d b y M e dtr o nic. I nf or m e d c o ns e nt m ust b e o bt ai n e d fr o m e ac h p ati e nt or l e g all y a ut h oriz e d r e pr es e nt ativ e pri or t o c o n d ucti n g a n y pr ot oc ol - i n d uc e d acti viti es b e y o n d st a n d ar d of c ar e, by usi n g t h e i nf or m e d c o ns e nt f or m (I C F) a p pr ov e d b y t h at sit e’s I R B/ E C a n d b y M e dtr o nic. T h e I C F m ust b e si g n e d a n d d at e d b y t h e p ati e nt or l e g al r e pr es e nt ativ e. A ny a d diti o n al p ers o ns r e q uir e d b y t h e sit e’s I R B/ E C t o si g n t h e i nf or m e d c o ns e nt f or m m ust als o c o m pl y. I n J a p a n, t h e r el ati o ns hi p b et w e e n t h e p ati e nt a n d l e g al r e pr es e nt ati v e m ust b e d oc u m e nt e d i n t h e I C F a n d I C pr oc ess if a l e g al r e pr es e nt ativ e si g n e d t h e I C F. T his st u dy h as t h e p ot e nti al t o i ncl u d e i n di vi d u als t h at m ay b e c o nsi d er e d v ul n er a b l e. T h e I nv esti g at or s h o ul d c o nsi d er t h e d efi niti o n of v ul n er a bl e p er I S O 1 4 1 5 5, w hic h d efi n es v ul n er a bl e p ati e nts as: “t h os e p ati e nts t h at c o ul d b e u n d ul y i nfl u e nc e d b y t h e ex p ect ati o n or b e n efits ass oci at e d wit h p artici p ati o n or of r et ali at or y r es p o ns e f r o m s e ni or m e m b ers of a hi er arc h y i n c as e of r ef us al t o p artici p at e. F or ex a m pl e, t his c o ul d i ncl u d e I n di vi d u als wit h l oss of a ut o n o m y d u e t o i m m at urity or t hr o u g h m e nt al dis a bilit y, p ers o ns i n n ursi n g h o m es, c hil dr e n, i m p ov eris h e d p ers o ns, s u bj ects i n e m e r g e nc y sit u ati o ns, et h nic mi n ority gr o u ps, h o m el ess p ers o ns, n o m a ds, r ef u g e es, a n d t h os e i nc a p a bl e of givi n g i nf or m e d c o ns e nt. Ot h er v ul n er a bl e s u bj ects c o ul d i ncl u d e, f or ex a m pl e, m e m b ers of a gr o u p wit h a hi er arc hic al str uct ur e s uc h as u ni v ersity st u d e nt s, s u b or di n at e h os pit al a n d l a b or at ory p ers o n n el, e m pl oy e es of t h e s p o ns or, m e m b ers of t h e ar m e d f orc es, a n d p ers o ns k e pt i n d et e nti o n.” A ny a d diti o n al r e q uir e m e nts by t h e sit e’s I R B/ E C or l oc al r e g ul ati o ns r e g ar di n g t h e i nf or m e d c o ns e nt pr oc ess r e q uir e m e n ts r el ati n g t o v ul n er a bl e p o p ul ati o ns m ust b e f oll o w e d. I nf or m e d ass e nt s h o ul d b e c o nsi d er e d d e p e n di n g o n t h e a g e a n d u n d erst a n di n g of t h e s u bj ect p er I R B/ E C r e q uir e m e nt a n d l oc al r e g ul ati o ns or w h e n t h e i n v esti g at or f e els t h at a mi n or c a n n ot u n d erst a n d th e c o nt e nt of t h e I C F s uffici e ntl y b ef or e a mi n or will b e e nr oll e d i n t h e st u dy. W h e n r e q uir e d, i nf or m e d ass e nt m ust b e o bt ai n e d usi n g t h e I R B/ E C a p pr o v e d f or m."
21,page_21,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 2 of 1 2 1 Pri or t o t h e p ati e nt or l e g al r e pr es e nt ativ e si g ni n g t h e I C F, t h e i nv esti g at or or a ut h oriz e d d esi g n e e will full y ex pl ai n t o t h e p ati e nt or l e g al r e pr es e nt ativ e t h e n at ur e of t h e r es e arc h, st u dy pr oc e d ur es, a ntici p at e d b e n efits, a n d p ot e nti al ris ks of p artici p ati o n i n t h e st u dy. T h e i n v esti g at or or d esi g n e e will all o w a d e q u at e ti m e f or t h e p ati e nt or l e g al r e pr es e nt ati v e t o r e a d t h e c o ns e nt f or m a n d t o ask q u esti o ns. Si g ni n g t h e I C F s er v es t o d oc u m e nt t h e writt e n a n d v er b al i nf or m ati o n t h at t h e i n v esti g at or or d esi g n e e pr o vi d e d t o t h e p ati e nt or l e g al r e pr es e nt ati v e, t h e p ati e nt or l e g al r e pr es e nt ati v e’s u n d erst a n di n g of t h e i nf or m ati o n, a n d t h eir a gr e e m e nt t o p artici p at e. T h e c as e hist or y f or e ac h p ati e nt s h all d oc u m e nt t h e e ntir e i nf or m e d c o ns e nt pr oc ess i ncl u di n g w h o p artici p at e d i n t h e c o ns e nt disc ussi o ns a n d t h at i nf or m e d c o ns e nt w as o bt ai n e d pri or t o p artici p ati o n i n t h e st u dy. T h e ori gi n al si g n e d c o ns e nt f or m will b e r et ai n e d i n t h e p ati e nt’ s st u dy r ec or ds a n d a c o py of t h e i nf or m e d c o ns e nt will b e pr o vi d e d t o t h e p ati e nt or l e g al r e pr es e nt ativ e. T h e p oi nt at w hic h t h e I C F ( a n d i nf or m e d ass e nt as a p plic a bl e) is ex ec ut e d b y all p arti es will b e c o nsi d er e d t h e p oi nt of e nr oll m e nt f or t his st u dy , a n d t h e s u bj ect will b e assi g n e d a s u bj ect I D n u m b er. T h e I C F will b e r e vis e d w h e n e v er i m p ort a nt n e w i nf or m ati o n b ec o m es a v ail a bl e, or t h er e is a n a m e n d m e nt t o t h e pr ot oc ol w hic h n ec essit at es a c h a n g e t o t h e I C F. All r evisi o ns t o t h e c o ns e nt f or m m ust b e a p pr ov e d i n a dv a nc e by t h e I R B/ E C a n d l oc al r e g ul at ory b o dy, as a p pr o pri at e. T h e s u bj ect s h o ul d b e r e -c o ns e nt e d acc or di n g t o I R B/ E C r e q uir e m e nts f oll o wi n g t h e pr oc ess as d escri b e d a b ov e. If r e q uir e d, t h e i n v esti g at or or d esi g n e e s h o ul d r e -c o ns e nt t h e s u b j ect i n a ti m ely m a n n er. 8. 3. S u bj e ct S cr e e ni n g All c o ns e nt e d s u bj ects will b e assi g n e d a s u bj ect I D a n d will b e c o nsi d er e d e nr oll e d i nt o t h e st u dy. All c o ns e nt e d s u bj ects w h o exit t h e st u dy pri or t o st u dy c o m pl eti o n will h av e t h e r e as o n f or exit d oc u m e nt e d o n t h e St u dy Exit c as e r e p ort f or m as w ell as i n t h e m e dic al r ec or d. Aft er o bt ai ni n g i nf or m e d c o ns e nt, t h e f oll o wi n g pr oc ess f or p ati e nt scr e e ni n g will b e f oll o w e d: 1. T h e st u dy sit e will assi g n a u ni q u e s u bj ect I D n u m b er t o all e nr oll e d (c o ns e nt e d) s u bj ects. 2. T h e s u bj ect will h a v e tr a nst h or acic ec h oc ar di o gr a p hy 2 ( T T E) a n d c ar di ac m a g n etic r es o n a nc e ( C M R) ex a ms 3 t o a ss ess p ul m o n ary r e g ur git ati o n a n d R V siz e a n d f u ncti o n, if n ot alr e a d y perf or m e d p er r e q uir e m e nts gi v e n i n 3. S u bj ects t h at d o n ot m e et ec h oc ar di o gr a p hic a n d/ or C M R crit eri a will b e exit e d fr o m t h e st u dy. S u bj ects t h at m e et t h e ec h oc ar di o gr a p hic a n d C M R crit eri a will u n d er g o b as eli n e c ar di ac"
22,page_22,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 3 of 1 2 1 c o m p ut e d t o m o gr a p hy ( C T) a n gi o gr a p hy p er 4. A n at o mic m e as ur e m e nts will b e p erf or m e d b y M e dtr o nic fr o m t h e C T i m a g es a n d e v al u at e d p er d e vic e sizi n g g ui d eli n es gi v e n i n 5. It is p ossi bl e t h at s u bj ects d e e m e d eli gi bl e f or i m pl a nt m ay n ot m e et all sizi n g g ui d eli n es d u e t o v ari ati o n i n R V O T a n at o m y. T h e i nv esti g at or c a n us e t h e crit eri a d escri b e d i n as a g ui d eli n e t o ass ess t h e s u bj ect’s c a n di d ac y f or T P V i m pl a nt ati o n 6. M e dtr o nic will pr ovi d e t h e sizi n g e v al u ati o n ( p eri m et er pl ot) t o t h e i n v esti g at or. If t h e I nv esti g at or c o nsi d ers t h e s u bj ect a n at o mic all y s uit a bl e f or i m pl a nt ati o n of t h e H ar m o ny T P V, t h e f oll o wi n g cli nic al i nf or m ati o n fr o m t h e s u bj ect will b e s u b mitt e d t o t h e Scr e e ni n g C o m mitt e e: a. Cli nic al ass ess m e nts a n d m e dic al hist ory b. Ec h oc ar di o gr a p hic, C M R, a n d C T d at a o n a n at o mic al s uit a bilit y 7. T h e Scr e e ni n g C o m mitt e e will r evi e w t h e scr e e ni n g d at a a n d pr ovi d e a r ec o m m e n d ati o n t o t h e i nv esti g at or, i ncl u di n g v al v e siz e, w h o will m a k e t h e fi n al d et er mi n ati o n of i m pl a nt ati o n s uit a bilit y. If it is d et er mi n e d t h e s u bj ect’s a n at o m y is n ot s uit a bl e f or i m pl a nt ati o n, t h e s u bj ect will b e exit e d fr o m t h e st u dy. S u bj ects ori gi n ally scr e e n e d f or T P V 2 2 w h o w er e exit e d d u e t o scr e e n f ail ur e m a y b e r e -scr e e n e d f or T P V 2 5 or m T P V 2 5 aft er b ei n g r e -c o ns e nt e d. F or t h os e su bj ects r e -scr e e n e d, a u ni q u e s u bj ect I D will b e assi g n e d. 8. S u bj ects w h o ar e d et er mi n e d t o b e d evic e c a n di d at es by t h e i nv esti g at or ar e eli gi bl e f or c ar di ac c at h et eriz ati o n a n d H ar m o ny T P V i m pl a nt ati o n. I m pl a nt att e m pt is c o nsi d er e d t h e p oi nt at w hic h t h e i nv esti g ati o n al pr o d uct is i ntr o d uc e d i nt o t h e s u bj ect’s b o dy. I m pl a nt ati o n pr oc e d ur es ar e d escri b e d i n t h e I F U d oc u m e nt. 8. 4. H ar m o n y T P V 2 5 R oll -I n P h a s e Pri or t o a n y i m pl a nt of t h e H ar m o ny T P V 2 5, t h er e w ill b e a R oll -I n p h as e t o i ncl u d e a c o h ort of s u bj ects f or t h e i m pl a nt of t h e T P V 2 5. R oll -i n O bj e cti v e s: T h e o bj ectiv e of t h e H ar m o ny T P V 2 5 R oll -I n P h as e is t o c o nfir m t h e pr oc e d ur al f e asi bilit y, h e m o dy n a mic p erf or m a nc e a n d s af et y pr ofil e of t h e H ar m o ny T P V 2 5 pri or t o t h e H ar m o ny T P V 2 5 b ec o mi n g a v ail a bl e f or i m pl a nt at all sit es. Als o, t h e R oll -I n p h as e is i nt e n d e d pr ovi d e St u dy Pr oct ors f a mili arity a n d a d d e d ex p ertis e i n t h e i m pl a nt t ec h ni q u e f or H ar m o ny T P V 2 5 pri or t o pr oct ori n g all sit es i n i m pl a nt i n g t h e H ar m o ny T P V 2 5. R oll -i n M et h o d ol o g y: S u bj ects e nr oll e d i n t h e R oll -i n p h as e will f oll o w all m et h o ds a n d pr oc e d ur es acc or di n g t o t h e CI P. T his s ecti o n will pr ovi d e i nf or m ati o n o n m et h o ds a n d r e q uir e m e nts s p ecific t o t h e R oll -i n p h as e of t h e st u dy."
23,page_23,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 4 of 1 2 1 R oll -i n P h as e D esi g n: T h e R oll -i n p h as e is s p ecific t o t h e i niti al i m pl a nts of t h e H ar m o ny T P V 2 5, t o c o nfir m t h e pr oc e d ur al f e asi bilit y, h e m o dy n a mic p erf or m a nc e a n d s af et y pr ofil e of t h e d e vic e b ef or e all sit es c a n i m pl a nt t h e H ar m o ny T P V 2 5. T his p h as e of i niti al H ar m o ny T P V i m pl a nts will b e li mit e d t o t h e i n v esti g ati v e sit es wit h ex p eri e nc e d i m pl a nt ers ( St u dy Pr oct ors). I n v esti g ati v e Sit es: T h e R oll -i n s u bj ects will b e i m pl a nt e d at u p t o f o ur i nv esti g ativ e sit es w h er e t h e i m pl a nti n g p hysici a n is a n ex p eri e nc e d i m pl a nt er a n d is c urr e ntl y pr oct ori n g ot h er sit es o n t h e H ar m o ny T P V i m pl a nt ati o n pr oc e d ur e ( St u dy Pr oct or). N u m b er of S u bj ects: A mi ni m u m of fiv e a n d u p t o ei g ht q u alif yi n g s u bj ects will b e i m pl a nt e d wit h t h e H ar m o ny T P V 2 5 at u p t o f o ur St u dy Pr oct or sit es. E ac h St u dy P r oct or sit e c a n i m pl a nt u p t o t hr e e s u bj ects. S u bj ect S el ecti o n Crit eri a Pr os p ectiv e s u bj ects f or t h e R oll -i n p h as e m ust m e et all s u bj ect s el ecti o n crit eri a f or e nr oll m e nt i n t h e M e dtr o nic H ar m o ny T P V Cli nic al St u dy (s e e S ecti o n 7. S el ecti o n of S u bj ects ). I nf or m e d C o ns e nt: Pri or t o e nr olli n g i n t h e st u dy, p ati e nts will b e f ull y i nf or m e d of t h e d et ails of st u dy p artici p ati o n i n t h e R oll -I n P h as e as r e q uir e d by a p plic a bl e r e g ul ati o ns, t h e sit e’s I R B/ E C a n d b y M e dtr o nic. Scr e e ni n g a n d E nr oll m e nt: S e e S ecti o n 7. S el ecti o n of S u bj ects f or scr e e ni n g a n d e nr oll m e nt i nf or m ati o n. R oll -i n C o h ort A n al y si s: T h e pr oc e d ur al f e asi bilit y, a n d h e m o dy n a mic p erf or m a nc e a n d s af et y pr ofi l e at h os pit al disc h ar g e f oll o wi n g H ar m o ny T P V 2 5 i m pl a nt ati o n of t h e R oll -I n c o h ort will b e a n alyz e d . T h e o utc o m e m e as ur es ar e d efi n e d as: Pr oc e d ur al F e asi bilit y: • N o d evic e - or pr oc e d ur al -r el at e d m ort ality, wit h • s ucc essf ul acc ess, d eliv ery a n d r e m o v al of t h e d eli v ery s yst e m, a n d • d e pl o y m e nt a n d c orr ect p ositi o ni n g (i ncl u di n g mi n or r e p ositi o ni n g if n e e d e d ) of t h e d e vic e. H e m o d y n a mic P erf or m a nc e: • M e a n R V O T gr a di e nt ≤ 4 0 m m H g as m e as ur e d b y ec h oc ar di o gr a p hy S af et y Pr ofil e: N o n e of t h e f oll o wi n g d e vic e - or pr oc e d ur e -r el at e d s eri o us a d v ers e ev e nts:"
24,page_24,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 5 of 1 2 1 • Lif e -t hr e at e ni n g m aj or bl e e d • M aj or v asc ul ar or c ar di ac str uct ur al c o m plic ati o ns r e q uir e d u n pl a n n e d r ei nt er v e nti o n or s ur g ery • P ul m o n ar y e m b olis m R oll -i n c o h ort s u bj ects will b e f oll o w e d p er t h e CI P. R oll -i n d at a f o r t h e f oll o w -u p p h as e will b e i ncl u d e d i n t h e 4 0 -s u bj ect pi v ot al c o h ort as a p pr ov e d b y F D A. If R oll -i n p h as e o utc o m e m e as ur es ar e m et a n d n o c o nc er ns ar e r ais e d by t h e D M C, St e eri n g C o m mitt e e or M e dtr o nic, t h e H ar m o ny T P V 2 5 will b e m a d e av ail a bl e t o all p artici p ati n g H ar m o ny T P V st u dy sit es. H ar m o ny T P V 2 5 s u bj ects i m pl a nt e d f oll o wi n g t h e R oll -i n p h as e will als o b e i ncl u d e d i n t h e 4 0 -s u bj ect pi v ot al c o h ort. 8. 5. A d diti o n of m T P V 2 5 C o h ort F oll o wi n g t h e c o m pl eti o n of t h e 4 0 piv ot al c o h ort of T P V 2 2 a n d T P V 2 5 , t h e T P V 2 5 w as m o difi e d. T h er e will b e a n a d d e d c o h ort of u p t o 1 5 s u bj ects i m pl a nt e d wit h t h e m T P V 2 5. T his a d diti o n al c o h ort will i ncl u d e 1 0 U S i m pl a nts a n d u p t o 5 O U S i m pl a nts fr o m C a n a d a a n d/ or J a p a n. m T P V 2 5 C o h ort O bj e cti v e s: T h e o bj ectiv e of t h e m T P V 2 5 a d diti o n is t o c o nfir m t h e pr oc e d ur al f e asi bility, h e m o dy n a m ic p erf or m a nc e, a n d s af et y pr ofil e of t h e m T P V 2 5. m T P V 2 5 M et h o d ol o g y: S u bj ects e nr oll e d i n t h e m T P V 2 5 c o h ort will f oll o w all m et h o ds a n d pr oc e d ur es acc or di n g t o t h e CI P. T his s ecti o n will pr ovi d e i nf or m ati o n o n m et h o ds a n d r e q uir e m e nts s p ecific t o t h e m T P V 2 5 c o h ort a d diti o n i nt o t h e st u dy. m T P V 2 5 St u d y D esi g n: T h e a d diti o n of t h e m T P V 2 5 c o h ort i nt o t h e st u dy will f oll o w t h e s a m e st u dy d esi g n of t h e st u dy d escri b e d i n S ecti o n 5. S el ecti o n of S u bj ects . I n v esti g ati v e Sit es: T h e st u dy sit es i ncl u d e 9 US sit es, 2 C a n a d a sit es, a n d 1 J a p a n sit e. N u m b er of S u bj ects: T h er e will b e 1 0 U S i m pl a nts a n d u p t o 5 O U S i m pl a nts fr o m C a n a d a a n d/ or J a p a n. S u bj ect S el ecti o n Crit eri a Pr os p ectiv e s u bj ects f or t h e m T P V 2 5 c o h ort m ust m e et all s u bj ect s el ecti o n crit eri a f or e nr oll m e nt i n t h e M e dtr o nic H ar m o ny T P V Cli nic al St u dy (s e e S ecti o n 7. S el ecti o n of S u bj ects )."
25,page_25,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 6 of 1 2 1 I nf or m e d C o ns e nt: Pri or t o e nr olli n g i n t h e st u dy, p ati e nts will b e f ull y i nf or m e d of t h e d et ails of st u dy p artici p ati o n i n t h e m T P V 2 5 c o h ort as r e q uir e d b y a p plic a bl e r e g ul ati o ns, t h e sit e’s I R B/ E C a n d b y M e dtr o nic. Scr e e ni n g a n d E nr oll m e nt: S e e S ecti o n 7. S el ecti o n of S u bj ects f or scr e e ni n g a n d e nr oll m e nt i nf or m ati o n. m T P V 2 5 C o h ort A n al y si s: T h e pr oc e d ur al f e asi bilit y, h e m o dy n a mic p erf or m a nc e, a n d s af et y pr ofil e of m T P V 2 5 at 1 m o nt h f oll o wi n g m T P V 2 5 i m pl a nt ati o n will b e a n alyz e d. T h e o utc o m e m e as ur es ar e d efi n e d as: Pr oc e d ur al F e asi bilit y: • N o d evic e - or pr oc e d ur al -r el at e d m ort ality, wit h • s ucc essf ul acc ess, d eliv ery a n d r e m o v al of t h e d eli v ery s yst e m, a n d • d e pl o y m e nt a n d c orr ect p ositi o ni n g (i ncl u di n g mi n or r e p ositi o ni n g if n e e d e d) of t h e d e vi c e. H e m o d y n a mic P erf or m a nc e: • M e a n R V O T gr a di e nt ≤ 4 0 m m H g as m e as ur e d b y ec h oc ar di o gr a p hy S af et y Pr ofil e: N o n e of t h e f oll o wi n g d e vic e - or pr oc e d ur e -r el at e d s eri o us a d v ers e ev e nts: • Lif e -t hr e at e ni n g m aj or bl e e d • M aj or v asc ul ar or c ar di ac str uct ur al c o m plic ati o ns r e q uir e d u n pl a n n e d r ei nt er v e nti o n or s ur g ery • P ul m o n ar y e m b olis m m T P V 2 5 s u bj ects will b e f oll o w e d p er t h e CI P. A s u p pl e m e nt al a n al ysis f or t h e m T P V 2 5 s u bj ects f or o utc o m es of pr oc e d ur al f e asi bilit y, h e m o dy n a mic p erf or m a nc e a n d s af et y pr ofil e will b e p erf or m e d s e p ar at ely w h e n m T P V 2 5 s u bj ects h av e b e e n f oll o w e d f or 1 m o nt h. 8. 6. I m pl a nt C at h eri z ati o n Pr o c e d ur e C ar di ac c at h et eriz ati o n is p erf or m e d acc or di n g t o t h e st a n d ar d pr oc e d ur es of t h e i nt er v e nti o n al c ar di ol o gist. D et ail e d o utli n e of t h e c at h et eriz ati o n pr oc e d ur e r ec o m m e n d ati o ns is pr ovi d e d i n t h e I F Us f or H ar m o ny T P V 2 2, H ar m o ny T P V 2 5, a n d H ar m o ny m T P V 2 5. T h e Pri nci p al I nv esti g at or is a ntici p at e d t o b e t h e pri m ar y o p er at or f or t h e i m pl a nt pr oc e d ur e m ust st a y c o nsist e nt t hr o u g h o ut t h e d ur ati o n of t h e st u dy f or all i m pl a nt e d p a ti e nts at e ac h sit e, u nl ess pri or"
26,page_26,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 7 of 1 2 1 a p pr o v al is r ec ei v e d fr o m M e dtr o nic. S u b -i nv esti g at ors wit h a p pr o pri at e tr ai ni n g a n d ex p eri e nc e m ay assist i n t h e i m pl a nt pr oc e d ur e at t h e discr eti o n o f t h e Pri nci p al I nv esti g at or. 8. 6. 1. P o st -Pr o c e d ur e C ar e P ost -pr oc e d ur e c ar e is c arri e d o ut acc or di n g t o t h e st a n d ar d p ost -pr oc e d ur e c ar e of t h e i nt erv e nti o n al c ar di ol o gist at his or h er discr eti o n. It is r ec o m m e n d e d i n v esti g at ors c o m ply wit h t h e A H A/ A C C g ui d eli n es f or bi o pr ost h etic tiss u e v alv es a n d pr escri b e lif el o n g As piri n t h er a py a n d pr o p hyl actic a nti bi otic t h er a py pri or t o d e nt al pr oc e d ur es. 3 5 F or a n y i m a gi n g p erf or m e d (i. e. i ntr ac ar di ac ec h oc ar di o gr a p hy, tr a ns es o p h a g e al ec h oc ar di o gr a p hy, or ot h er i m a gi n g) p ost pr oc e d ur e, b ef or e l e a vi n g t h e c at h et eriz ati o n l a b, p er st a n d ar d of c ar e at t h e i nv esti g ati o n al sit e, a c o py of t h e i m a gi n g m a y b e r e q u est e d by M e dtr o nic f or r e vi e w. 8. 6. 2. Di s c h ar g e Crit eri a F oll o wi n g c o m pl eti o n of Disc h ar g e pr oc e d ur es d escri b e d i n S ecti o n 8. 1. Sc h e d ul e d of E v e nts , h os pit al disc h ar g e will occ ur at t h e discr e ti o n of t h e i nv esti g at or. 8. 6. 3. D e vi c e E x pl a nt I n t h e ev e nt of a m e dic ally i n dic at e d ex pl a nt of t h e H ar m o ny T P V, t h e ex pl a nti n g p hysici a n will f oll o w st a n d ar d l oc al ex pl a nt pr oc e d ur es. S u bj ects will b e f oll o w e d t hr o u g h disc h ar g e of t h e ex pl a nt h os pit aliz ati o n o r u ntil st u dy cl os ur e, w hic h ev er occ urs fi rst. St u dy sit es s h o ul d att e m pt t o o bt ai n c o pi es of a ut o ps y r e p orts a n d t h e d e at h c ertific at e i n t h e ev e nt of a s u bj ect’s d e at h. R e q uir e m e nts s p ecific t o ex pl a nt ati o n at r e o p er ati o n or a ut o ps y ar e d escri b e d i n A p p e n di x I X: E X PL A N T P R O T O C OL . T h e ex pl a nt e d H ar m o ny T P V s h o ul d b e r et ur n e d t o M e dtr o nic as o utli n e d i n S ecti o n 6. 6 . Pr o d uct R et ur n . 8. 7. S u bj e ct E v al u ati o n s S u bj ects i n w h o m t h e H ar m o ny T P V w as i m pl a n t e d will b e e v al u at e d at h os pit al disc h ar g e, o n e m o nt h, six m o nt hs, o n e y e ar, a n d a n n u ally t h er e aft er t hr o u g h fi v e y e ars or u ntil t h e H ar m o ny T P V is ex pl a nt e d. Pr ot oc ol -r e q uir e d ev al u ati o ns s h o ul d b e p erf or m e d at t h e st u dy sit e w h e n p ossi bl e. E v al u ati o ns t o b e p erf or m e d ar e s u m m ariz e d i n S ecti o n 8. 1. Sc h e d ul e of E v e nts . If t h e s u bj ect is s e e n at a cli nic n ot ass oci at e d wit h t h e st u dy sit e, all eff orts s h o ul d b e m a d e t o o bt ai n c o pi es of m e dic al r ec or ds fr o m t h at visit. D at a o bt ai n e d fr o m t h es e o utsi d e m e dic al r ec or ds c a n b e us e d t o s u p p ort d at a e ntry f or t h at visit. 8. 7. 1. U n pl a n n e d Vi sit s U n pl a n n e d s u bj ect visits t h at ar e n ot d et ail e d i n S ecti o n 8. 1 . Sc h e d ul e of E v e nts a n d ar e d e e m e d n ec ess ary i n or d er t o ev al u at e t h e H ar m o ny T P V ar e c o nsi d er e d u n pl a n n e d visits f or t h e p ur p os es of t h e pr ot oc ol a n d d o n ot n e e d t o t ak e pl ac e at t h e st u dy sit e. A d diti o n ally, o nly d at a t h at c a n b e o bt ai n e d b y t h e st u dy sit es ar e r e q uir e d t o b e r e p ort e d. P ot e nti al r el e v a nt u n pl a n n e d pr oc e d ur es i ncl u d e:"
27,page_27,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 8 of 1 2 1 • Cli nic al ass ess m e nt • Ec h oc ar di o gr a p hy • C M R • C T c ar di ac a n gi o gr a p hy • R a di o gr a p hy 8. 7. 2. Mi s s e d Vi sit s E v ery eff ort s h o ul d b e m a d e t o e ns ur e s u bj ects r et ur n t o t h e st u dy sit e f or all pr ot oc ol r e q uir e d f oll o w - u p visits. If t h e s u bj ect is u n a bl e t o r et ur n f or a n i n -p ers o n cli nic visit, t h e i n v esti g at or, or d esi g n e e, s h o ul d d oc u m e nt i n t h e s u bj ect r ec or d t h e r e as o n t h e s u bj ect w as u n a bl e t o c o m pl et e t h e visit a n d, if a p plic a bl e, f oll o w t h e r e q uir e m e nts f or d evi ati o n r e p orti n g o utli n e d i n S ec ti o n 8. 1 0. D e vi ati o n H a n dli n g . I n t h e c as e t h at t h e s u bj ect will n ot b e s e e n f or a pr ot oc ol r e q uir e d f oll o w -u p visit, t h e i nv esti g at or s h o ul d m ak e e v er y eff ort t o c o nt act t h e s u bj ect or s u bj ect’s l e g al r e pr es e nt ati v e wit hi n t h e visit wi n d o w t o c oll ect t h e s u bj ect’s vit al st at us as w ell as i nf or m ati o n r el at e d t o p ot e nti al a dv ers e e v e nts, s af ety d at a, a n d h os pit aliz ati o ns. 8. 8. Su b st a nti al R a di ati o n D o s e L e v el A S u bst a nti al R a di ati o n D os e L e v el ( S R DL) is a n a p pr o pri at el y s el ect e d r ef er e nc e v al u e us e d t o tri g g er a d diti o n al d os e m a n a g e m e nt acti o ns d uri n g a pr oc e d ur e a n d m e dic al f oll o w -u p f or a r a di ati o n l e v el t h at mi g ht pr o d uc e a cl i nic all y r el e v a nt i nj ur y i n a n a v er a g e p ati e nt. T h er e is n o i m plic ati o n t h at r a di ati o n l e v els a b ov e t h e S R DL will al w a ys c a us e a n i nj ur y or t h at r a di ati o n l e v els b el o w t h e S R DL will n e v er c a us e a n i nj ur y. T h e est a blis h e d S R DL f or t his st u dy is a k er m a -ar e a pr o d uct of 5 0 0 G y *c m 2. W h e n t h e S R DL h as b e e n exc e e d e d, t h e S u bst a nti al R a di ati o n D os e L e v el el ectr o nic c as e r e p ort f or m ( e C R F) s h o ul d b e c o m pl et e d a n d cli nic al f oll o w -u p is r e q uir e d. T h e s u bj ect s h o ul d b e a dvis e d of t h e p ossi bilit y of a s ki n i nj ury d u e t o a tiss u e r e acti o n a n d i nstr uct e d t o ex a mi n e t h e b e a m e ntr a nc e sit e f or 2-4 w e e ks p ost -pr oc e d ur e. T h e s u bj ect s h o ul d r e p ort a ny s ki n c h a n g es. I n t h e e v e nt t h e s u bj ect d o es n ot c o nt act t h e sit e wit hi n 3 0 d a ys aft er t h e pr oc e d ur e, t h e sit e s h o ul d f oll o w -u p wit h t h e s u bj ect t o ass ess if a p ot e nti al ski n i nj ur y h as t a k e n pl ac e. If a s ki n i nj ur y is s us p ect e d, t h e s u bj ect s h o ul d b e s e e n at a cli nic visit a n d a p pr o pri at e f oll o w -u p c ar e s h o ul d b e d et er mi n e d. I n t h e e v e nt a s ki n i nj ur y occ urs, a n A dv ers e E v e nt e C R F m ust b e c o m pl et e d t o d oc u m e nt t h e i nj ur y. 8. 9. A s s e s s m e nt of S af et y M et h o ds a n d ti mi n g f or ass essi n g, r ec or di n g, a n d a n alyzi n g s af ety p ar a m et ers ar e ex pl ai n e d i n S ecti o n 1 0. A d v ers e E v e nts a n d D e vic e D efici e nci es . A n ext er n al, i n d e p e n d e nt cli nic al e v e nts c o m mitt e e ( C E C) will r e vi e w a n d a dj u dic at e all e n d p oi nt r el at e d A Es a n d s u bj ect d e at hs."
28,page_28,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 2 9 of 1 2 1 A n ext er n al, i n d e p e n d e nt d at a m o nit ori n g c o m mitt e e ( D M C) will ass ess i nt eri m st u dy d at a a n d pr o vi d e r ec o m m e n d ati o ns t o M e dtr o nic r e g ar di n g st u dy c o n d uct, s h o ul d t h e y i d e ntif y a ny iss u es t h at m ay aff ect t h e s af et y of t h e st u dy s u bj ects. 8. 1 0. R e c or di n g D at a St u dy sit es will assi g n a u ni q u e s u bj ect I D n u m b er t o e ac h e nr oll e d (c o ns e nt e d) s u bj ect. R ec or ds of t h e s u bj ect/s u bj ect I D r el ati o ns hi p will b e m ai nt ai n e d by t h e st u dy sit e. I n di vi d u al s u bj ect m e dic al i nf or m ati o n o bt ai n e d as a r es ult of t his st u dy will b e c o nsi d er e d c o nfi d e nti al. T his st u dy will utiliz e Or acl e Cli nic al R e m ot e D at a C a pt ur e ( R D C) s yst e m t h at is t h e pr o p ert y of M e dtr o nic. R e q uir e d d at a will b e r ec or d e d o n e C R Fs by a ut h oriz e d sit e p ers o n n el as i n dic at e d o n t h e D el e g ati o n T as k List ( D TL). St u dy p ers o n n el d el e g at e d f or e C R F c o m pl eti o n a n d/ or a p pr o v al will b e tr ai n e d o n t h e us e of t h e R D C syst e m a n d t h er e aft er pr o vi d e d wit h a u ni q u e us er n a m e a n d p ass w or d t o acc ess t h e syst e m. T h e e C RFs m ust b e c o m pl et e d a n d/ or u p d at e d t o r efl ect t h e l at est o bs erv ati o ns o n s u bj ects p artic i p ati n g i n t h e st u dy. T h e Pri nci p al I nv esti g at or ( or a p pr o pri at el y d el e g at e d s u b - i nv esti g at or) will el ectr o nic ally si g n (i. e. a p pr o v e) e ac h e C R F att esti n g t o t h e acc ur ac y of t h e d at a pr o vi d e d. T h e R D C syst e m will m ai nt ai n a n a u dit tr ail of e C R F d at a e ntri es a n d c orr ecti o ns. If sit e p ers o n n el m ak e c orr ecti o ns t o a pr evi o usly a p pr o v e d e C R F, a n a p pr o pri at ely d el e g at e d i nv esti g at or s h all r e -a p pr o v e t his e C R F. D at a fr o m t h e c or e l a b will b e e nt er e d i nt o t h e R D C syst e m b y c or e l a b p ers o n n el p er t h eir pr oc e d ur es est a blis h e d f or t h e st u dy. All st u dy -r el at e d d oc u m e nts m ust b e r et ai n e d u ntil n otifi e d b y M e dtr o nic t h at r et e nti o n is n o l o n g er r e q uir e d. M e dtr o nic will i nf or m t h e i n v esti g at or/i nstit uti o n w h e n t h es e d oc u m e nts ar e n o l o n g er r e q uir e d t o b e r et ai n e d. N o st u dy d oc u m e nt or i m a g e s h o ul d b e d estr o y e d wit h o ut pri or writt e n a gr e e m e nt b et w e e n M e dtr o nic a n d t h e i nv esti g at or. S h o ul d t h e i nv esti g at or wis h t o assi g n t h e st u dy r ec or ds t o a n ot h er p art y or m o v e t h e m t o a n ot h er l oc ati o n, a dv a nc e writt e n n otic e m ust b e giv e n t o M e dtr o nic. 8. 1 1. D e vi ati o n H a n dli n g A pr ot oc ol d evi ati o n is d ef i n e d as a n occ urr e nc e w h er e t h e st u dy w as n ot c o n d uct e d acc or di n g t o t h e pr ot oc ol or t h e I nv esti g at or A gr e e m e nt. Ex a m pl es of pr ot oc ol d e vi ati o ns i ncl u d e b ut ar e n ot li mit e d t o: • F ail ur e t o o bt a i n i nf or m e d c o ns e nt pri or t o st u dy p artici p ati o n • I nc orr ect v ersi o n of t h e i nf or m e d c o ns e nt f or m us e d • F ail ur e t o o bt ai n I R B/ E C a p pr o v al b ef or e t h e st art of t h e st u dy"
29,page_29,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 3 0 of 1 2 1 • E nr oll e d s u bj ect di d n ot m e et i ncl usi o n/ excl usi o n crit eri a 4 • R e q uir e d t esti n g a n d/ or m e as ur e m e nts n ot d o n e or i nc orr ectl y d o n e • F oll o w -u p visit miss e d or c o m pl et e d o utsi d e wi n d o w • U n a ut h oriz e d us e of i n v esti g ati o n al d evic es • A dv ers e ev e nts n ot r e p ort e d i n t h e r e q uir e d ti m e fr a m e as d efi n e d b y r e g ul ati o n or t h e CI P • C o ntr ol of st u dy d e vic es n ot m ai nt ai n e d • S o urc e d at a p er m a n e ntly l ost • E nr oll m e nt of p ati e nts d uri n g l a ps e of I R B/ E C a p pr ov al E v ery att e m pt s h o ul d b e m a d e t o a v oi d pr ot oc ol d evi ati o ns. I nv esti g at ors s h o ul d o bt ai n pri or a p pr ov al fr o m M e dtr o nic b ef or e i niti ati n g a n y c h a n g e or d e vi ati o n fr o m t h e CI P, exc e p t w h er e n ec ess ary t o pr ot ect t h e ri g hts, s af ety or w ell b ei n g of a s u bj ect i n a n e m er g e ncy sit u ati o n. S uc h a p pr o v al s h all b e d oc u m e nt e d i n writi n g a n d m ai nt ai n e d i n t h e I nv esti g at or Sit e Fil e. Pri or a p pr o v al is g e n er ally n ot ex p ect e d i n sit u ati o ns w h er e u nf or es e e n circ u mst a nc es ar e b e y o n d t h e i n v esti g at or’s c o ntr ol ( e. g., s u bj ect di d n ot att e n d sc h e d ul e d f oll o w -u p visit). D evi ati o ns will b e r e p ort e d t o M e dtr o nic r e g ar dl ess of w h et h er t h e occ urr e nc e w as m e dic all y j ustifi a bl e, pr e -a p pr o v e d b y M e dtr o nic, or t a k e n t o pr ot ect t h e s u bj ect i n a n e m er g e ncy. St u dy d e vi ati o ns s h o ul d b e r e p ort e d t o M e dtr o nic vi a t h e St u dy D evi ati o n e C R F. 5 I nv esti g at ors s h o ul d r e p ort t h e f oll o wi n g d evi ati o ns t o M e dtr o nic a n d t h eir r e vi e wi n g I R B/ E C (if r e q uir e d by l oc al r e g ul ati o n) wit hi n 5 w or ki n g d ays of t h e occ urr e nc e of t h e d evi ati o ns: • F ail ur e t o o bt ai n writt e n i nf or m e d c o ns e nt • D evi ati o ns t o pr ot ect t h e lif e or p hysic al w ell -b ei n g of a s u bj ect i n a n e m er g e nc y I n a d diti o n, i n v esti g at ors ar e r e q uir e d t o a d h er e t o l oc al I R B/ E C pr oc e d ur es f or r e p orti n g d evi ati o ns. M e dtr o nic is r es p o nsi bl e f or a n al yzi n g d e vi ati o ns, ass essi n g t h eir si g nific a nc e, a n d i d e ntif yi n g a n y c orr ecti v e a n d/ or pr e v e ntiv e acti o ns t h at m ay b e w arr a nt e d. R e p etitiv e or s eri o us i nv esti g at or c o m pli a nc e iss u es m a y r e pr es e nt a n e e d t o i niti at e a c orr ecti v e acti o n pl a n, w hic h m a y i ncl u d e s us p e nsi o n of e nr oll m e nt or t er mi n ati o n of t h e i nv esti g at or or sit e’s p artici p ati o n i n t h e st u dy. 4 S u bj e cts m us t m e et all i n cl usi o n/ e x cl usi o n cr it eri a t o b e eli gi bl e f or i m pl a nt ati o n. H o w e v er, it will n ot b e c o nsi d er e d a pr ot o c ol d e vi ati o n if n e w st u d y r el at e d t esti n g ( e. g., e c h o, C T c ar di a c a n gi o gr a p h y, or S cr e e ni n g C o m mitt e e ass ess m e nt) of a c o ns e nt e d s u bj e ct i d e ntifi es i m pl a nt ati o n eli gi bilit y crit eri a t h at ar e n ot m et. 5 I n t h e c as e of a miss e d st u d y visit or a n o ut of wi n d o w visit ( e. g., f oll o w -u p visit), o n e e C R F is r e q uir e d. A d e vi ati o n e C R F is n ot r e q uir e d f or e a c h ass ess m e nt miss e d at o n e visit."
30,page_30,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 3 1 of 1 2 1 8. 1 2. S u bj e ct Wit h dr a w al or Di s c o nti n u ati o n All i m pl a nt e d s u bj ects will b e e nc o ur a g e d t o r e m ai n i n t h e st u dy t hr o u g h t h e fi n al f oll o w -u p visit at 5 y e ars. S u bj ects w h o disc o nti n u e p artici p ati o n pr e m at ur el y will b e i ncl u d e d i n t h e a n alysis of r es ults ( as a p pr o pri at e) a n d wi ll n ot b e r e pl ac e d i n t h e e nr oll m e nt of t ot al st u dy s u bj ects. T h e r e as o n f or pr e m at ur e disc o nti n u ati o n s h o ul d b e d oc u m e nt e d i n t h e s u bj ect fil e a n d vi a t h e St u dy Exit e C R F. T h e st u dy sit e will m ak e e v er y eff ort t o h av e i m pl a nt e d s u bj ects c o m pl et e t h e f oll o w -u p visit sc h e d ul e. A s u bj ect will n ot b e c o nsi d er e d l ost t o f oll o w -u p u nl ess all eff orts t o o bt ai n c o m pli a nc e ar e u ns ucc essf ul. At a mi ni m u m, t h e eff ort t o o bt ai n f oll o w -u p i nf or m ati o n m ust i ncl u d e at mi ni m u m 3 att e m pts t o m a k e c o nt act vi a t el e p h o n e or e-m ail. If t h es e c o nt act att e m pts ar e n ot s ucc essf ul, a tr ac e a bl e l ett er fr o m t h e i nv esti g at or s h o ul d b e s e nt t o t h e s u bj ect’s l ast k n o w n a d dr ess a n d t h e s u bj ect’s pri m ar y p hysici a n c o nt act e d. S u bj ects will t h e n b e d e e m e d l ost t o f oll o w u p. All c o nt act eff orts t o o bt ai n f oll o w -u p m ust b e d oc u m e nt e d i n t h e s u bj ect’s m e dic al r ec or ds. If a s u bj ect disc o nti n u es t h e st u dy pr e m at ur ely, is wit h dr a w n fr o m t h e st u dy b y t h e i nv esti g at or, or c o m pl et es all pr ot oc ol r e q uir e d f oll o w -u p, t h e y s h o ul d c o nti n u e t o b e f oll o w e d by t h e i m pl a nti n g sit e acc or di n g t o t h eir r o uti n e cli nic al pr actic e f or p ul m o n ar y v al v e p ati e nts. If, f or a n y r e as o n, t his is n ot p ossi bl e, or i f s u bj ect n e e ds t o c h a n g e his/ h er f oll o w -u p sit e at a n y ti m e p oi nt aft er c o ncl usi o n of t h e st u dy, i n v esti g at o rs s h o ul d r ef er s u bj ects t o a l oc al sit e wit h a p pr o pri at e tr ai ni n g a n d ex p eri e nc e i n m a n a gi n g p ati e nts wit h i m pl a nt e d p ul m o n ar y v alv es. 9. 1. P ot e nti al Ri s k s All m at eri als us e d i n t h e H ar m o ny T P V h av e b e e n us e d pr e vi o usl y i n i m pl a nt a bl e m e dic al d e vic es wit h lo n g -st a n di n g cli nic al ex p eri e nc e. T h e fr a m e is c o nstr uct e d fr o m niti n ol, w hic h h as b e e n us e d i n c or o n ar y a n d p eri p h er al art eri al st e nti n g a p plic ati o ns as w ell as i n tr a nsc at h et er a ortic v alv es wit h cli nic all y acc e pt a bl e p erf or m a nc e. Gl ut ar al d a hy d e -fix e d p o rci n e tiss u e wit h A O A ® h as b e e n us e d i n c o m m erci ally av ail a bl e bi o pr ost h etic h e art v al v es si nc e 1 9 9 2. T h er ef or e, t h e m at eri als us e d i n t h e H ar m o ny T P V d o n ot r e pr es e nt u nr e as o n a bl e risks t o p ati e nts. N o c ar di ac c at h et eriz ati o n pr oc e d ur e c a n b e c o nsi d er e d e ntir ely wit h o ut ris ks, disc o mf ort, distr ess, or i nc o nv e ni e nc e. As wit h a ny c ar di ac c at h et eriz ati o n pr oc e d ur e, c ert ai n c o m plic ati o ns m ay occ ur t hr o u g h p artici p ati o n i n t h e cli nic al st u dy. T h er e m a y b e risks t h at w e d o n ot k n o w y et. T h er e m a y b e risks t h at w e d o n ot k n o w h o w oft e n will h a p p e n or h o w s e v er e t h e y will b e w h e n t h ey h a p p e n. T his is b ec a us e t h e st u dy is i n t h e e arly p h as e a n d w e d o n ot h a v e m uc h ex p eri e nc e wit h t his d evic e. Alt h o u g h C T t ests ar e b ec o mi n g t h e st a n d ar d m et h o d of ass ess m e nt f or tr a n sc at h et er v al v e i m pl a nt ati o n, t h er e is a n a d diti o n al ris k of i ncr e as e d r a di ati o n ex p os ur e fr o m t h e r e q uir e d C T t est f or t his cli nic al st u dy. 9. Ri s k s a n d B e n efit s"
31,page_31,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 3 2 of 1 2 1 If t h e s u bj ect is a f e m al e of c hil d b e ari n g p ot e nti al, a pr e g n a nc y t est will t ak e pl ac e b ef or e t h e C T t est a n d a g a i n b ef or e t h e i m pl a nt pr oc e d ur e t o m a k e s ur e t h e s u bj ect is n ot pr e g n a nt as t h er e m a y b e ris ks t o t h e e m bry o or f et us t h at ar e c urr e ntl y u n k n o w n. Pl e as e r ef er t o t h e H ar m o ny T P V I F U d oc u m e nt f or a f ull listi n g of risks a n d f urt h er i nf or m ati o n o n t h e ris ks of t h e H ar m o ny T P V. 9. 2. P ot e nti al B e n efit s T h e pri m ar y p ot e nti al b e n efit of t h e H ar m o ny T P V t o p ati e nts is r est or ati o n of h e m o dy n a mic f u ncti o n of his or h er p ul m o n ar y v alv e wit h o ut t h e n e e d f or i nv asiv e c ar di ac s ur g ery. S p ecif ic ally, t h e H ar m o ny T P V is i nt e n d e d t o r est or e a n d m ai nt ai n p ul m o n ary v al v e c o m p et e nc e f or p ati e nts wit h p ul m o n ary r e g ur git ati o n. R e d ucti o n i n r e g ur git a nt v ol u m e c o ul d r es ult i n i m pr ov e d or pr es erv ati o n of ri g ht v e ntric ul ar f u ncti o n, a d ecr e as e i n t h e i nci d e nc e of arr hyt h mi as, a n d a n i m p r ov e m e nt i n eff ort t ol er a nc e. T h es e p ot e nti al b e n efits c o ul d d el ay t h e n ext s ur gic al i nt er v e nti o n, i d e ally r e d uci n g t h e n u m b er of c ar di ac s ur g eri es a p ati e nt r e q uir es ov er his or h er lif eti m e. A d diti o n all y, d at a g ai n e d fr o m t his st u dy m ay b e n efit ot h ers i n t h e f ut ur e. D u e t o t h e r el ati v el y s m all ex p eri e nc e wit h t his d e vic e, t h es e b e n efits ar e p ossi biliti es a n d n ot k n o w n f or c ert ai n. 9. 3. Ri s k -B e n efit R ati o n al e T h e H ar m o ny T P V e arly f e asi bilit y st u dy d e m o nstr at e d t h at H ar m o ny T P V i m pl a nt ati o n m a y b e a s af e a n d e ff ectiv e tr e at m e nt o pti o n f or p ati e nts wit h r e p air e d c o n g e nit al h e art dis e as e wit h p ul m o n ar y r e g ur git ati o n. Alt h o u g h t h er e ar e ris ks ass oci at e d wit h i m pl a nt ati o n of t h e H ar m o ny T P V as o utli n e d i n S ecti o n 9. 1. P ot e nti al Ris ks , t h e y ar e n ot a ntici p at e d t o b e w ors e t h a n t h e risks ass oci at e d wit h c urr e nt i nt er v e nti o ns f or d ysf u ncti o n al p ul m o n ary v alv es, n a m el y s ur gic al r e pl ac e m e nt. T h e p ot e nti al b e n efits of t h e st u dy as o utli n e d i n S ecti o n 9. 2. P ot e nti al B e n efits o ut w ei g h t h e p ot e nti al risks; t h er ef or e, t h e i nv esti g ati o n is j ustifi e d. T h e f oll o wi n g m e as ur es will b e i m pl e m e nt e d t o mi ni miz e ris ks t o t h e st u dy s u bj ects: • All s u bj ects will b e acc e pt a bl e s ur gic al c a n di d at es • I m pl a nti n g p hysici a ns will h a v e c o nsi d er a bl e ex p eri e nc e i n i nt erv e nti o n al c o n g e nit al c ar di ol o gy pr oc e d ur es • St u dy sit es will h av e c o m pr e h e ns i v e c o n g e nit al c ar di ol o gy a n d s ur g er y pr o gr a ms wit h est a blis h e d c a p acit y f or e m er g e nc y c at h et eriz ati o n a n d c ar di ac s ur g ery, if n ec ess ar y • P ati e nts b ei n g c o nsi d er e d f or t h e st u dy will b e ri g or o usl y scr e e n e d • S u bj ects will u n d er g o t h or o u g h ass ess m e nts d uri n g t h eir pr e -i m pl a nt w or k u p"
32,page_32,
33,page_33,
34,page_34,
35,page_35,
36,page_36,
37,page_37,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 3 8 of 1 2 1 1 0. 2. 3. Cl a s sifi c ati o n of S eri o u s A d v er s e E v e nt s A ny ev e nt t h at m e ets t h e S A E crit eri a pr ovi d e d i n T a bl e 1: A d v ers e e v e nt d efi niti o ns f or r e p or ti n g r e q uir e m e nts is t o b e cl assifi e d as a s eri o us a d v ers e ev e nt ( S A E). 1 0. 2. 4. Cl a s sifi c ati o n of C a u s al R el ati o n s hi p s F or e ac h o bs er v e d A E, t h e c a us al r el ati o ns hi p b et w e e n t h e A E a n d t h e T P V, t h e A E a n d t h e D S, a n d t h e A E a n d t h e i m pl a nt pr oc e d ur e will b e c at e g oriz e d as: c a us al r el ati o ns hi p, pr o b a bl e r el ati o ns hi p, p ossi bl e r el ati o ns hi p, u nli k el y r el ati o ns hi p, a n d n ot r el at e d, acc or di n g t o t h e d efi niti o ns pr o vi d e d b el o w. 3 7 It s h o ul d b e ass u m e d t h er e is a c a us al or pr o b a bl e r el ati o ns hi p t o t h e T P V, D S, or i m pl a nt pr oc e d ur e u nl ess a n ot h er c a us e is i d e ntifi e d as a p ossi bility. C a us al R el ati o ns hi p T h e ev e nt is ass oci at e d wit h t h e T P V, D S, or i m pl a nt pr oc e d ur e w h e n: • t h e ev e nt is a k n o w n si d e eff ect of t h e pr o d uct c at e g or y t h e T P V or D S b el o n gs t o or of si mil ar d e vic es a n d pr oc e d ur es; • th e ev e nt h as a t e m p or al r el ati o ns hi p wit h T P V or D S us e/ a p plic ati o n or i m pl a nt pr oc e d ur e; • t h e ev e nt i n v ol v es a b o dy -sit e or or g a n t h at o t h e T P V, D S, or i m pl a nt pr oc e d ur e ar e a p pli e d t o; o t h e T P V, D S, or i m pl a n t pr oc e d ur e h av e a n eff ect o n; • t h e ev e nt f oll o ws a k n o w n r es p o ns e p att er n t o t h e T P V, D S, or i m pl a nt pr oc e d ur e (if t h e r es p o ns e p att er n is pr evi o usl y k n o w n); • t h e disc o nti n u ati o n of T P V or D S a p plic ati o n ( or r e d ucti o n of t h e l ev el of acti v ati o n/ ex p os ur e) a n d r ei ntr o d ucti o n of its us e ( or i ncr e as e of t h e l ev el of acti v ati o n/ ex p os ur e) h as a n i m p act o n t h e e v e nt ( w h e n cli nic all y f e asi bl e); • ot h er p ossi bl e c a us es ( e. g. a n u n d erl yi n g or c o nc urr e nt ill n ess/ cli nic al c o n diti o n or/ a n d a n eff ect of a n ot h er d evic e, dr u g or tr e at m e nt) h av e b e e n a d e q u at ely r ul e d o ut; • h ar m t o t h e s u bj ect is d u e t o err or i n us e. N ot e: I n or d er t o est a blis h t h e r el at e d n ess, n ot all t h e crit eri a list e d a b o v e mi g ht b e m et at t h e s a m e ti m e, d e p e n di n g o n t h e ty p e of i n v esti g ati o n al d e vic e/i m pl a n t pr oc e d ur e a n d t h e ev e nt. Pr o b a bl e R el ati o ns hi p T h e r el ati o ns hi p wit h t h e us e of t h e T P V, D S, or i m pl a nt pr oc e d ur e s e e ms r el e v a nt a n d/ or t h e ev e nt c a n n ot b e ex pl ai n e d by a n ot h er c a us e, b ut a d diti o n al i nf or m ati o n m ay b e o bt ai n e d. P ossi bl e R el ati o ns hi p T h e r el ati o ns hi p wit h t h e us e o f t h e T P V, D S, or i m pl a nt pr oc e d ur e is w e a k b ut c a n n ot b e r ul e d o ut c o m pl et el y. Alt er n ativ e c a us es ar e als o p ossi bl e ( e. g. a n u n d erl yi n g or c o nc urr e nt ill n ess/ cli nic al c o n diti o n or/ a n d a n eff ect of a n ot h er d e vic e, dr u g or tr e at m e nt)."
38,page_38,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 3 9 of 1 2 1 C as es w h er e r el at e d n ess c a n n ot b e ass ess e d or n o i nf or m ati o n h as b e e n o bt ai n e d s h o ul d als o b e cl assifi e d as p ossi bl e. U nli k el y R el ati o ns hi p T h e r el ati o ns hi p wit h t h e us e of t h e T P V, D S, or i m pl a nt pr oc e d ur e s e e ms n ot r el e v a nt a n d/ or t h e ev e nt c a n b e r e as o n a bl y ex pl ai n e d by a n ot h er c a us e, b ut a d diti o n al i nf or m ati o n m ay b e o bt ai n e d. N ot r el at e d R el ati o ns hi p t o t h e T P V, D S, or i m pl a nt pr oc e d ur e c a n b e excl u d e d w h e n: • t h e ev e nt is n ot a k n o w n 6 si d e eff ect of t h e pr o d uct c at e g or y t h e d e vic e b el o n gs t o or of si mil ar d e vic es a n d pr oc e d ur es; • t h e ev e nt h as n o t e m p or al r el ati o ns hi p wit h t h e us e of t h e i nv esti g ati o n al d evic e or t h e pr oc e d ur es; • t h e s eri o us ev e nt d o es n ot f oll o w a k n o w n r es p o ns e p att er n t o t h e m e dic al d evic e (if t h e r es p o ns e p att er n is pr evi o usly k n o w n) a n d is bi ol o gic ally i m pl a usi bl e; • t h e disc o nti n u ati o n of m e dic al d e vic e a p plic ati o n or t h e r e d ucti o n of t h e l ev el of acti v ati o n/ ex p os ur e - w h e n cli nic all y f e asi bl e - a n d r ei ntr o d ucti o n of its us e ( or i ncr e as e of t h e l e v el of ac ti v ati o n/ ex p os ur e), d o n ot i m p act o n t h e s eri o us ev e nt; • t h e ev e nt i n v ol v es a b o dy -sit e or a n or g a n n ot ex p ect e d t o b e aff ect e d b y t h e d evic e or pr oc e d ur e; • t h e s eri o us e v e nt c a n b e attri b ut e d t o a n ot h er c a us e ( e. g. a n u n d erl yi n g or c o nc urr e nt ill n es s/ cli nic al c o n diti o n, a n eff ect of a n ot h er d e vic e, dr u g, tr e at m e nt or ot h er ris k f act ors); • h ar ms t o t h e s u bj ect ar e n ot cl e arl y d u e t o us e err or; • I n or d er t o est a blis h t h e n o n -r el at e d n ess, n ot all t h e crit eri a list e d a b o v e mi g ht b e m et at t h e s a m e t i m e, d e p e n di n g o n t h e t y p e of d e vic e/ pr oc e d ur es a n d t h e s eri o us ev e nt. 1 0. 2. 5. R e p orti n g of D e vi c e D efi ci e n ci e s D evic e d efici e nc y i nf or m ati o n will b e c oll ect e d t hr o u g h o ut t h e st u dy a n d r e p ort e d t o M e dtr o nic. D evic e d efici e nci es t h at l e d t o a n A E ar e r e p ort e d o n t h e A E e C R F. D e vic e d efici e nci es t h at di d n ot l e a d t o a n A E s h o ul d b e r e p ort e d o n a D evic e D efici e ncy e C R F ( o n e f or e ac h d evic e d efici e ncy). 6 W h e n t h e e v e nt is n ot a k n o w n si d e eff e ct of t h e pr o d u ct c at e g or y t h e d e vi c e b el o n gs t o or of si mil ar d e vi c es a n d pr o c e d ur es, it g e n er all y is c o nsi d er e d “ n ot r el at e d”. Y et, t h e u n e x p e ct e d eff e ct s h all n ot b e e x cl u d e d fr o m e v al u ati o n a n d r e p orti n g."
39,page_39,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 0 of 1 2 1 1 0. 3. A nti ci p at e d A d v er s e E v e nt s A ntici p at e d A Es f or s u bj ects p artici p ati n g i n t h e st u dy ar e o utli n e d i n S ecti o n 9. 1 . P ot e nti al Ris ks . F urt h er i nf or m ati o n is pr o vi d e d i n t h e I nv esti g at or’s Br oc h ur e a n d I F U. 1 0. 4. E m er g e n c y C o nt a ct D et ail s f or R e p orti n g S A E, U A D E, a n d D e vi c e D efi ci e n ci e s I nv esti g at ors s h o ul d c o nt act t h e M e dtr o nic st u dy m a n a g er or sit e m a n a g er if t h ey h a v e a ny q u esti o ns r e g ar di n g r e p ort a bl e A Es. M e dtr o nic will m ai nt ai n a listi n g of c urr e nt st u dy c o nt act d et ails a n d pr ovi d e t o e ac h sit e 1 1. 1. S cr e e ni n g C o m mitt e e • A Scr e e ni n g C o m mitt e e will b e us e d t o e ns ur e p ati e nt s el ecti o n is a p pr o pri at e a n d c o nsist e nt a m o n g tri al sit es. T h e r ol e of t h e Scr e e ni n g C o m mitt e e will i ncl u d e t h e f oll o wi n g: C o nfir m ati o n t h at s u bj ects m e et i n cl usi o n / excl usi o n crit eri a • C o nfir m ati o n t h at s u bj ects ar e a n at o mic all y s uit a bl e f or H ar m o ny T P V i m pl a nt T h e Scr e e ni n g C o m mitt e e will b e c o m pris e d of a s u bs et of st u dy i n v esti g at ors wit h ex p ertis e i ncl u di n g: • C o n g e nit al H e art Dis e as e • I nt er v e nti o n al C ar di ol o gy • C ar di ac S ur g ery • C ar di ac I m a gi n g 1 1. 2. Cli ni c al E v e nt s C o m mitt e e A Cli nic al E v e nts C o m mitt e e ( C E C) will pr ovi d e i n d e p e n d e nt m e dic al r evi e w a n d a dj u dic ati o n of a d v ers e e v e nt d at a us e d i n t h e s af et y ass ess m e nt of t h e i nv esti g ati o n al d evic e. T h e C E C will a dj u dic at e, at a mi ni m u m, all d e at hs a n d e n d p oi nt r el at e d a d v ers e ev e nts, as o utli n e d i n t h e C E C c h art er. A ny r el at e d s o urc e d oc u m e nt ati o n pr ovi d e d t o t h e S p o ns or f or C E C r e vi e w a n d a dj u dic ati o n will b e d e -i d e ntifi e d. All eff orts s h o ul d b e m a d e by t h e PI t o pr ovi d e s o urc e d oc u m e nt ati o n f or r e vi e w as r e q u est e d by t h e C E C. I n t h e ev e nt s o urc e d oc u m e nt ati o n c a n n ot b e o bt ai n e d, a s u m m ary of t h e ev e nt a n d r el at e d cli nic al fi n di n gs m a y b e pr ovi d e d by t h e PI. T h e a n al ysis of t h e st u dy s af et y d at a will b e b as e d o n C E C a dj u dic ati o ns. T h e C E C m e m b ers will b e fr e e fr o m bi as t o w ar ds t h e st u dy a n d will b e i n d e p e n d e nt fr o m t h e st u dy i nv esti g at ors a n d M e dtr o nic. T h e c o m mitt e e will c o nsist of at l e ast 3 i n d e p e n d e nt ex p erts ( n o n -M e dtr o nic e m pl o y e d p hysici a ns ) wit h ex p ertis e r el e v a nt t o t h e st u dy. T his m a y i ncl u d e ex p eri e nc e i n t h e ar e as of: 1 1. D at a R e vi e w C o m mitt e e s"
40,page_40,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 1 of 1 2 1 • C o n g e nit al H e art Dis e as e • I nt er v e nti o n al C ar di ol o gy • C ar di ac S ur g ery 1 1. 3. D at a M o nit ori n g C o m mitt e e A D at a M o nit ori n g C o m mitt e e ( D M C) will ass ess i nt eri m st u dy d at a a n d pr ovi d e r ec o m m e n d ati o ns t o M e dtr o nic r e g ar di n g st u dy c o n d uct, s h o ul d t h ey i d e ntif y a ny iss u es t h at m ay aff ect t h e s af et y of t h e st u dy s u bj ects. D M C m e m b ers will b e fr e e fr o m bi as t o w ar ds t h e st u dy a n d will b e i n d e p e n d e nt fr o m t h e st u dy i n v esti g at ors, a n d M e dtr o nic. T h e D M C will c o nsist of a mi ni m u m of 3 m e m b ers w h o m a y h a v e ex p eri e nc e i n t h e ar e as of: • C o n g e nit al H e art Dis e as e • I nt er v e nti o n al C ar di ol o gy • C ar di a c S ur g ery T h e D M C will m e et (vi a t el ec o nf er e nc e or i n p ers o n) t o est a blis h pr oc e d ur es f or s af et y d at a r e vi e w, c h air a p p oi nt m e nt, a n d g ui d eli n es f or st u dy r ec o m m e n d ati o ns. T h e D M C will m e et o n a p eri o dic b asis t o p er f or m a c o m pr e h e nsi v e d at a r evi e w, i ncl u di n g at a mi ni m u m, all S A Es a n d d e at hs, a n d will m e et m or e fr e q u e ntl y w h e n n e e d e d. S af et y -r el at e d e n d p oi nts m ay als o b e r e vi e w e d at t h es e m e eti n gs. D M C m e eti n gs m a y c o nsist of b ot h o p e n a n d cl os e d s essi o ns. M e dtr o nic p ers o n n el m ay f acilit at e t h e D M C m e eti n g b ut will n ot h a v e v oti n g privil e g es. F oll o wi n g e ac h m e eti n g, t h e D M C will r e p ort t o M e dtr o nic i n writi n g a n d m a y r ec o m m e n d c h a n g es i n t h e c o n d uct of t h e st u dy. T h e D M C r ec o m m e n d ati o ns m a y i ncl u d e r ec o m m e n d ati o ns o n st u dy st at us s uc h as c o nti n ui n g t h e st u d y wit h o ut m o dific ati o ns, c o nti n ui n g t h e st u dy wit h m o dific ati o ns, st o p pi n g or s us p e n di n g e nr oll m e nt, or r ec o m m e n d ati o ns r e g ar di n g st u dy c o n d uct i ncl u di n g r ec o m m e n d ati o ns ar o u n d e nr oll m e nt or pr ot oc ol d evi ati o ns. I n t h e c as e of U A D Es, if M e dtr o nic a n d t h e D M C d et er mi n e t h at t h e ev e nt pr es e nts a n u nr e as o n a bl e risk t o t h e p artici p ati n g s u bj ects, M e dtr o nic m ust t er mi n at e t h e cli nic al st u dy wit hi n 5 w or ki n g d ays aft er m a ki n g t h at d et er mi n ati o n a n d n o l a t er t h a n 1 5 w or ki n g d a ys aft er M e dtr o nic first r ec ei v es n ot ic e of t h e eff ect. All st u dy sit es will b e n otifi e d of t his acti o n. T h e D M C m ay c all a d diti o n al m e eti n gs if, at a ny ti m e, t h er e is c o nc er n a b o ut a ny as p ect of t h e st u dy. All d at a pr es e nt e d at t h e m e eti n gs will b e c o nsi d er e d c o nfi d e nti al."
41,page_41,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 2 of 1 2 1 T h e pri m ar y a n alysis f or s af et y a n d eff ecti v e n ess will b e p erf or m e d w h e n t h e first 4 0 i m pl a nt e d s u bj ects h a v e c o m pl et e d t h eir 6 -m o nt h f oll o w -u p. 7 A s u p pl e m e nt al a n al ysis will b e p erf or m e d w h e n t h e 1 0 U S i m pl a nt s of m T P V 2 5 c o h ort h a v e c o m pl et e d t h eir 1 -m o nt h f oll o w -u p. B ot h c o h orts will b e p o ol e d f or a d diti o n al a n al ysis o ut t o 5 y e ars aft er t h e pr e vi o usl y m e nti o n e d a n a lys es ar e c o m pl et e d. 1 2. 1. A n al y si s S et s T h e a n al ysis s u bs ets ar e d efi n e d as f oll o ws: E nr oll e d C o h o rt T h e e nr oll e d c o h ort c o nsists of all e nr oll e d s u bj ects. S u bj ects ar e c o nsi d er e d e nr oll e d at t h e p oi nt of si g ni n g t h e I nf or m e d C o ns e nt F or m. C at h et eriz e d C o h ort T h e c at h et eriz e d c o h ort c o nsists of all s u bj ects w h o u n d er g o c at h et eriz ati o n f or p ossi bl e i m p l a nt ati o n of t h e H ar m o ny T P V. Att e m pt e d I m pl a nt C o h ort T h e att e m pt e d i m pl a nt c o h ort c o nsists of all s u bj ects w h o u n d er g o c at h et eriz ati o n a n d a H ar m o ny T P V i m pl a nt ati o n w as att e m pt e d ( H ar m o ny T P V is i ntr o d uc e d i nt o t h e s u bj ect’s b o dy). I m pl a nt e d C o h ort T h e i m pl a nt e d c o h ort c o nsists of all s u bj ects w h o u n d er g o c at h et eriz ati o n a n d a H ar m o ny T P V w as i m pl a nt e d. I m pl a nt e d > 2 4 h o urs C o h ort T h e i m pl a nt e d > 2 4 h o urs c o h ort c o nsists of all s u bj ects w h o h a v e a H ar m o ny T P V i m pl a nt e d w hic h r e m ai ns i m pl a nt e d f or gr e at er t h a n 2 4 h o urs. 1 2. 2. Pri m ar y O bj e cti v e s T h e pri m ar y o bj ecti v es ar e d escri pti v e, a n d n o st atistic al hy p ot h esis t est will b e p erf or m e d. T h er e is n o s a m pl e siz e c alc ul ati o n f or t h e pri m ar y o bj ecti v es. T h e a n alysis p o p ul ati o n will i ncl u d e d at a fr o m t his st u dy i n c o m bi n ati o n wit h t h e d at a fr o m t h e N ati v e O utfl o w Tr act Tr a nsc at h et er P ul m o n ary V alv e R es e arc h Cli nic al St u dy (I D E # G 1 2 0 1 7 5). 7 W hil e t h e pri m ar y s af et y e n d p oi nt is m e as ur e d at 3 0 d a ys, pri m ar y o bj e cti v e a n al ysis will b e c o m pl et e d u p o n c o m pl eti o n of t h e pri m ar y effi c a c y e n d p oi nt, w hi c h is m e as ur e d at 6 m o nt hs. 1 2. St ati sti c al D e si g n a n d M et h o d s"
42,page_42,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 3 of 1 2 1 T h e a n al ysis f or pri m ar y o bj ectiv es will b e p erf or m e d w h e n all s u bj ects h av e r e ac h e d t h eir 6 -m o nt h e n d p oi nt. 8 1 2. 2. 1. Pri m ar y S af et y E n d p oi nt T h e pri m ar y s af ety e n d p oi nt is fr e e d o m fr o m pr oc e d ur e or d e vic e -r el at e d m ort alit y. C E C a dj u dic at e d d at a will b e us e d t o ass ess t h e s af ety e n d p oi nt. T h e a n al ysis c o h ort will b e t h e c at h et eriz e d c o h ort. T h e e n d p oi nt will b e d escri b e d b y K a pl a n -M ei er st atistics. T h e l o gl o g tr a nsf or m e d t w o -si d e d 9 5 % c o nfi d e nc e i nt erv al usi n g t h e P et o st a n d ar d err or at 3 0 d a ys will b e pr es e nt e d. T h e pri m ary s af et y o bj ectiv e w ill b e m et if t h e p oi nt esti m at e of t h e fr e e d o m fr o m pr oc e d ur e or d evic e -r el at e d m ort ality r at e at 3 0 d a ys p ost -pr oc e d ur e is e q u al t o or gr e at er t h a n t h e p erf or m a nc e t ar g et of 9 5 %. 1 2. 2. 2. Pri m ar y Effi c a c y E n d p oi nt T h e pri m ar y effic acy e n d p oi nt is p erc e nt a g e of s u bj ects wit h acc e pt a bl e h e m o dy n a mic f u ncti o n c o m p osit e at 6 m o nt hs as d efi n e d b y: • M e a n R V O T gr a di e nt as m e as ur e d by c o nti n u o us -w av e D o p pl er ec h oc ar di o gr a p hy ≤ 4 0 m m H g o If a c at h et eriz ati o n is p erf or m e d f or cli nic al p ur p os es, t h e c at h et eriz ati o n p e a k gr a di e nt m e as ur e m e nt will s u p ers e d e t h e c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy m e as ur e m e nt a n d b e us e d t o s u p p ort t h e pri m ary e n d p oi nt. Acc e pt a bl e h e m o dy n a mic f u ncti o n as m e as ur e d by c at h et eriz ati o n will b e c o nsi d er e d t o b e p e a k gr a di e nt ≤ 4 0 m m H g . -A N D - • P ul m o n ar y r e g ur git a nt fr acti o n as m e as ur e d by m a g n etic r es o n a nc e i m a gi n g < 2 0 % o If m a g n etic r es o n a nc e i m a gi n g is c o ntr ai n dic at e d, a c o nti n u o u s-w a v e D o p pl er ec h oc ar di o gr a p hy m e as ur e m e nt will b e us e d t o s u p p ort t h e pri m ary e n d p oi nt. Acc e pt a bl e h e m o dy n a mic f u ncti o n as m e as ur e d by c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy will b e c o nsi d er e d t o b e < m o d er at e p ul m o n ar y r e g ur git ati o n. C or e l a b d at a wi ll b e us e d t o ass ess t h e effic acy e n d p oi nt, wit h a n exc e pti o n i n t h e c as e t h at a c at h et eriz ati o n is p erf or m e d t o m e as ur e m e a n R V O T gr a di e nt, i n w hic h sit e r e p ort e d d at a will b e utiliz e d. 8 W hil e t h e pri m ar y s af et y e n d p oi nt is m e as ur e d at 3 0 d a ys, pri m a r y o bj e cti v e a n al ysis will b e c o m pl et e d u p o n c o m pl eti o n of t h e pri m ar y effi c a c y e n d p oi nt, w hi c h is m e as ur e d at 6 m o nt hs."
43,page_43,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 4 of 1 2 1 T h e a n al ysis c o h ort f or t h e pri m ar y effic acy e n d p oi nt will b e t h e i m pl a nt e d > 2 4 h o urs c o h ort. T h e p erc e nt a g e of s u bj ects wit h acc e pt a bl e h e m o dy n a mic f u ncti o n at 6 m o nt hs a n d a t w o -si d e d 9 5 % Cl o p p er -P e ars o n i nt erv al wil l b e pr ovi d e d. T h e pri m ary effic ac y o bj ectiv e will b e m et if t h e p oi nt esti m at e is e q u al t o or gr e at er t h a n t h e p erf or m a nc e t ar g et of 7 5 %. 1 2. 3. A d diti o n al O ut c o m e M e a s ur e s T e c h nic al s ucc ess at e xit fr o m c at h et eriz ati o n l a b/ o p er ati n g r o o m ( O R) T ec h nic al s ucc ess is d efi n e d as: • N o d evic e - or pr oc e d ur al -r el at e d m ort ality, wit h • S ucc essf ul acc ess, d eli v er y a n d r etri ev al of t h e d eliv ery s yst e m, a n d • D e pl oy m e nt a n d c orr ect p ositi o ni n g (i ncl u di n g mi n or r e p ositi o ni n g if n e e d e d) of t h e si n gl e i nt e n d e d d evic e, a n d • N o n e e d f or a d diti o n al u n pl a n n e d or e m er g e ncy s ur g er y or r e -i nt er v e nti o n r el at e d t o t h e d e vic e or acc ess pr oc e d ur e T h e a n al ysis c o h ort f or t ec h nic al s ucc ess will b e t h e att e m pt e d i m pl a nt c o h ort. T h e p erc e nt a g e of s u bj ects wit h t ec h nic al s ucc ess will b e pr es e nt e d. If a n el e m e nt of t h e c o m p osit e is missi n g a n d av ail a bl e el e m e nts m e et t h e s ucc ess crit eri a, t h e s u bj ect will b e excl u d e d fr o m t h e a n al ysis. D e vic e s ucc ess o ut t o 5 y e ars D evic e s ucc ess is d efi n e d as: • N o d evic e - or pr oc e d ur al -r el at e d m ort ality, wit h • Ori gi n al i nt e n d e d d evic e i n pl ac e, a n d • N o a d diti o n al s ur gic al or i nt er v e nti o n al pr oc e d ur es r el at e d t o acc ess or t h e d e vic e si nc e c o m pl eti o n of t h e ori gi n al pr oc e d ur e (i. e., exit fr o m t h e c at h et eriz ati o n l a b), a n d • I nt e n d e d p erf or m a nc e of t h e d e vic e, as d efi n e d as: o Str uct ur al p erf or m a nc e: N o mi gr ati o n, e m b oliz ati o n, d et ac h m e nt, m aj or st e nt fr act ur e, h e m ol ysis, t hr o m b osis, e n d oc ar ditis, a n d o H e m o dy n a mic p erf or m a nc e: R eli ef of i ns uffi ci e nc y ( P R < m o d er at e) wit h o ut pr o d uci n g t h e o p p osit e ( m e a n R V O T gr a di e nt > 4 0 m m H g) as m e as ur e d by c o nti n u o us -w a v e D o p pl er ec h oc ar di o gr a p hy 9, a n d • A bs e nc e of p ar a -d evic e c o m plic ati o ns, as d efi n e d by: o P VL ≥ m o d er at e, or o Er osi o n, or o R V O T or P A r u pt ur e 9 If a c at h et eriz ati o n is p erf or m e d f or cli ni c al p ur p os es, t h e c at h et eri z ati o n p e a k gr a di e nt m e as ur e m e nt will s u p ers e d e t h e c o nti n u o us -w a v e D o p pl er e c h o c ar di o gr a p h y m e as ur e m e nt a n d b e u s e d t o s u p p ort t h e o ut c o m e m e as ur e."
44,page_44,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 5 of 1 2 1 T h e a n al ysis c o h ort f or pr oc e d ur al s ucc ess wil l b e t h e att e m pt e d i m pl a nt c o h ort. T h e e n d p oi nt will b e d escri b e d by K a pl a n -M ei er st atistics. T h e l o gl o g tr a nsf or m e d t w o -si d e d 9 5 % c o nfi d e nc e i nt erv al usi n g t h e P et o st a n d ar d err or at 6 m o nt hs ( 1 8 3 d a ys), 1 y e ar ( 3 6 5 d ays), 2 y e ars ( 7 3 0 d a ys), 3 y e ars ( 1 0 9 5 d a ys), 4 y e ars ( 1 4 6 0 d a ys) a n d 5 y e ars ( 1 8 2 5 d a ys) will b e pr es e nt e d. Pr oc e d ur al s ucc ess at 3 0 d a ys Pr oc e d ur al s ucc ess is d efi n e d as: • D evic e s ucc ess at 3 0 d a ys, a n d • N o n e of t h e f oll o wi n g d e vic e - or pr oc e d ur e -r el at e d s eri o us a d v ers e ev e nts: o Lif e -t hr e at e ni n g m aj or bl e e d o M aj or v asc ul ar or c ar di ac str uct ur al c o m plic ati o ns r e q uir e d u n pl a n n e d r ei nt erv e nti o n or s ur g er y o St a g e 2 or 3 ac ut e ki d n e y i nj ur y ( A KI) (i ncl u d es n e w di al ysis) o P ul m o n ar y e m b ol is m o S e v er e h e art f ail ur e ( H F) or h y p ot e nsi o n r e q uiri n g I V i n otr o p e, ultr afiltr ati o n, or m ec h a nic al circ ul at ory s u p p ort o Pr ol o n g e d i nt u b ati o n > 4 8 h o urs T h e a n al ysis c o h ort f or pr oc e d ur al s ucc ess will b e t h e att e m pt e d i m pl a nt c o h ort. T h e p erc e nt a g e of s u bj ect s wit h pr oc e d ur al s ucc ess will b e pr es e nt e d. If a n el e m e nt of t h e c o m p osit e is missi n g a n d a v ail a bl e el e m e nts m e et t h e s ucc ess crit eri a, t h e s u bj ect will b e excl u d e d fr o m t h e a n al ysis. Fr e e d o m fr o m T P V d ysf u ncti o n o ut t o 5 y e ars T P V dysf u ncti o n is d efi n e d as a n y o n e of t h e f oll o wi n g: • R V O T r e o p er ati o n f or d e vic e -r el at e d r e as o ns • C at h et er r e -i nt er v e nti o n of T P V • H e m o dy n a mic dysf u ncti o n of t h e T P V ( m o d er at e or gr e at er p ul m o n ar y r e g ur git ati o n, a n d/ or a m e a n R V O T gr a di e nt > 4 0 m m H g) T h e a n al ysis c o h ort will b e t h e i m pl a nt e d l o n g er t h a n 2 4 h o urs c o h ort. T h e e n d p oi nt will b e d escri b e d b y K a pl a n -M ei er st atistics. T h e l o gl o g tr a nsf or m e d t w o -si d e d 9 5 % c o nfi d e nc e i nt erv al usi n g t h e P et o st a n d ar d err or at 6 m o nt hs ( 1 8 3 d ays), 1 y e ar ( 3 6 5 d a ys), 2 y e ars ( 7 3 0 d ays), 3 y e ar s ( 1 0 9 5 d ays), 4 y e ars ( 1 4 6 0 d a ys) a n d 5 y e ars ( 1 8 2 5 d ays) will b e pr es e nt e d. Ass ess m e nt of s af et y Ass ess m e nt of s af ety is d efi n e d as ass ess m e nt of: • All pr oc e d ur e -r el at e d s eri o us a d v ers e e v e nts • All d e vic e -r el at e d s eri o us a dv ers e ev e nts • D e at h ( all -c a us e, p r oc e d ur al, a n d d e vic e -r el at e d) F or ass ess m e nt of s af ety, t h e C E C d at a will b e us e d f or a n al ysis. T h e a n al ysis c o h orts ar e:"
45,page_45,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 6 of 1 2 1 • All pr oc e d ur e -r el at e d a d v ers e ev e nts: C at h et eriz e d c o h ort • All d e vic e -r el at e d a d v ers e e v e nts: Att e m pt e d I m pl a nt c o h ort • D e at h ( all -c a us e, pr oc e d ur al, a n d d e vic e -r el at e d): C at h et eriz e d c o h ort A dv ers e ev e nts will b e a n alyz e d eit h er vi a s urvi v al a n al ysis usi n g t h e K a pl a n -M ei er m et h o d or s u m m ariz e d b y c o u nt a n d p erc e nt as a p pr o pri at e. C h ar act eriz ati o n of q u alit y of lif e sc or es o v er ti m e Q u alit y of lif e sc or e ov er ti m e will b e ass ess e d b y t h e S F -3 6 at pr e -i m pl a nt, 1 m o nt h p ost -i m pl a nt, 6 m o nt hs p ost -i m pl a nt, a n d a n n u ally p ost -i m pl a nt o ut t o 5 y e ars. T h e a n al ysis c o h ort will b e t h e i m pl a nt e d > 2 4 h o urs c o h ort. S u m m ary st atistics s uc h as m e a n , st a n d ar d d evi ati o n, mi ni m u m, m e di a n, a n d m axi m u m will b e pr o vi d e d f or q u alit y of lif e sc or es o v er ti m e as ass ess e d by t h e S F -3 6 at pr e -i m pl a nt, 1 m o nt h p ost -i m pl a nt, 6 m o nt hs p ost -i m pl a nt, a n d a n n u ally p ost -i m pl a nt o ut t o 5 y e ars. C h ar act eriz ati o n of ri g ht v e ntricl e r e m o d eli n g f oll o wi n g T P V i m pl a nt as ass ess e d vi a C M R Ri g ht v e ntricl e r e m o d eli n g will b e ass ess e d vi a C M R at pr e -i m pl a nt, 6 m o nt hs p ost -i m pl a nt, 2 y e ars p ost - i m pl a nt, a n d 5 y e ars p ost -i m pl a nt. T h e a n alysis c o h ort will b e i m pl a nt e d l o n g er t h a n 2 4 h o urs c o h ort. S u m m ary st atistics s uc h as m e a n, st a n d ar d d evi ati o n, mi ni m u m, m e di a n, a n d m axi m u m will b e pr o vi d e d f or c o nti n u o us v ari a bl es a n d c o u nt a n d p erc e nt a g e will b e pr ovi d e d f or c at e g oric al v ari a bl es. Fi n al A n al ysis Fi n al a n al ysis o n t h e a d diti o n al o utc o m e m e as ur es will b e p erf or m e d w h e n t h e i m pl a nt e d s u bj ects h av e r e ac h e d t h eir 5 y e ar e n d p oi nts, wit h t h e exc e pti o n of t h e f oll o wi n g e n d p oi nts, w hic h will b e a n alyz e d i n c o nj u ncti o n wit h t h e pri m ar y o bj ectiv e a n alysis ( w h e n all i m pl a nt e d s u bj ects h a v e r e ac h e d t h eir 6 - m o nt h visit): • T ec h nic al s ucc ess at exit fr o m c at h et eriz ati o n l a b/ o p er ati n g r o o m ( O R) • Pr oc e d ur al s ucc ess at 3 0 d ays 1 3. 1. St at e m e nt ( s ) of C o m pli a n c e T his st u dy w as d esi g n e d t o r efl ect t h e G o o d Cli nic al Pr actic e ( G C P) pri nci pl es o utli n e d i n I S O 1 4 1 5 5: 2 0 1 1. T h es e i ncl u d e t h e pr ot ecti o n of t h e ri g hts, s af ety a n d w ell -b ei n g of h u m a n s u bj ects, c o ntr ols t o e ns ur e t h e sci e ntific c o n d uct a n d cr e di bilit y of t h e cli nic al i nv esti g ati o n a n d t h e d efi niti o n of r es p o nsi biliti es of th e s p o ns or a n d i nv esti g a t ors. T h e st u dy will b e c o n d uct e d acc or di n g t o f e d er al, n ati o n al a n d l oc al l a ws, r e g ul ati o ns, st a n d ar ds, a n d r e q uir e m e nts of t h e c o u ntri es/ g e o gr a p hi es w h er e t h e st u dy is b ei n g c o n d uct e d, i ncl u di n g d at a pr ot ecti o n l a ws, t h e Cli nic al St u dy A gr e e m e nt a n d t h e CI P. T h e st u dy will als o b e c o n d uct e d i n 1 3. Et hi c s"
46,page_46,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 7 of 1 2 1 acc or d a nc e wit h t h e D ecl ar ati o n of H elsi nki. T h e pri nci pl es of t h e D ecl ar ati o n of H elsi n ki ar e i m pl e m e nt e d i n t his st u dy by m e a ns of t h e P ati e nt I nf or m e d C o ns e nt (I C) pr oc ess, I R B/ E C a p pr ov al, st u dy tr ai ni n g, cli nic al st u dy r e gistr ati o n, pr e -cli nic al t esti n g, ris k b e n efit ass ess m e nt, a n d p u blic ati o n p olic y. I n t h e U nit e d St at es, t h e st u dy will b e c o n d uct e d u n d er a n F D A I nv esti g ati o n al D e vic e Ex e m pti o n (I D E) i n c o m pli a nc e wit h 2 1 C o d e of F e d er al R e g ul ati o ns ( C F R) P arts 1 1, 5 0, 5 4, 5 6 a n d 8 1 2. I n C a n a d a, t h e st u dy will b e c o n d uct e d u n d er a n I nv esti g ati o n al T est i n g A ut h oriz ati o n i n c o m pli a nc e wit h S O R/ 9 8 -2 8 2 S ecti o n 7 9 -8 8. I n J a p a n, t h e st u dy will b e c o n d uct e d i n acc or d a nc e wit h t h e J a p a n G C P Or di n a nc e a n d t h e P h ar m a c e utic al a n d M e dic al D evic e Act. I n a d diti o n, t h e st u dy will b e c o n d uct e d i n c o m pli a nc e wit h 2 1 C F R P arts 1 1 a n d 5 4 i n all p artici p ati n g g e o gr a p hi es. R e g ul at ory a ut h ority n otific ati o n/ a p pr ov al t o c o n d uct t h e st u dy is r e q uir e d. I nv esti g ati o n al sit es will n ot b e activ at e d, n or b e gi n e nr olli n g s u bj ects, u ntil t h e r e q uir e d a p pr o v al fr o m t h e r e g ul at ory a g e ncy a n d I R B/ E C h as b e e n o bt ai n e d. A d diti o n ally, a ny r e q uir e m e nts i m p os e d b y a l oc al r e g ul at or y a g e ncy or I R B/ E C s h all b e f oll o w e d, as a p pr o pri at e. T his st u dy will b e p u blicl y r e gist er e d pri or t o first e nr oll m e nt i n acc or d a nc e wit h t h e 2 0 0 7 F o o d a n d Dr u g Ad mi nistr ati o n A m e n d m e nts Act ( F D A A A) a n d D ecl ar ati o n of H elsi n ki o n htt p://cli nic altri als. g o v ( PL 1 1 0 - 8 5, S ecti o n 8 1 0( a)). 1 3. 2. I n stit uti o n al R e vi e w B o ar d / Et hi c s C o m mitt e e T h e st u dy will b e c o n d uct e d i n acc or d a nc e wit h t h e r e q uir e m e nts of e ac h i n v esti g ati o n al sit e’s I R B/ E C. T h e r es p o nsi bl e I R B/ E C m ust a p pr ov e t h e CI P a n d I nf or m e d C o ns e nt f or m pri or t o i m pl e m e nt ati o n. St u dy activiti es will n ot c o m m e nc e pri or t o r ec ei pt of d oc u m e nt ati o n of I R B/ E C a p pr o v al by t h e sit e a n d M e dtr o nic. T h e i nv esti g at or a n d st u dy st aff m ust c o m pl y wit h t h e r e q uir e m e nts of t h eir I R B/ E C. Pri or t o e nr olli n g s u bj ects, e ac h st u dy sit e’s I R B/ E C wil l b e r e q uir e d t o a p pr ov e t h e c urr e nt CI P, t h e I nf or m e d C o ns e nt f or m, a n d a n y ot h er writt e n i nf or m a ti o n t o b e pr ovi d e d t o t h e s u bj ects. St u dy sit es i n t h e U nit e d St at es m ust als o utiliz e I R B a p pr ov e d H e alt h I ns ur a nc e P ort a bilit y a n d Acc o u nt a bility Act ( HI P A A) A ut h oriz ati o n. I R B/ E C a p pr ov al of t h e st u dy m ust b e r ec eiv e d i n t h e f or m of a l ett er a n d pr ovi d e d t o M e dtr o nic b ef or e c o m m e nc e m e nt of t h e st u dy at a n i nv esti g ati o n al sit e. T h e a p pr ov al l ett er m ust c o nt ai n e n o u g h i nf or m ati o n t o i d e ntif y t h e v ersi o n or d at e of t h e d oc u m e nts a p pr ov e d. I n a d diti o n t o t h e a p pr o v al l ett er, a n I R B/ E C r ost er or l ett er of c o m pli a nc e m ust b e s u b mitt e d t o M e dtr o nic t o all o w v erific ati o n t h at t h e i n v esti g at or, ot h er c e nt er st u dy st aff, a n d/ or M e dtr o nic p ers o n n el ar e n ot m e m b ers of t h e I R B/ E C. If t h ey ar e m e m b ers of t h e I R B/ E C, writt e n d oc u m e nt ati o n is r e q uir e d st ati n g t h at h e/s h e di d n ot p artici p at e i n t h e a p pr o v al pr oc ess. I n v esti g at ors m ust i nf or m M e dtr o nic of a ny c h a n g e i n st at us of"
47,page_47,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 8 of 1 2 1 I R B/ E C a p pr ov al o nc e t h e i nv esti g ati o n sit e h as st art e d e nr oll m e nt. If a n y acti o n is t a k e n b y a n I R B/ E C wit h r es p ect t o t h e s t u dy, t h at i nf or m ati o n m ust b e f or w ar d e d t o M e dtr o nic. 1 3. 3. R e g ul at or y S u b mi s si o n s E ac h st u dy sit e m ust f ulfill all l oc al r e g ul at or y r e q uir e m e nts pri or t o e nr olli n g s u bj ects. E ac h st u dy sit e m ust h av e writt e n d oc u m e nt ati o n of sit e/i nv esti g at or r e a di n ess, i ncl u di n g b ut n ot li mit e d t o I R B/ E C a p pr o v al of t h e c urr e nt v ersi o n of t h e CI P, I C F, a si g n e d I nv esti g at or’s A gr e e m e nt, c urr e nt i nv esti g at or c urric ul u m vit a e ( C V), a n d d oc u m e nt ati o n of tr ai ni n g. T h e pri nci p al i nv esti g at ors a n d t h eir i nstit uti o ns s h all a gr e e t o t his CI P a n d a ny a m e n d m e nts a n d i n dic at e t h eir a p pr ov al by si g ni n g a n d d ati n g t h e Cli nic al St u dy A gr e e m e nt. I n t h e U nit e d St at es a n d C a n a d a, e ac h st u dy sit e is r e q uir e d t o h a v e a c o py of t h e a p pr o v al l ett er fr o m t h e r es p ectiv e g e o gr a p hy’s r e g ul at ory a g e nc y pri or t o t h eir first s u bj ect e nr oll m e nt. M e dtr o nic will o bt ai n a c o py of t h e a p pr ov al l ett er fr o m t h e r e g ul at or y a g e nci es. Ot h er d oc u m e nts r ef err e d t o i n t his CI P ar e list e d as f oll o ws a n d will b e m a d e a v ail a bl e u p o n r e q u est: • M o nit ori n g Pl a n • D at a M a n a g e m e nt Pl a n • St atistic al A n alysis Pl a n • Cli nic al S af ety M a n a g e m e nt a n d P ot e nti al C o m pl ai nts Pl a n • El ectr o nic C as e R e p ort F or ms ( e C R Fs) If a r e g ul at or y a g e nc y i m p os es a ny a d diti o n al r e q uir e m e nts ( e. g. s af ety r e p orts, pr o gr ess r e p orts, etc.), M e dtr o nic will pr e p ar e t h e r e q uir e d d oc u m e nts a n d s e n d t h e m t o t h e a p plic a bl e r e g ul at ory a g e ncy. A ny r evisi o ns or a m e n d m e nts t o t h e CI P, R e p orts of Pri or I nv esti g ati o ns, or I nf or m e d C o ns e nt t e m pl a t e d oc u m e nts will b e s u b mitt e d t o t h e r e g ul at or y a g e nci es. A fi n al r e p ort w ill b e s u b mitt e d t o t h e r e g ul at ory a g e nci es, if r e q u est e d, u p o n st u dy cl os ur e. 1 3. 4. Et hi c al C o n d u ct of t h e St u d y T h e st u dy will b e c o n d uct e d i n acc or d a nc e wit h t h e d esi g n a n d s p ecific p r ovisi o ns of t his pr ot oc ol, i n acc or d a nc e wit h t h e et hic al pri nci pl es t h at h av e t h eir ori gi n i n t h e D ecl ar ati o n of H elsi n ki, a n d t h at ar e c o nsist e nt wit h G C P, l oc al l a ws a n d t h e a p plic a bl e r e g ul at or y r e q uir e m e nts. T h e st u dy will b e gi n i n e ac h g e o gr a p hy o nl y w h e n all t h e r e q uir e m e nts of t h e a p pr o pri at e r e g ul at or y a ut h ority h a v e b e e n f ulfill e d. T h e pri nci pl es of t h e D ecl ar ati o n of H elsi nki h a v e all b e e n i m pl e m e nt e d by m e a ns of t h e p ati e nt I nf or m e d C o ns e nt pr oc ess, I R B/ E C a p pr ov al, st u dy tr ai ni n g, cli nic al st u dy r e gistr ati o n, pr ecli nic al t esti n g, ris k b e n efit ass ess m e nt, a n d p u blic ati o n p olic y."
48,page_48,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 4 9 of 1 2 1 1 4. 1. Sit e A cti v ati o n All l oc al a n d r e gi o n al r e g ul ati o n r e q uir e m e nts will b e f ulfill e d pri or t o sit e acti v ati o n a n d e nr oll m e nt of s u bj ects i nt o t h e st u dy. E ac h i n v esti g ati o n al sit e m ust h a v e writt e n i n d oc u m e nt ati o n of sit e r e a di n ess, i ncl u di n g b ut n ot li mit e d t o: • I R B a p pr ov al l ett er • F ull y ex ec ut e d Cli nic al Tri al A gr e e m e nt ( C T A) • Fi n a nci al Discl os ur e f or I nv esti g at ors • D el e g at e d T as k List • Tr ai ni n g d oc u m e nt ati o n 1 4. 2. M o nit ori n g I nv esti g ati o n al sit es will b e m o nit or e d t o e ns ur e c o m pl i a nc e wit h t h e st u dy pr ot oc ol, a d h er e nc e t o a p plic a bl e r e g ul ati o ns, a n d acc ur ac y of st u dy d at a. A m o nit ori n g visit will b e c o n d uct e d pri m arily t o e ns ur e t h e s af et y a n d w ell -bei n g of t h e s u bj ects is pr es er v e d. M o nit ori n g visits will als o b e us e d t o v erify th at st u dy d at a s u b mitt e d o n c as e r e p ort f or ms ar e c o m pl et e a n d acc ur at e wit h r es p ect t o t h e s u bj ect cli nic al r ec or ds a n d t o v erify d evic e acc o u nt a bilit y. Sit e p ers o n n el will c o m pl et e e C R Fs f oll o wi n g e ac h s u bj ect visit. St u dy d at a s u b mitt e d will b e r evi e w e d a g ai nst s u bj ect c h arts a n d ot h er s o urc es c o nt ai ni n g ori gi n al r ec or ds of s u bj ect d at a. S o urc e d oc u m e nt v erific ati o n will occ ur i n acc or d a nc e t o t h e M o nit ori n g Pl a n. T h e i nv es ti g at or a n d/ or i nstit uti o n s h all p er mit M e dtr o nic m o nit ori n g r e pr es e nt ativ es dir ec t acc ess t o s o urc e d at a a n d d oc u m e nts. All m o nit ori n g activiti es s h all b e d oc u m e nt e d p er t h e m o nit ori n g pl a n. I n J a p a n, t h e m o nit or will c o nfir m p eri o dic t esti n g, c ali br ati o n a n d m ai nt e n a nc e of e q ui p m e nt us e d f or st u dy ass ess m e nts acc or di n g t o l oc al st a n d a r d of pr actic e. It is r ec o m m e n d e d f or all m e dic al r ec or ds t o b e cl e arl y m ar k e d t o i n dic at e t h at t h e s u bj ect is e nr oll e d i n t his st u dy. T h e pr o gr ess of t h e st u dy will b e m o n it or e d b y: • O n -sit e r e vi e w, a n d/ or r e m ot e d at a cl arific ati o n a n d v erific ati o n, as d e e m e d a p pr o pri at e b y M e dtr o nic • T el e p h o n e c o m m u nic ati o ns b et w e e n t h e sit e p ers o n n el ( e. g., i nv esti g at or, st u dy c o or di n at or) a n d st u dy m o nit ors • R e vi e w of e C R Fs a n d t h e ass oci at e d cli nic al r ec or ds • R e vi e w of r e g ul at ory d oc u m e nts 1 4. St u d y A d mi ni str ati o n"
49,page_49,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 5 0 of 1 2 1 M o nit ori n g a n d m o nit ori n g ov ersi g ht will b e pr ovi d e d by M e dtr o nic. R e pr es e nt ati v es of M e dtr o nic (i. e. c o ntr act ors a n d d esi g n e es) m ay als o act as st u dy m o nit ors. 1 4. 2. 1. Pr e -St u d y Vi sit s Pri or t o e nr oll m e nt, M e d tr o nic p ers o n n el will visit t h e st u dy sit e(s) t o v e rify t h e i nv esti g at or a n d f aciliti es ar e pr e p ar e d f or t h e st u dy a n d t h at r e q uir e m e nts f or st u dy i niti ati o n w er e c o m pl et e d or i n pr o gr ess at t h e ti m e of t h e visit. 1 4. 2. 2. I nt eri m M o nit ori n g T h e st u dy will b e m o ni t or e d t hr o u g h o ut its c o urs e. Fr e q u e nc y of m o nit ori n g visits will b e d et er mi n e d o n a c as e -by -c as e b asis. T h e m o nit or m ay v erify t h e f oll o wi n g d uri n g m o nit ori n g visits: • T h e st u dy is b ei n g c o n d uct e d acc or di n g t o t h e pr ot oc ol a n d a p plic a bl e r e g ul ati o ns • C h a n g e s t o t h e pr ot oc ol r e q uiri n g I R B/ E C r e vi e w h av e b e e n a p pr o v e d • Acc ur at e, c o m pl et e, a n d c urr e nt r ec or ds ar e b ei n g m ai nt ai n e d • A p pr o v e d i nf or m e d c o ns e nt f or ms ar e b ei n g c o m pl et e d c orr ectly (i ncl u di n g d oc u m e nt ati o n t h at t h e s u bj ect w as giv e n a m pl e ti m e t o r e vi e w t h e c o ns e nt, t h at a c o py of t h e c o ns e nt w as giv e n t o e ac h s u bj ect, a n d t h at n o st u dy pr oc e d ur es occ urr e d pri or t o c o ns e nt) • T h e c o ns e nt pr oc ess is b ei n g d oc u m e nt e d c orr ectl y • Ti m ely r e p orts ( a n n u al r e p orts, a d v ers e e v e nts, pr ot oc ol d evi ati o ns) ar e b ei n g m a d e t o t h e s p o ns or a n d I R B/ E C as r e q uir e d In a d diti o n, t h e f oll o wi n g acti viti es m a y occ ur d uri n g m o nit ori n g visits: • C as e r e p ort f or m r evi e w • I nf or m e d c o ns e nt r e vi e w • I nv esti g ati o n al pr o d uct acc o u nt a bilit y r evi e w • R e vi e w of d evic e st or a g e l oc ati o n 1 4. 2. 3. St u d y Cl o s e -O ut A fi n al visit t o t h e c e nt er m a y b e m a d e at st u dy c o ncl usi o n or at t h e e n d of t h e sit e’s p artici p ati o n. T h e f oll o wi n g it e ms m ay b e v erifi e d d uri n g t h e cl os e o ut pr oc ess: • I nv esti g at or/st u dy a d mi nistr ati o n fil es ar e c o m pl et e a n d acc ur at e • Fi n al r ec ei pt of e C R Fs c o nfir m e d; missi n g d at a or cl arifi c ati o n iss u es cl os e d • A n n u al a n d i nt eri m r e p orts (if a ny) ar e u p t o d at e • R e p ort e d d efici e nci es f or t h e sit e h a v e b e e n r es ol v e d or cl os e d • I nv esti g ati o n al pr o d uct acc o u nt a bilit y ( e. g. dis p ositi o n l o gs) b al a nc e a n d ar e c u rr e nt"
50,page_50,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # MD T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 5 1 of 1 2 1 • Sc h e d ul e d et er mi n e d f or fi n al st u dy r e p ort s u b missi o n b y i nv esti g at or t o t h e r es p ecti v e I R B/ E C • R ec or d r et e nti o n r e q uir e m e nts disc uss e d a n d a gr e e d t o by t h e i nv esti g at or Aft er t h e st u dy h as b e e n c o m pl et e d, m e dic al c ar e will b e pr ovi d e d t o t h e s u bj ec ts u p o n t h e discr eti o n of t h e tr e ati n g p hysici a n. 1 4. 3. A u diti n g M e dtr o nic m ay c o n d uct a u dits at p artici p ati n g st u dy sit es. T h e p ur p os e of a n a u dit is t o v erify t h e p erf or m a nc e of t h e m o nit ori n g pr oc ess a n d t h e st u dy c o n d uct, i n d e p e n d e nt of t h e p ers o n n el dir ect l y i nv olv e d i n t h e st u dy. R e g ul at ory b o di es, s uc h as t h e F o o d a n d Dr u g A d mi nistr ati o n, H e alt h C a n a d a or P M D A m a y als o p erf or m i ns p ecti o ns at p artic i p ati n g sit es. T h e i nv esti g at or a n d/ or i nstit uti o n s h all p er mit M e dtr o nic a n d r e g ul at ory b o di es dir ect acc ess t o s o urc e d at a a n d d oc u m e nts. 1 4. 4. S o ur c e D at a / D o c u m e nt s S o urc e d at a/ d oc u m e nt ati o n is d efi n e d as t h e first ti m e t h e d at a a p p e ar a n d m ay i ncl u d e all cli nic al r ec or ds, h os pit al r ec or ds, pr oc e d ur al r e p orts, a ut o psy r e p orts, a n d a n y ot h er m at eri al t h at c o nt ai ns ori gi n al i nf or m ati o n us e d f or st u dy d at a c oll ecti o n or a dv ers e ev e nt r e p orti n g. D at a e nt er e d i nt o t h e st u dy d at a b as e m ust b e tr ac e a bl e t o s o urc e d oc u m e nts. T h e e C R Fs m a y n ot s erv e as s o urc e d oc u m e nts. S o urc e d oc u m e nt ati o n f or d at a el e m e nts n ot r o uti n ely c a pt ur e d i n m e dic al r ec or ds ( e g, ec h oc ar di o gr a p hy v ari a b l es, i n v esti g at or ass ess m e nt of a d v ers e e v e nts, r e as o n f or st u dy exit, r e as o n f or st u dy d evi ati o ns) m ay v ary fr o m c e nt er t o c e nt er. F or ex a m pl e, t h e sit e m a y us e t ec h nic al w or ks h e ets if t h e y ar e cl e arly i d e ntifi e d as s o urc e d oc u m e nts a n d si g n e d a n d d at e d b y t h e p ers o n c o m pl eti n g t h e w or ks h e et a n d a st u dy i n v esti g at or. S o urc e d oc u m e nts ar e r e q uir e d t o b e m ai nt ai n e d f oll o wi n g t h e r ec or d r et e nti o n p olici es o utli n e d i n S ecti o n 1 5. 3 . R ec or d R et e nti o n . S o urc e d oc u m e nts m ust b e m a d e av ail a bl e f or m o nit ori n g or a u diti n g by t h e s p o ns or’s r e pr es e nt ati v e or r e pr es e nt ativ es of a p plic a bl e r e g ul at or y a g e nci es or t h e I R B/ E C. T h e i nv esti g at or m ust e ns ur e t h e a v ail a bility of all s o urc e d o c u m e nts fr o m w hic h d at a o n t h e e C R Fs w er e d eri v e d. W h e r e pri nt o uts of el ectr o nic m e dic al r ec or ds ( E M R) ar e pr o vi d e d as s o urc e d oc u m e nts, or w h er e c o pi es of m e dic al r ec or ds ar e r et ai n e d as s o urc e d oc u m e nts, t h e y m ust b e i d e ntifi e d as c ertifi e d c o pi es t h at f oll o w a d oc u m e nt e d c ertific ati o n pr oc ess attri b uti n g t o t h eir acc ur acy a n d c o m pl et e n ess. I n a d diti o n, t h e m e dic al r ec or ds of st u dy s u bj ects s h o ul d b e m ark e d i n s uc h a w a y t o i n dic at e t h eir p artici p ati o n i n t h e st u dy."
51,page_51,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # MD T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 5 2 of 1 2 1 1 4. 5. C o nfi d e nti alit y All i nf or m ati o n a n d d at a s e nt t o p arti es i n v ol v e d i n st u dy c o n d uct c o nc er ni n g s u bj ects or t h eir p artici p ati o n i n t his st u dy will b e c o nsi d er e d c o nfi d e nti al. St u dy sit es will assi g n a u ni q u e s u bj ect i d e ntific ati o n n u m b er (I D) t o e ac h s u bj ect. R ec or ds of t h e s u bj ect/I D r el ati o n s hi p will b e m ai nt ai n e d by t h e st u dy sit e. T h e I D is t o b e r ec or d e d o n all st u dy d oc u m e nts t o li n k t h e m t o t h e s u bj ect’s m e dic al r ec or ds at t h e sit e. T o m ai nt ai n c o nfi d e nti alit y, t h e s u bj ect’s n a m e or a n y ot h er p ers o n al i d e ntifi ers s h o ul d n ot b e r ec or d e d o n a ny st u dy d oc u m e nt ot h er t h a n t h e i nf or m e d c o ns e nt f or m. I n t h e e v e nt a s u bj ect’s n a m e is i ncl u d e d f or a n y r e as o n, it will b e m as k e d as a p plic a bl e. I n t h e e v e nt of i n a bilit y t o m as k t h e i d e ntific ati o n ( e. g., di git al m e di a), it will b e h a n dl e d i n a c o nfi d e nti al m a n n er by t h e a ut h oriz e d p ers o n n el. St u dy i nf or m ati o n a n d d at a m ay b e s h ar e d wit h t h e f oll o wi n g f or r e as o ns i ncl u di n g, b ut n ot li mi t e d t o, m o nit ori n g or a u diti n g p ur p os es: • Wit h t h e st u dy s p o ns or, M e dtr o nic a n d its a g e nts a n d c o ntr act ors (t o g et h er “ M e dtr o nic”); • Wit h ot h er r es e arc h ers i n t h e st u dy t o s u p p ort st u dy c o n d uct or pr oc ess es ( e. g., p ati e nt scr e e ni n g); • Wit h g ov er n m e nt or g a niz a ti o ns a n d r e vi e w b o ar ds r e q uir e d t o w atc h ov er t h e s af et y a n d eff ectiv e n ess of m e dic al pr o d ucts a n d t h er a pi es a n d t h e c o n d uct of r es e arc h; a n d • Wit h ot h er p ers o ns w h o ar e r e q uir e d t o w atc h ov er t h e s af et y a n d eff ecti v e n ess of m e dic al pr o d ucts a n d t h er a pi es a n d t h e c o n d uct of r es e arc h. T h e pri v ac y of e ac h s u bj ect a n d c o nfi d e nti alit y of his/ h er i nf or m ati o n s h all b e pr es erv e d i n r e p orts a n d w h e n p u blis hi n g a n y d at a. I nv esti g ati o n al sit es will pr ot ect t h e p ers o n al i nf or m ati o n of s u bj ects i n acc or d a nc e wit h a p plic a bl e l a ws, r e g ul ati o ns a n d I R B/ E C r e q uir e m e nts. 1 4. 6. D at a M a n a g e m e nt M e dtr o nic will b e r es p o nsi bl e f or t h e pr oc essi n g a n d q u alit y c o ntr ol of t h e d at a. D at a r e vi e w, d at a b as e cl e a ni n g a n d iss ui n g a n d r es ol vi n g d at a q u eri es will b e d o n e acc o r di n g t o M e dtr o nic i nt er n al st a n d ar d o p er ati n g pr oc e d ur es ( S O Ps) a n d t h e D at a M a n a g e m e nt Pl a n f or t his st u dy. T h e st u dy d at a b as e will e m pl o y v ali d ati o n pr o gr a ms ( e. g. r a n g e a n d l o gic c h ecks) o n c ert ai n e nt er e d d at a t o i d e ntif y p ossi bl e d at a e ntry err ors a n d t o f acilit at e d at a v ali d ati o n. R e q uir e d i m a g es f or M e dtr o nic or C or e L a b e v al u ati o n will b e d e -i d e ntifi e d a n d el ectr o nic all y tr a nsf err e d usi n g a s ec ur e fil e tr a nsf er or ot h er s ec ur e m et h o ds as a p pr o pri at e. All st u dy i m a gi n g i ncl u di n g pr ot oc ol r e q uir e d as s ess m e nts, i m pl a nt a n gi o gr a p hy, a n d a ny u nsc h e d ul e d i m a gi n g p erf or m e d t o ass ess t h e H ar m o ny T P V s h o ul d b e s e nt t o M e dtr o nic."
52,page_52,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # MD T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 5 3 of 1 2 1 1 4. 7. Li a bilit y S u bj ect c o m p e ns ati o n, i n d e m nific ati o n a n d li a bility i ns ur a nc e c o v er a g e ar e i ncl u d e d I n t h e Cli nic al St u dy A gr e e m e nt f or e ac h p artici p ati n g c e nt er . M e dtr o nic m ai nt ai ns a p pr o pri at e cli nic al st u dy li a bility i ns ur a nc e c o v er a g e as r e q uir e d u n d er a p plic a bl e l a ws a n d r e g ul ati o ns a n d will c o m pl y wit h a p plic a bl e l oc al l a w a n d c ust o ms c o nc er ni n g s p ecific i ns ur a nc e c o v e r a g e. If r e q uir e d, a cli nic al st u dy i ns ur a nc e st at e m e nt/c ertific at e will b e pr o vi d e d t o t h e I R B/ H e a d of M e dic al I nstit uti o n. 1 4. 8. C I P A m e n d m e nt s T h e i nv e sti g at or m ay pr o p os e a ny a p pr o pri at e m o dific ati o n(s) of t h e CI P or i n v esti g ati o n al d evic e or i nv esti g ati o n al d evic e us e. M e dtr o nic will r evi e w t his pr o p os al a n d d eci d e w h et h er t h e m o dific ati o n(s) will b e i m pl e m e nt e d. M e dtr o nic will s u b mit a ny si g nific a nt a m e n d m e nt t o t h e CI P, i ncl u di n g a j ustific ati o n f or t h e a m e n d m e nt, t o t h e a p plic a bl e r e g ul at o r y a g e nc y(i es) a n d t o t h e i n v esti g at ors t o o bt ai n a p pr ov al fr o m t h eir I R B/ E C. T h e i nv esti g at or will o nly i m pl e m e nt t h e a m e n d m e nt aft er r ec ei vi n g a p pr o v al fr o m t h e I R B/ E C, a p plic a bl e r e g ul at or y a g e nci es a n d M e dtr o nic. A d mi nistr ativ e a m e n d m e nts t o t h e CI P wi ll b e s u b mitt e d t o t h e I R B/ E C f or n otific ati o n. 1 4. 9. P u bli c ati o n a n d U s e of I nf or m ati o n M e dtr o nic is c o m mitt e d t o t h e wi d es pr e a d diss e mi n ati o n of all pri m ar y a n d a d dit i o n al e n d p oi nt r es ults. A P u blic ati o n Pl a n will b e i m pl e m e nt e d a n d f oll o w e d. At t h e c o ncl usi o n of t h e st u dy, a m ultisit e a bstr act r e p orti n g t h e pri m ar y r es ults will b e pr e p ar e d b y t h e Pri nci p al I nv esti g at or (i n c oll a b or ati o n wit h ot h ers) f or s u bs e q u e nt pr e s e nt ati o n at a n a n n u al sci e ntific m e eti n g. A m ultisit e p u blic ati o n will si mil arly b e pr e p ar e d f or p u blic ati o n i n a r e p ut a bl e sci e ntific j o ur n al. T h e p u blic ati o n of t h e pri nci p al r es ults fr o m a ny si n gl e sit e ex p eri e nc e wit hi n t h e st u dy is n ot all o w e d u ntil b ot h t h e pr e p ar ati o n a n d p u blic ati o n of t h e m ultisit e r es ults, a n d t h e n o nl y wit h writt e n p er missi o n fr o m M e dtr o nic. F oll o wi n g a n alysis a n d pr es e nt ati o n of t h e e n d p oi nt r es ults, activ e p artici p ati o n of all p artici p ati n g i nv esti g at ors, C E C c o m mitt e e m e m b er s, D M C m e m b ers, a n d c or e l a b or at or y p ers o n n el will b e s olicit e d f or d at a a n alysis a n d a bstr ac t a n d m a n uscri pt pr e p ar ati o n. S u b missi o n of all a bstr acts a n d p u blic ati o ns fr o m t h e st u dy r e q uir es a p pr o v al by t h e st e eri n g c o m mitt e e a n d p u blic ati o n c o m mitt e e. A s e p ar at e P u blic ati o n Pl a n will pr ovi d e d et ail e d i nf or m ati o n a b o ut t h e p u blic ati o n c o m mitt e e, a ut h ors hi p, p u blic ati o n pr o p os als, a n d r e q u ests f or d at a."
53,page_53,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # MD T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 5 4 of 1 2 1 1 4. 1 0. S u s p e n si o n or E arl y T er mi n ati o n of t h e St u d y M e dtr o nic m ay d eci d e t o s us p e n d or pr e m at ur el y t er mi n at e t h e st u dy. If t h e st u dy is t er mi n at e d pr e m at ur el y or s us p e n d e d, M e dtr o nic s h all pr o m ptly i nf or m t h e cli nic al i n v esti g at ors a n d r e g ul at or y a ut h oriti es of t h e t er mi n ati o n or s us p e nsi o n a n d t h e r e as o n(s) f or t his. T h e i nv esti g at or s h all t h e n pr o m ptly i nf or m t h e r evi e wi n g I R B/ E C. M e dtr o nic will, as s o o n as p ossi bl e, pr o vi d e a writt e n st at e m e nt t o t h e i n v esti g at ors t o e n a bl e pr o m pt n otific ati o n of t h e I R B/ E C. If st u dy e nr oll m e nt is t er mi n at e d e arl y, f oll o w -u p visits will c o nti n u e f or all e nr oll e d s u bj ects. 1 4. 1 1. S u s p e n si o n or E arl y T er mi n ati o n of a St u d y Sit e M e dtr o nic m ay d eci d e t o s us p e n d or pr e m at ur el y t er mi n at e a st u dy sit e ( e. g. i n c as e of ex piri n g a p pr o v al of t h e r e vi e wi n g I R B/ E C, n o n -c o m pli a nc e t o t h e CI P, or l ac k of e nr oll m e nt). If a st u dy sit e is s us p e n d e d or pr e m at ur ely t er mi n at e d, M e dtr o nic s h all pr o m ptl y i nf or m t h e i n v esti g at or(s) of t h e t er mi n ati o n or s us p e nsi o n a n d t h e r e as o n(s) f or t his. T h e i nv esti g at or s h all t h e n pr o m ptly i nf or m t h e r e vi e wi n g I R B/ E C. 1 5. 1. R e s p o n si biliti e s of t h e I n v e sti g at or T h e i nv esti g at or is r es p o nsi bl e f or t h e pr e p ar ati o n, r evi e w, a n d si g n at ur e ( as a p plic a bl e), a n d r et e nti o n of t h e f oll o wi n g r ec or ds: • All ess e nti al c orr es p o n d e nc e t h at p ert ai ns t o t h e i nv esti g ati o n • D evic e us e/ dis p ositi o n r ec or ds • R ec or ds of e ac h s u bj ect’s c as e hist or y a n d ex p os ur e t o t h e d evic e. C as e hist ori es i ncl u d e t h e e C R Fs a n d s u p p orti n g d at a (s o urc e d oc u m e nt ati o n), i ncl u di n g, f or ex a m pl e: • Si g n e d a n d d at e d c o ns e nt f or ms • M e dic al r ec or ds, i ncl u di n g, f or ex a m pl e, pr o gr ess n ot es of t h e p hysici a ns , t h e s u bj ect’s h os pit al c h art(s) a n d t h e n urs es’ n ot es • All a dv ers e ev e nt/ d evic e d efici e ncy i nf or m ati o n • A r ec or d of t h e ex p os ur e of e ac h s u bj ect t o t h e i nv esti g ati o n al d evic e ( e. g., d at e of i m pl a nt pr oc e d ur e a n d f oll o w -u p ass ess m e nt d at es) • D oc u m e nt ati o n of a ny d e vi ati o n fr o m t h e C I P, i ncl u di n g t h e d at e a n d t h e r ati o n al e f or s uc h d e vi ati o n • Si g n e d I nv esti g at or A gr e e m e nt, si g n e d a n d d at e d c urric ul u m vit a e of t h e PI, s u b -i nv esti g at or(s) a n d k e y m e m b ers, si g n e d D el e g at e d T as k List • I n C a n a d a, I nv esti g at or’s A gr e e m e nt i n acc or d a nc e wit h S u bs ecti o n 8 1( k) of t h e M e dic al D evic es R e g ul ati o ns 1 5. R e c or d R et e nti o n a n d R e p orti n g R e s p o n si biliti e s"
54,page_54,
55,page_55,
56,page_56,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # MD T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 5 7 of 1 2 1 All d e vi ati o ns, r e g ar dl ess of t h e r e as o n, s h all b e s u b mitt e d t o t h e s p o ns or. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 6 6) S u m m ary of t h e Cli nic al St u dy St at us H e a d of M e dic al I nstit uti o n T h e pri nci p al i nv esti g at or s h all s u b mit a s u m m ary of t h e cli nic al st u dy st at us t o t h e H e a d of M e dic al I nstit uti o n i n writi n g o nc e a y e ar, or m or e fr e q u e ntl y if r e q u est e d by t h e I R B/ E C, t o r ec eiv e t h e c o nti n u ati o n r e vi e w by t h e I R B/ E C. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 6 8) Pr e m at ur e T er mi n ati o n or S us p e nsi o n of t h e Cli nic al I nv esti g ati o n H e a d of M e dic al I nstit uti o n W h e n t h e pri nci p al i nv esti g at or disc o nti n u es or s us p e n ds t h e cli nic al st u dy, h e or s h e s h all pr o m ptly n otif y t h e H e a d of M e dic al I nstit uti o n t h er e of i n writi n g, a n d ex pl ai n i n d et ail i n writi n g t h e disc o nti n u ati o n or s us p e nsi o n. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Ar ticl e 6 9) C o m pl eti o n of t h e Cli nic al I nv esti g ati o n H e a d of M e dic al I nstit uti o n W h e n t h e cli nic al st u dy is c o m pl et e d, t h e pri nci p al i nv esti g at or s h all n otify t h e H e a d of M e dic al I nstit uti o n t h er e of i n writi n g a n d r e p ort o n a s u m m ar y of t h e cli nic al st u dy r es ults i n writi n g. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 6 9) 1 5. 2. R e s p o n si biliti e s of t h e S p o n s or T h e S p o ns or will m ai nt ai n t h e f oll o wi n g r ec or ds, i ncl u di n g b ut n ot li mit e d t o: • All ess e nti al c orr es p o n d e nc e r el at e d t o t h e cli nic al st u dy • Si g n e d I nv esti g at or A gr e e m e nt • Si g n e d a n d d at e d c urr e nt c urric ul u m vit a e f or e ac h i nv esti g at or • R ec or ds of d evic e s hi p m e nt a n d dis p ositi o n (s hi p pi n g r ec ei pts, m at eri al d estr uct r ec or ds, etc.) • A dv ers e ev e nt a n d d e vic e d efi ci e nc y i nf or m ati o n • All d at a f or ms, pr e p ar e d a n d si g n e d b y t h e i nv esti g at ors, a n d r ec ei v e d s o urc e d oc u m e nt ati o n a n d c or e l a b r e p orts • CI P, i nv esti g at or br oc h ur e or r e p ort of pri or i nv esti g ati o ns a n d s u bs e q u e nt a m e n d m e nts • Sit e m o nit ori n g r e p orts • Fi n a nci al dis cl os ur e i nf or m ati o n • St u dy tr ai ni n g r ec or ds f or sit e p artici p a nts a n d i nt er n al st u dy st aff m e m b ers • C o nt act lists of all p artici p ati n g i n v esti g at ors/i nv esti g ati v e sit es, st u dy m o nit ors a n d S p o ns or st aff m e m b ers; S p o ns or will m ai nt ai n t h es e lists a n d pr o vi d e u p d at es t o t h e n ec ess ar y p arti es • S a m pl e of d evic e l a b eli n g att ac h e d t o i nv esti g ati o n al d e vic e • I ns ur a nc e c ertific at es • Et hics B o ar d a p pr ov al d oc u m e nt ati o n a n d v oti n g list"
57,page_57,
58,page_58,
59,page_59,
60,page_60,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 1 of 1 2 1 h e a ds of all t h e m e dic al i nstit uti o ns ot h er f aciliti es e n g a g e d i n t h e cli nic al tri al t h er e of a n d t h e d et ail e d r e as o n t h er ef or i n writi n g. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 3 2 ) I nv esti g at or List H e a d of M e dic al I nstit uti o n P M D A T h e s p o ns or s h all b ef or e h a n d s u b mit t h e list of i nv esti g at ors t o P M D A a n d H e a d of M e dic al I nstit uti o n. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 1 0, P h ar m ac e utic al a n d M e dic al D evic e Act E nf orc e m e nt R e g ul ati o ns, Articl e 2 6 9, 2 7 5) T h e s p o ns or s h all s u b mit t h e list of i nv esti g at ors t o P M D A a n d H e a d of M e dic al I nstit uti o n w h e n m a ki n g a ny c h a n g es i n t h e list. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 5 1, P h ar m ac e utic al a n d M e dic al D evic e Act E nf orc e m e nt R e g ul a ti o ns, Articl e 2 7 0, 2 7 5) W h e n n e w, i m p ort a nt i nf or m ati o n is o bt ai n e d, t h e I m p ort a nt i nf or m ati o n c o nc er ni n g t h e q u alit y, effic ac y, a n d s af et y of t h e i nv esti g ati o n al d evic e Pri nci p al I nv esti g at or H e a d of M e dic al I nstit uti o n P M D A s p o ns or s h all r evis e t h e i nv esti g at or’s br oc h ur e. I n a d diti o n, pri or t o r evisi n g t h e i nv esti g at or’s br oc h ur e, t h e s p o ns or s h all r e p ort t h e i nf or m ati o n t o t h e pri nci p al i nv esti g at or, H e a d of M e dic al I nstit uti o n, a n d r e g ul at ory a ut h oriti es. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 2 8) Cli nic al Tri al R e p ort P M D A u p o n r e q u est T h e s p o ns or s h all pr e p ar e, acc or di n g t o t h e pr oc e d ur e, a cli nic al st u dy r e p ort t h at s u m m ariz es t h e r es ults, etc., of a cli nic al st u dy w h e n it is c o m pl et e d or disc o nti n u e d. ( M HL W Or di n a nc e 3 6, Articl e 3 3) E ns ur e t h at all d evi ati o ns fr o m t h e CI P ar e r e vi e w e d wit h t h e a p pr o pri at e cli nic al i nv esti g at or(s), ar e r e p ort e d o n t h e c as e r e p ort f or ms a n d t h e fi n al Pri nci p al r e p ort of t h e cli nic al i n v esti g ati o n. (IS O 1 4 1 5 5: 2 0 1 1) St u dy d e vi ati o n I nv esti g at or H e a d of M e dic al I nstit uti o n as n ec ess ar y W h e n t h e m o nit or c o nfir ms d e vi ati o n as a r es ult of m o nit ori n g, t h e m o nit or s h all n otify t h e pri nci p al i nv esti g at or a n d, as n ec ess ar y, t h e H e a d of M e dic al I nstit uti o n t h er e of. T h e m o nit or s h all als o r e q u est f or a p pr o p ri at e m e as ur es t o b e t a k e n t o pr ev e nt s uc h d e vi ati o n i n t h e f ut ur e. ( M HL W Or di n a nc e 3 6, 2 0 0 5 Articl e 3 0)"
61,page_61,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 2 of 1 2 1 1 5. 3. R e c or d R et e nti o n T h e i nv esti g at or m ust r et ai n t h e I nv esti g at or Sit e Fil e, s o urc e d oc u m e nts, a n d t h e r ec or ds list e d i n S ecti o n 1 5. 1 . R es p o nsi biliti es of t h e I n v esti g at or , u ntil i nf or m e d b y M e dtr o nic t h e y n o l o n g er n e e d t o b e r et ai n e d. At a mi ni m u m, t h e i nv esti g at or m ust r et ai n r ec or ds f or at l e ast 3 y e ars ( or l o n g er if r e q uir e d by l oc al l a w) aft er t h e l ast a p pr o v a l of a m ar k eti n g a p plic ati o n a n d u ntil t h er e ar e n o p e n di n g or c o nt e m pl at e d m ar k eti n g a p plic ati o ns, or at l e ast 3 y e ars h a v e el a ps e d si nc e t h e f or m al disc o nti n u ati o n of t h e cli nic al st u dy or cli nic al d e v el o p m e nt of t h e i n v esti g ati o n al d evic es. T h e i nv esti g at or s h o ul d t a k e m e as ur es t o pr e v e nt acci d e nt al or e arly d estr ucti o n of t h e st u dy r el at e d m at eri als. M e dtr o nic will m ai nt ai n st u dy r ec or ds u n d er its r es p o nsi bilit y i n acc or d a nc e wit h f e d er al l a ws a n d r e g ul ati o ns, J -G C P a n d M e dtr o nic p olic y. 1. T h erri e n J, Pr o v ost Y, M erc h a nt N, Willi a ms W, C ol m a n J, W e b b G. O pti m al ti mi n g f or p ul m o n ary v al v e r e pl ac e m e nt i n a d ults aft er t etr al o gy of F all ot r e p air. T h e A m eric a n j o ur n al of c ar di ol o gy 2 0 0 5; 9 5: 7 7 9 -8 2. 2. L ucr o n H, M arc o n F, B oss er G, L et h or J P, M ari e P Y, Br e m bill a -P err ot B. I n d ucti o n of s ust ai n e d v e ntric ul ar t ac hyc ar di a aft er s ur gic al r e p air of t etr al o gy of F all ot. T h e A m eric a n j o ur n al of c ar di ol o gy 1 9 9 9; 8 3: 1 3 6 9 -7 3. 3. H or n eff er PJ, Z a h k a K G, R o w e S A, et al. L o n g -t er m r es ults of t ot al r e p air of t etr al o gy of F all ot i n c hil d h o o d. T h e A n n als of t h or acic s ur g er y 1 9 9 0; 5 0: 1 7 9 -8 3; disc ussi o n 8 3 -5. 4. G atz o ulis M A, B al aji S, W e b b er S A, et al. Risk f act ors f or arr hyt h mi a a n d s u d d e n c ar di ac d e at h l at e aft er r e p air of t etr al o gy of F all ot: a m ultic e ntr e st u dy. L a nc et 2 0 0 0; 3 5 6: 9 7 5 -8 1. 5. R ot h m a n A, P erry S B, K e a n e J F, L oc k J E. E arly r es ults a n d f oll o w -u p of b all o o n a n gi o pl ast y f or br a nc h p ul m o n ar y art ery st e n os es. J o ur n al of t h e A m eric a n C oll e g e of C ar di ol o gy 1 9 9 0; 1 5: 1 1 0 9 -1 7. 6. K a v ey R E, T h o m as F D, Byr u m CJ, Bl ac k m a n M S, S o n d h ei m er H M, B o v e EL. V e ntric ul ar arr hyt h mi as a n d bi v e ntric ul ar d ysf u ncti o n aft er r e p air of t etr al o gy of F all ot. J o ur n al of t h e A m eric a n C oll e g e of C ar di ol o gy 1 9 8 4; 4: 1 2 6 -3 1. 7. B o v e EL, B yr u m CJ, T h o m as F D, et al. T h e i nfl u e nc e of p ul m o n ary i ns uffici e nc y o n v e ntric ul ar f u ncti o n f oll o wi n g r e p air of t etr al o gy of F all ot. E v al u ati o n usi n g r a di o n ucli d e v e ntric ul o gr a p hy. T h e J o ur n al of t h or acic a n d c ar di o v asc ul ar s ur g ery 1 9 8 3; 8 5: 6 9 1 -6. 8. G atz o ulis M A, Till J A, S o m er vill e J, R e di n gt o n A N. M ec h a n o el ectric al i nt er acti o n i n t etr al o gy of Fall ot. Q R S pr ol o n g ati o n r el at es t o ri g ht v e ntric ul ar siz e a n d pr e dicts m ali g n a nt v e n tric ul ar arr hyt h mi as a n d s u d d e n d e at h. Circ ul ati o n 1 9 9 5; 9 2: 2 3 1 -7. 9. C ar v al h o J S, S hi n e b o ur n e E A, B usst C, Ri g by ML, R e di n gt o n A N. Ex ercis e c a p acit y aft er c o m pl et e r e p air of t etr al o gy of F all ot: d el et eri o us eff ects of r esi d u al p ul m o n ar y r e g ur git ati o n. Britis h h e art j o ur n al 1 9 9 2; 6 7: 4 7 0 -3. 1 0. T h erri e n J, Si u S C, H arris L, et al. I m p act of p ul m o n ar y v al v e r e pl ac e m e nt o n arr hyt h mi a pr o p e nsit y l at e aft er r e p air of t etr al o gy of F all ot. Circ ul ati o n 2 0 0 1; 1 0 3: 2 4 8 9 -9 4. 1 1. E ys k e ns B, R ey br o uc k T, B o g a ert J, et al. H o m o gr aft i ns erti o n f or p ul m o n ar y r e g ur git ati o n aft er r e p air of t etr al o gy of f all ot i m pr ov es c ar di or es pir at or y ex ercis e p erf or m a nc e. T h e A m eric a n j o ur n al of c ar di ol o gy 2 0 0 0; 8 5: 2 2 1 -5. 1 6. R ef er e n c e s"
62,page_62,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 3 of 1 2 1 1 2. K a nt er K R, B u d d e J M, P ar ks WJ, et al . O n e h u n dr e d p ul m o n ary v al v e r e pl ac e m e nts i n c hil dr e n aft er r eli ef of ri g ht v e ntric ul ar o utfl o w tr act o bstr ucti o n. T h e A n n als of t h or acic s ur g er y 2 0 0 2; 7 3: 1 8 0 1 -6; disc ussi o n 6-7. 1 3. Bi el ef el d M R, Bis h o p D A, C a m p b ell D N, Mi tc h ell M B, Gr o v er FL, Cl ar k e D R. R e o p er ati v e h o m o gr aft ri g ht v e ntric ul ar o utfl o w tr act r ec o nstr ucti o n. T h e A n n als of t h or acic s ur g er y 2 0 0 1; 7 1: 4 8 2 -7; disc ussi o n 7-8. 1 4. C h e at h a m J P, H ell e n br a n d W E, Z a h n E M, et al. Cli nic al a n d H e m o dy n a mic O utc o m es U p t o 7 Y e ar s Aft er Tr a nsc at h et er P ul m o n ary V alv e R e pl ac e m e nt i n t h e U S M el o dy V al v e I nv esti g ati o n al D evic e Ex e m pti o n Tri al. Circ ul ati o n 2 0 1 5. 1 5. Sc hi e v a n o S, C o ats L, Mi gli av acc a F, et al. V ari ati o ns i n ri g ht v e ntric ul ar o utfl o w tr act m or p h ol o gy f oll o wi n g r e p air of c o n g e nit al h e art dis e as e: i m plic ati o ns f o r p erc ut a n e o us p ul m o n ary v al v e i m pl a nt ati o n. J o ur n al of c ar di o v asc ul ar m a g n etic r es o n a nc e : offici al j o ur n al of t h e S oci ety f or C ar di o v asc ul ar M a g n etic R es o n a nc e 2 0 0 7; 9: 6 8 7 -9 5. 1 6. d e R uijt er F T, W e e ni n k I, Hitc hc ock J F, B e n ni nk G B, M eij b o o m EJ. Ri g ht v e ntric u l ar d ysf u ncti o n a n d t h e r ol e of p ul m o n ary v al v e r e pl ac e m e nt aft er c orr ecti o n of t etr al o gy of F all ot. N et h erl a n ds h e art j o ur n al : m o nt hl y j o ur n al of t h e N et h erl a n ds S oci ety of C ar di ol o gy a n d t h e N et h erl a n ds H e art F o u n d at i o n 2 0 0 1; 9: 2 6 9 -7 4. 1 7. Disci gil B, D e ar a n i J A, P u g a FJ, et al. L at e p ul m o n ar y v al v e r e pl ac e m e nt aft er r e p air of t etr al o gy of F all ot. T h e J o ur n al of t h or acic a n d c ar di o v asc ul ar s ur g er y 2 0 0 1; 1 2 1: 3 4 4 -5 1. 1 8. B o v e EL, K a v e y R E, Byr u m CJ, S o n d h ei m er H M, Bl ack m a n M S, T h o m as F D. I m pr o v e d ri g ht v e ntric ul ar f u ncti o n f oll o wi n g l at e p ul m o n ar y v alv e r e pl ac e m e nt f or r esi d u al p ul m o n ary i ns uffici e nc y or st e n osis. T h e J o ur n al of t h or acic a n d c ar di o v asc ul ar s ur g er y 1 9 8 5; 9 0: 5 0 -5. 1 9. B o u dj e mli n e Y, A g n ol etti G, B o n n e t D, Si di D, B o n h o ef f er P. P erc ut a n e o us p ul m o n ar y v al v e r e pl ac e m e nt i n a l ar g e ri g ht v e ntric ul ar o utfl o w tr act: a n ex p eri m e nt al st u dy. J o ur n al of t h e A m eric a n C oll e g e of C ar di ol o gy 2 0 0 4; 4 3: 1 0 8 2 -7. 2 0. B o u dj e mli n e Y, Sc hi ev a n o S, B o n n et C, et al. Off -p u m p r e pl a c e m e nt of t h e p ul m o n ar y v al v e i n l ar g e ri g ht v e ntric ul ar o utfl o w tr acts: a h y bri d a p pr o ac h. T h e J o ur n al of t h or acic a n d c ar di o v asc ul ar s ur g er y 2 0 0 5; 1 2 9: 8 3 1 -7. 2 1. Dittric h S, Gl o ec kl er M, Ar n ol d R, et al. Hy bri d p ul m o n ar y v alv e i m pl a nt ati o n: i nj ecti o n of a s elf - ex p a n di n g tiss u e v alv e t hr o u g h t h e m ai n p ul m o n ar y art er y. T h e A n n als of t h or acic s ur g er y 2 0 0 8; 8 5: 6 3 2 - 4. 2 2. Sc hr ei b er C, H or er J, V o gt M, et al. A n e w tr e at m e nt o pti o n f or p ul m o n ar y v alv ar i ns uffici e nc y: first ex p eri e nc es wit h i m pl a nt ati o n of a s elf -ex p a n di n g st e nt e d v alv e wi t h o ut us e of c ar di o p ul m o n ary by p ass. E ur o p e a n j o ur n al of c ar di o -t h or acic s ur g er y : offici al j o ur n al of t h e E ur o p e a n Ass oci ati o n f or C ar di o -t h or acic S ur g ery 2 0 0 7 ; 3 1: 2 6 -3 0. 2 3. Bi er n ac k a E K, R uzyłł o W, D e m k o w M, et al. Tr a nsc at h et er p ul m o n ary v al v e i m pl a nt ati o n i n p ati e nts wit h ri g ht v e ntric ul ar o utfl o w tr act d ysf u ncti o n: E arly a n d mi d -t er m r es ults. J o ur n al of I nv asi v e C ar di ol o gy 2 0 1 5; 2 7: E 8 2 -E 9. 2 4. M e a d o ws JJ, M o or e P M, B er m a n D P, et al. Us e a n d P erf or m a nc e of t h e M el o dy Tr a nsc at h et er P ul m o n ar y V al v e i n N ativ e a n d P osts ur gic al, N o nc o n d uit Ri g ht V e ntric ul ar O utfl o w Tr acts. Circ ul ati o n C ar di o v asc ul ar i nt erv e nti o ns 2 0 1 4. 2 5. M al e kz a d e h -Mil a ni S, L a d o uc e ur M, C o h e n S, Is eri n L, B o u dj e mli n e Y. R es ults of tr a nsc at h et er p ul m o n ary v alv ul ati o n i n n ati v e or p atc h e d ri g ht v e ntric ul ar o utfl o w tr acts. Arc hiv es of c ar di ov asc ul ar dis e as es 2 0 1 4; 1 0 7: 5 9 2 -8."
63,page_63,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 4 of 1 2 1 2 6. P hilli ps A B, N evi n P, S h a h A, Ols h ov e V, G ar g R, Z a h n E M. D e v el o p m e nt of a n o v el h y bri d str at e gy f or tr a nsc at h et er p ul m o n ary v alv e pl ac e m e nt i n p ati e nts f oll o wi n g tr a ns a n n ul ar p atc h r e p air of t etr al o gy of f all ot. C at h et eriz ati o n a n d c ar di o v asc ul ar i nt er v e nti o ns : offici al j o ur n al of t h e S oci ety f or C ar di ac A n gi o gr a p hy & I nt er v e nti o ns 2 0 1 6; 8 7: 4 0 3 -1 0. 2 7. Pr o m p h a n W, Pr ac h asilc h ai P, Siri p or n pit a k S, Q ur es hi S A, L a y a n g o ol T. P erc ut a n e o us p ul m o n ar y v al v e i m pl a nt ati o n wit h t h e V e n us P -v alv e: cli nic al ex p eri e nc e a n d e arl y r es ults. C ar di ol o gy i n t h e y o u n g 2 0 1 6; 2 6: 6 9 8 -7 1 0. 2 8. C a o QL, K e n ny D, Z h o u D, et al. E arly cli nic al ex p eri e nc e wit h a n ov el s elf -ex p a n di n g p erc ut a n e o us st e nt -v alv e i n t h e n ativ e r i g ht v e ntric ul ar o utfl o w tr act. C at h et eriz ati o n a n d c ar di ov asc ul ar i nt er v e nti o ns : offici al j o ur n al of t h e S oci et y f or C ar di ac A n gi o gr a p hy & I nt erv e nti o ns 2 0 1 4; 8 4: 1 1 3 1 -7. 2 9. B os h off D E, C o ols BL M, H eyi n g R, et al. Off -l a b el us e of p erc ut a n e o us p ul m o n ary v al v e d st e nts i n t h e ri g ht v e ntric ul ar o utfl o w tr act: Ti m e t o r e writ e t h e l a b el ? C at h et eriz ati o n a n d C ar di o v asc ul ar I nt er v e nti o ns 2 0 1 3; 8 1: 9 8 7 -9 5. 3 0. D e m k o w M, R uzyłł o W, Bi er n ac k a E K, et al. P erc ut a n e o us e d w ar ds S A PI E N T M v alv e i m pl a nt ati o n f or si g nific a nt p ul m o n ar y r e g ur git ati o n aft er pr e vi o us s ur gic al r e p air wit h a ri g ht v e ntric ul ar o utfl o w p atc h. C at h et eriz ati o n a n d C ar di o v asc ul ar I nt erv e nti o ns 2 0 1 4; 8 3: 4 7 4 -8 1. 3 1. H a as N A, M o ysic h A, N e u d orf U, et al. P erc ut a n e o us i m pl a nt ati o n of t h e E d w ar ds S A PI E N ™ p ul m o nic v alv e: I niti al r es ults i n t h e first 2 2 p ati e nts. Cli nic al R es e arc h i n C ar di ol o gy 2 0 1 3; 1 0 2: 1 1 9 -2 8. 3 2. “ E d w ar ds S A PI E N P ul m o nic Tr a nsc at h er H e art V alv e.” [ O nli n e]. Av ail a bl e: htt p:// w w w. e d w ar ds.c o m/ e u/ pr o d ucts/tr a nsc at h et erv al v es/ P a g es/ p ul m o nic. as px . [ Acc ess e d: 1 8 -J ul - 2 0 1 6]. 3 3. Sc hi e v a n o S, T ayl or A M, C a p elli C, et a l. First -i n -m a n i m pl a nt ati o n of a n o v el p erc ut a n e o us v alv e: a n e w a p pr o ac h t o m e dic al d e vic e d ev el o p m e nt. E ur oI nt er v e nti o n : j o ur n al of E ur o P C R i n c oll a b or ati o n wit h t h e W or ki n g Gr o u p o n I nt er v e nti o n al C ar di ol o gy of t h e E ur o p e a n S oci ety of C ar di ol o gy 2 0 1 0; 5: 7 4 5 - 5 0. 3 4. B er g ers e n L, B e ns o n L N, Gill es pi e MJ, et al. H ar m o ny F e asi bilit y Tri al: Ac ut e a n d S h ort -T er m O utc o m es Wit h a S elf -Ex p a n di n g Tr a nsc at h et er P ul m o n ar y V alv e. J A C C C ar di o v asc ul ar i nt er v e nti o ns 2 0 1 7; 1 0: 1 7 6 3 -7 3. 3 5. Nis hi m ur a R A, Ott o C M, B o n o w R O, et al. 2 0 1 4 A H A/ A C C g ui d eli n e f or t h e m a n a g e m e nt of p ati e nts wit h v alv ul ar h e art dis e as e: a r e p ort of t h e A m eric a n C oll e g e of C ar di ol o gy/ A m eric a n H e art Ass oci ati o n T as k F orc e o n Pr actic e G ui d eli n es. J o ur n al of t h e A m eric a n C oll e g e of C ar di ol o gy 2 0 1 4; 6 3: e 5 7 -1 8 5. 3 6. “I nt er n ati o n al St a n d ar d I S O 1 4 1 5 5: 2 0 1 1( E). Cli nic al i nv esti g ati o n of m e dic al d evic es f or h u m a n s u bj ects - G o o d Cli nic al Pr actic e.”. 3 7. “ M E D D E V 2. 7/ 3 r evisi o n 3 M a y 2 0 1 5: G ui dli n es o n m e dic al d e vic es; Cli nic al i n v esti g ati o ns: s eri o us a dv ers e e v e nt r e p orti n g u n d er dir ectiv es 9 0/ 3 8 5/ E E C a n d 9 3/ 4 2/ E E C.” 3 8. “ U nit e d St at es F o o d a n d Dr u g A d mi nistr ati o n C o F R, 2 1 C F R P art 8 1 2. 3 (s).” . 3 9. Gill es pi e MJ, B e ns o n L N, B er g ers e n L, et al. P ati e nt S el ec ti o n Pr oc ess f or t h e H ar m o ny Tr a nsc at h et er P ul m o n ary V al v e E arl y F e asi bilit y St u dy. T h e A m eric a n j o ur n al of c ar di ol o gy 2 0 1 7. A p p e n dix I: I nf or m e d C o ns e nt T e m pl at e A p p e n dix II: A dv ers e E v e nt D efi niti o ns 1 7. A p p e n di c e s"
64,page_64,
65,page_65,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 6 of 1 2 1 4. 0 • Ad diti o n of J a p a n g e o gr a p h y • Ex p a n d e d sc o p e of d oc u m e nt t o i ncl u d e J a p a n r e g ul at or y r e q uir e m e nts • A dj ust m e nt of pr e -i m pl a nt wi n d o w f or i m a gi n g r e q uir e m e nts • A d diti o n of p ost -c ar e lif el o n g As piri n a n d pr o p h yl actic a nti bi otic t h er a py r ec o m m e n d ati o n • A d diti o n of s ecti o n r e g ar di n g r ol e & m e m b ers hi p of scr e e ni n g c o m mitt e e • R evis e d A p p e n dix VII A n at o mic C ar di ac M a g n etic R es o n a nc e I m a gi n g Pr ot oc ol t o b ec o m e a S u b -st u d y i ncl u di n g s u bs e q u e nt r e q uir e m e nts • R e m o v e d r e q uir e m e nt f or sit es t o p erf or m a n at o mic m e as ur e m e nts o n C T a n d M RI i m a g es • Mi n or a d mi nistr ati v e c h a n g es t hr o u g h o ut N ot e: V ersi o n 4. 0 of t his d oc u m e nt m a y n ot ali g n t o t h e v ersi o n of t h e d oc u m e nt d et er mi n e d i n t h e M e dtr o nic Tri al M ast er Fil e ( R A D) 5. 0 • A d d e d i nf or m ati o n d escri bi n g a d diti o n al siz e H ar m o n y T P V d evic e • A d diti o n of s ecti o n d escri bi n g a s u bs et of s u bj ects f or i niti al i m pl a nt of t h e H ar m o n y T P V 2 5 • A d diti o n of a p ost -i m pl a nt C T s u b -st u dy A p p e n dix XIII • A dj ust m e nt of pr e -i m pl a nt wi n d o w f or i m a gi n g r e q uir e m e nts • Mi n or a d mi nistr ati v e c h a n g es t hr o u g h o ut 6. 0 • A d d e d i nf or m ati o n d escri bi n g a d diti o n al m o difi e d T P V 2 5 siz e H ar m o n y T P V d evic e • R e m o v e d l a n g u a g e all o w i n g d ef erri n g s u bj ects • A d d e d disc h ar g e C T a n d o n e m o nt h p ost - i m pl a nt f u ncti o n al C M R f or m T P V 2 5 i m pl a nts • R e m o v e d scr e e ni n g l o g r e q uir e m e nts • U p d at e d A p p e n dix XII f or P ost I m pl a nt C T S u b -st u d y • Mi n or a d mi nistr ati v e c h a n g es t hr o u g h o ut"
66,page_66,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 7 of 1 2 1 A p p e n di x I: I N F O R M E D C O N S E N T T E M P L A T E"
67,page_67,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 8 of 1 2 1 A p p e n di x I I: A D V E R S E E V E N T D E F I N I T I O N S"
68,page_68,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
69,page_69,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 6 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
70,page_70,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 0 of 1 2 1"
71,page_71,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g at i o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 1 of 1 2 1"
72,page_72,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g at i o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 2 of 1 2 1"
73,page_73,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 3 of 1 2 1 A p p e n di x I I I: A D V E R S E E V E N T C O D E L I S T M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
74,page_74,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 4 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
75,page_75,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 5 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
76,page_76,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 6 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
77,page_77,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 7 of 1 2 1 A p p e n di x I V: E C H O C A R D I O G R A P H Y P R O T O C O L M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
78,page_78,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 8 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e"
79,page_79,H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 9 of 1 2 1
80,page_80,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 0 of 1 2 1 3. 4. 2."
81,page_81,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 1 of 1 2 1"
82,page_82,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 2 of 1 2 1"
83,page_83,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 3 of 1 2 1 4. 0"
84,page_84,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 4 of 1 2 1 A p p e n di x V: R A D I O G R A P H Y P R O T O C O L M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
85,page_85,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 5 of 1 2 1 4. 0 5. 0 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
86,page_86,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 6 of 1 2 1 A p p e n di x V I: C A R D I A C M A G N E T I C R E S O N A N C E I M A G I N G P R O T O C O L -F U N C T I O N A L P A R A M E T E R S M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
87,page_87,H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 7 of 1 2 1 M l
88,page_88,H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 8 of 1 2 1 M e dtr o ni c C o nfi d e nti al
89,page_89,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
90,page_90,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 9 0 of 1 2 1"
91,page_91,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 1 of 1 2 1"
92,page_92,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 2 of 1 2 1"
93,page_93,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 3 of 1 2 1"
94,page_94,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 4 of 1 2 1"
95,page_95,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 5 of 1 2 1"
96,page_96,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 6 of 1 2 1"
97,page_97,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 7 of 1 2 1"
98,page_98,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 8 of 1 2 1"
99,page_99,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 9 of 1 2 1"
100,page_100,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 0 of 1 2 1"
101,page_101,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 1 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
102,page_102,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 2 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
103,page_103,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 3 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x V I I: C O M P U T E D T O M O G R A P H I C A N G I O G R A P H Y ( C T ) I M A G I N G P R O T O C O L"
104,page_104,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 4 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e •"
105,page_105,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 5 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e • •"
106,page_106,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 6 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e 3. 0 4. 0"
107,page_107,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 7 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
108,page_108,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 1 0 8 of 1 2 1 A p p e n di x V I I I: A N A T O M I C M E A S U R E M E N T S A N D D E V I C E S I Z I N G G U I D E L I N E S M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n P l a n T e m pl at e"
109,page_109,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 1 0 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
110,page_110,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 0 of 1 2 1"
111,page_111,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 1 of 1 2 1 A p p e n di x I X: E X P L A N T P R O T O C O L 1. 0"
112,page_112,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 2 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x X: I N S T R U C T I O N S F O R U S E D O C U M E N T"
113,page_113,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 3 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x X I: S F -3 6 Q U E S T I O N N A I R E"
114,page_114,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 4 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
115,page_115,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 5 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
116,page_116,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 6 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
117,page_117,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 7 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
118,page_118,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 8 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
119,page_119,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x X I I: P O S T -I M P L A N T C O M P U T E D T O M O G R A P H I C A N G I O G R A P H Y ( C T A ) I M A G I N G S U B -S T U D Y P R O T O C O L"
120,page_120,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 2 0 of 1 2 1"
121,page_121,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 2 1 of 1 2 1 5. 0"
122,page_122,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 0 of 1 2 1"
123,page_123,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g at i o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 1 of 1 2 1"
124,page_124,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g at i o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 2 of 1 2 1"
125,page_125,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 3 of 1 2 1 A p p e n di x I I I: A D V E R S E E V E N T C O D E L I S T M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
126,page_126,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 4 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
127,page_127,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 5 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
128,page_128,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 6 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
129,page_129,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 7 of 1 2 1 A p p e n di x I V: E C H O C A R D I O G R A P H Y P R O T O C O L M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
130,page_130,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 8 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e"
131,page_131,H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 7 9 of 1 2 1
132,page_132,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 0 of 1 2 1 3. 4. 2."
133,page_133,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 1 of 1 2 1"
134,page_134,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 2 of 1 2 1"
135,page_135,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g a ti o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 3 of 1 2 1 4. 0"
136,page_136,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 4 of 1 2 1 A p p e n di x V: R A D I O G R A P H Y P R O T O C O L M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
137,page_137,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 5 of 1 2 1 4. 0 5. 0 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
138,page_138,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 6 of 1 2 1 A p p e n di x V I: C A R D I A C M A G N E T I C R E S O N A N C E I M A G I N G P R O T O C O L -F U N C T I O N A L P A R A M E T E R S M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
139,page_139,H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 7 of 1 2 1 M l
140,page_140,H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 8 of 1 2 1 M e dtr o ni c C o nfi d e nti al
141,page_141,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 8 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
142,page_142,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 9 0 of 1 2 1"
143,page_143,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 1 of 1 2 1"
144,page_144,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 2 of 1 2 1"
145,page_145,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 3 of 1 2 1"
146,page_146,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 4 of 1 2 1"
147,page_147,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 5 of 1 2 1"
148,page_148,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 6 of 1 2 1"
149,page_149,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 7 of 1 2 1"
150,page_150,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 8 of 1 2 1"
151,page_151,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 9 9 of 1 2 1"
152,page_152,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 0 of 1 2 1"
153,page_153,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 1 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
154,page_154,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 2 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
155,page_155,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 3 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x V I I: C O M P U T E D T O M O G R A P H I C A N G I O G R A P H Y ( C T ) I M A G I N G P R O T O C O L"
156,page_156,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 4 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e •"
157,page_157,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 5 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e • •"
158,page_158,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 6 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e 3. 0 4. 0"
159,page_159,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 0 7 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
160,page_160,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 1 0 8 of 1 2 1 A p p e n di x V I I I: A N A T O M I C M E A S U R E M E N T S A N D D E V I C E S I Z I N G G U I D E L I N E S M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n P l a n T e m pl at e"
161,page_161,"H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er s i o n 6. 0 P a g e 1 0 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
162,page_162,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 0 of 1 2 1"
163,page_163,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y ™ T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 1 of 1 2 1 A p p e n di x I X: E X P L A N T P R O T O C O L 1. 0"
164,page_164,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 2 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x X: I N S T R U C T I O N S F O R U S E D O C U M E N T"
165,page_165,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 3 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x X I: S F -3 6 Q U E S T I O N N A I R E"
166,page_166,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 4 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
167,page_167,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 5 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
168,page_168,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 6 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
169,page_169,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 7 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
170,page_170,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 8 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e"
171,page_171,"H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 1 9 of 1 2 1 M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e A p p e n di x X I I: P O S T -I M P L A N T C O M P U T E D T O M O G R A P H I C A N G I O G R A P H Y ( C T A ) I M A G I N G S U B -S T U D Y P R O T O C O L"
172,page_172,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 2 0 of 1 2 1"
173,page_173,"M e dtr o ni c C o nfi d e nti al T his d o c u m e nt is el e ctr o ni c all y c o ntr oll e d 0 5 6 -F 2 7 5, v A Cli ni c al I n v esti g ati o n Pl a n T e m pl at e H ar m o n y T P V Cli ni c al I n v e sti g ati o n Pl a n D o c u m e nt # M D T 1 6 0 0 4 C O N 0 0 1 V er si o n 6. 0 P a g e 1 2 1 of 1 2 1 5. 0"
